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ABSTRACT OF THE DISSERTATION
MicroRNAs in ALS: Defining Cell-Type Specific Expression, Developing Methods to
Modulate MicroRNAs in vivo, and Identifying Novel Therapeutic Targets
by
Erica Danielle Koval
Doctor of Philosophy in Biology & Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2014
Professor Timothy M Miller, M.D., Ph.D., Chairperson

Amyotrophic lateral sclerosis (ALS) is an adult-onset, fatal neuromuscular disease with no
adequate therapies. MicroRNAs (miRNAs) are dysregulated in a variety of disease states,
suggesting that this newly discovered class of gene expression repressors may be viable
therapeutic targets. A microarray of miRNA changes in ALS model SOD1G93A rodents identified
12 miRNAs as significantly changed. Six miRNAs tested in human ALS tissues were confirmed
increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords.
Generation of mice that express a GFP-tagged miRNA processing protein behind cell-type
specific promoters allowed for the identification of miRNA expression patterns in various neural
cell types. From this information, we focused on the role of miR-155 on glial cells and
particularly on neuroinflammatory pathways in ALS. miR-155, miR-146a, and miR-142-5p were
upregulated beginning in a mid-disease stage and were highly correlated with one another and
with various neuroinflammatory mediators. To test miRNA inhibition in the central nervous
system as a potential novel therapeutic, we developed oligonucleotide-based miRNA inhibitors
ix

(anti-miRs) that could inhibit miRNAs throughout the central nervous system and in the
periphery. Anti-miR-155 caused global derepression of targets in peritoneal macrophages and,
following intraventricular delivery, demonstrated widespread functional distribution in the brain
and spinal cord. After treating SOD1G93A mice with anti-miR-155, we significantly extended
survival by 10 days and disease duration by 15 days (38%) while a scrambled control anti-miR
did not significantly improve survival or disease duration. Therefore, antisense oligonucleotides
may be used to successfully inhibit miRNAs throughout the brain and spinal cord, and miR-155
is a promising new therapeutic target for human ALS.
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CHAPTER 1
Introduction and perspective

1

1.1)

ALS: epidemiology and pathology
Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig’s disease) is a

progressive, fatal, neurodegenerative disorder characterized by the selective death of motor
neurons in the brain and spinal cord. The annual incidence of ALS is 1.5-2.5 per 100,000
individuals with a typical age-of-onset between 40 and 70 years (Chio et al., 2013). Typically,
patients experience progressive muscle weakness, spasticity, and atrophy, followed by death
within two to four years of disease onset due to respiratory failure. Only 7% of patients live 5
years past diagnosis (del Aguila et al., 2003). Despite ALS being first characterized in 1869 by
Jean-Martin Charcot (Kumar et al., 2011), Riluzole remains the only FDA approved treatment
and only prolongs survival by two to three months (Miller et al., 2012).
While the majority of ALS cases are singleton cases with no known genetic cause or
family history, 5-10% are familial (Pasinelli and Brown, 2006). In 2011, two groups discovered
a hexanucleotide repeat expansion in C9orf72 that is responsible for up to 30-40% of familial
ALS in the United States (Laaksovirta et al., 2010; van Es et al., 2009) and up to an additional
7% of patients without known family history of ALS (Majounie et al., 2012). Many research
groups are actively pursuing the pathological mechanism of this hexanucleotide repeat. Theories
include a loss of function (Ciura et al., 2013), a gain of function due to sequestration of RNA
binding proteins (Donnelly et al., 2013), or buildup of toxic protein aggregates (Zu et al., 2013).
However, no C9orf72 mouse model has yet been generated that has an ALS phenotype, thus
relegating translational research in C9orf72 linked-ALS to cell culture systems for the time
being.
In contrast, a previously identified mutation in the copper-zinc superoxide dismutase 1
gene (SOD1) (Rosen, 1993) has led to the generation of a widely used ALS-rodent model
2

(Gurney et al., 1994). Up to 20% of familial cases of ALS have been linked to a mutation in
SOD1 (Al-Chalabi and Hardiman, 2013), and over 131 distinct ALS-associated SOD1 mutations
have been characterized (Andersen, 2006), including the SOD1G93A mutation. SOD1 is a
ubiquitously expressed protein that reduces free radicals to oxygen and hydrogen peroxide.
Because SOD1 knockout mice do not display overt ALS-like symptoms similar to that seen in
the SOD1G93A mouse model (Reaume et al., 1996), most groups consider SOD1 mutations to
likely confer a gain of function toxicity. SOD1G93A mice undergo normal development but at ~3
months of age, depending on the mouse strain, they begin to lose weight and develop atrophy in
hind limb muscles. This phenotype progresses rapidly with paralysis and death typically
occurring between 4 and 6 months of age. So while SOD1 mutations only account for
approximately 2% of total ALS cases, mouse models based on SOD1 mutation have provided a
useful in vivo system for studying ALS pathology and therapeutic targets. While other ALSmouse models have been created using known ALS-causing mutations including 12 other SOD1
variants, TAR DNA-binding protein-43 (TDP-43), and fused in sarcoma (FUS) (Qiu et al.,
2014), the SOD1G93A mouse model is by far the most widely used (Moser et al., 2013). Key
benefits of the SOD1G93A mouse line over other ALS models include its more predictable timing
of disease onset and progression (Leitner, 2009), its recapitulation of patient phenotypes, and its
genetic relevancy to a relatively large percentage of familial ALS patients.
In the studies presented here, our primary mouse model was the SOD1G93A model.
However, the TDP-43 mouse model was also used as confirmation of our therapeutic targets.
TDP-43 was identified biochemically as a component of cellular aggregates associated with
ALS and Frontotemporal Dementia (Neumann et al., 2006). Subsequently, in 2008, a causative
mutation in TDP-43 was identified; TDP-43 mutations are thought to account for ~5% of
3

familial ALS (Gitcho et al., 2008; Kabashi et al., 2008). A transgenic mouse line was then
developed that expresses this human mutation, TDP-43A315T (Wegorzewska et al., 2009). TDP43A315T mice develop progressive weakness and difficulty walking associated with loss of motor
neurons and have ubiquitinated inclusions in motor neurons and layer V cortical neurons
(Wegorzewska et al., 2009; Wils et al., 2010). Spinal cords and brains from these mice show
neuron loss, as well as astrocyte and microglial activation (Wegorzewska et al., 2009). The
utility of this line has since been questioned because of an obstructive bowel phenotype that
eclipses a phenotype that would result from classical motor neuron loss in the brain and spinal
cord (Hatzipetros et al., 2013). Therefore, our use of this line is as a second confirmation of
interesting targets and not as a primary source in identifying therapeutic targets. By using two
genetic models for validation, top therapeutic targets were more rigorously chosen for future
large-scale therapeutic experiments that have a greater chance of success for translating to ALS
patients broadly.
Growing controversy exists on the usefulness of the ALS-rodent model as more clinical
trials fail to translate rodent targets to patients (Benatar, 2007; Perrin, 2014). This may be due to
attempts at applying experiments based on a single genetic mutation, often SOD1G93A, to patients
of whom over 98% do not harbor this mutation. Also, many therapeutic targets found in the
rodent are not well validated in ALS patients before completing a clinical trial based on that
target. Importantly, most therapeutic experiments in ALS-model mice that report a positive effect
serve to delay onset (on average by 12 days) but do not robustly extend disease duration (on
average 3 days) (Benatar, 2007). As ALS patients typically enter the clinic after symptom onset,
the most relevant therapeutic targets will likely be those that slow disease progression. We aimed
to strengthen our ability to identify therapeutic targets with translational potential in two ways
4

against these justified concerns. First, we used the TDP-43A315T mouse line as a second validator
of our top targets before deciding to continue with more ambitious intervention experiments.
Second, we used human autopsy tissue from both familial and sporadic ALS patients to validate
our targets of interest in Chapter 2. We also robustly followed onset and survival measures in our
mice to accurately determine if we were delaying symptom onset or extending disease duration.
Despite the numerous emerging genetic causes for ALS including SOD1, C9orf72, TDP43, ataxin 2 (ATXN2), valosin-containing protein (VCP), and others (Al-Chalabi and Hardiman,
2013), several pathological pathways remain consistent across patients. For example,
endoplasmic reticulum (ER) stress is a result of the accumulation of misfolded proteins that
results in an unfolded-protein response (UPR). While initially a protective pathway, sustained
activation of the UPR can lead to apoptosis (Ferraiuolo et al., 2011) and is thought to be one of
several toxic pathways that contribute to neuronal death in ALS (Ilieva et al., 2009). Next,
several studies have observed excess glutamate and signs of excitotoxicity in both patients and in
the ALS-mouse model. The ability of Riluzole to reduce presynaptic glutamate release is
considered one potential mechanism in which Riluzole leads to a survival benefit in patients
(Cheah et al., 2010). Some of the other well studied pathogenic pathways in ALS include
mitochondrial dysfunction, (Damiano et al., 2006), synaptic vesicle defects (Ilieva et al. 2009),
impaired axonal transport (De Vos et al., 2007), and neuroinflammation.

1.2)

Neuroinflammation in ALS

ALS is a non-cell autonomous disease
ALS is a non-cell autonomous disease in which astrocytes, microglia, oligodendrocytes,
and neurons all play critical rolls in disease progression (Ferraiuolo et al., 2011; Ilieva et al.,
5

2009). The impact of non-neuronal cells on ALS was made clear through experiments that
performed genetic ablation of the ALS-causing SOD1 mutation in distinct cell types. For this,
Boillee et al created mice that harbored the SOD1G37R mutation flanked by LoxP sequences
(Boillee et al., 2006). Upon removal of SOD1G37R expression exclusively in motor and dorsal
root ganglion neuron progenitors using the Islet-1 transcription factor promoter to drive Cre
recombinase expression, mice lived on average 64 days longer as compared to mice that
maintained ubiquitous SOD1G37R expression. Given that ALS symptoms are the result of a
selective loss of motor neurons in the brain and spinal cord, it is not surprising that removal of
the ALS-causing gene in neurons is significant. More interesting, removal of SOD1G37R
expression in glial cells also extended survival. Using a CD11b Cre recombinase driver,
SOD1G37R was specifically ablated from myeloid cells including monocytes, macrophages, and
microglia resulting in a survival benefit of 99 days (Boillee et al., 2006). Also, selectively
removing SOD1G37R from astrocytes using the GFAP Cre recombinase driver resulted in a
survival extension of 60 days (Yamanaka et al., 2008), and selective removal in oligodendrocytes
using the PDGFαR Cre recombinase driver extended survival by 130 days (Kang et al., 2013).
These studies show that motor neuron survival is greatly influenced by surrounding glial cells
and that ALS is a non-cell autonomous disease. Non-neuronal cells are important mediators of
disease pathogenesis and may themselves be valid therapeutic targets. However, their specific
supportive or maladaptive roles remained unclear with these genetic ablation experiments.
Recently, experiments that aim to elucidate the complex and critical roles glial cells in ALS have
gained greater attention. I will highlight the roles of the innate and adaptive immune response in
ALS by detailing multiple critical cell types involved in neuroinflammation, their trafficking,
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signaling, and activation, and the mixed success achieved with immunomodulatory therapies in
ALS-model mice.

Innate immune system in ALS
Neuroinflammation is characterized by the integrated response of multiple cell types in
the central nervous system to injury, insult, or disease. Commonly in neurodegenerative
disorders, neuroinflammation involves in part the activation and proliferation of resident
microglia and the infiltration of peripheral immune cells including macrophages and
lymphocytes. Macrophages are white blood cells derived from monocytes, and microglia are the
resident macrophages in the brain and spinal cord. Originally thought to be derived from bone
marrow precursor cells, fate mapping (Ginhoux et al., 2010) and gene expression experiments
(Butovsky et al., 2012; Chiu et al., 2013) have since confirmed microglia to be a unique type of
mononuclear phagocyte that derives from the yolk sac (Alliot et al., 1999). Microglia populate
the brain and spinal cord early in embryogenesis, are long-lived, and self-renew (Ajami et al.,
2007; Mildner et al., 2007). Both microglia and peripheral macrophages require the transcription
factor PU.1 for maturation (McKercher et al., 1996) but have recently been further distinguished
in their expression of Ly6C (splenic monocytes) and CD39 (resident microglia) (Butovsky et al.,
2012; Yamasaki et al., 2014).
Under basal conditions, the inappropriately named “resting microglia” serve active
surveillance and supportive roles to the brain and spinal cord. Under resting, physiological
conditions, microglia are important in synapse maintenance (Wake et al., 2009) and cell survival
in part by providing trophic support (Nakajima et al., 2001). Furthermore, two-photon imaging
of mice expressing a GFP-tagged chemokine receptor, CX3CR1, serving to label lymphocytes
7

and myeloid cells, showed that as a class, microglia are motile cells that use their dynamically
extended processes to survey the complete parenchyma once every few hours (Nimmerjahn et
al., 2005). In response to a variety of CNS insults, microglia withdraw these surveying processes
and activate in order to act at the first line of defense (Tambuyzer et al., 2009). While microglia
activation has been well studied in a myriad of diseases and conditions, I will focus here on the
responses of microglia most relevant to ALS research.
Mirroring research on the response of microglia to a bacterial toxin, lipopolysaccharide
(LPS), Dr. Appel’s group has published several papers thoroughly characterizing the dynamic
polarization of microglia from ALS-model mice throughout disease progression (Beers et al.,
2008; Beers et al., 2011; Liao et al., 2012). They observed that early in disease, microglia enter
an M2 alternatively activated state in which they serve neuroprotective roles. M2 microglia
secrete anti-inflammatory cytokines (IL-4, IL-10), neurotrophic factors (IGF-1, GDNF), and
recruit T-helper type 2 (Th2) cells and T regulatory cells (Tregs) from the periphery to further
strengthen this protective response (Lewis et al., 2012). However, later in disease, they found
that microglia change their polarized activated state from M2 to the classical activated M1 state.
M1 microglia are thought to serve neurotoxic functions. M1 microglia secrete pro-inflammatory
cytokines (IL-6, IL-1β, TNFα), pro-apoptotic signals (reactive oxygen species (ROS), glutamate)
(Zhao et al., 2004), and secrete chemokines (CXCL9, CXCL10) to recruit T-helper type 1 cells
(Th1) and cytotoxic CD8 cells from the periphery to further augment the neurotoxic response
(reviewed: (Evans et al., 2013; Lewis et al., 2012; Prinz and Priller, 2014). These three microglia
responses are sometimes referred to as “the good” (M2), “the bad” (M1), and “the resting” (nonactivated) (Henkel et al., 2009).
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However, others believe that the concept of polarization to be inaccurate. By performing
deep RNA sequencing, microglia from ALS-model mice were shown to have the potential to be
concurrently both cytotoxic and protective by expressing a mixture of “M2” and “M1” genes
including IGF-1, Progranulin, DAP12 and MMP-12, Optineurin, and Nox2 respectively (Chiu et
al., 2013). Therefore, the concept of microglia polarization to M1 and M2 derived from LPS
experiments may not be accurate to describe the complex nature of microglial responses during
ALS. It remains unknown whether ‘good’ or ‘bad’ microglia exist as potential ALS therapeutic
targets and if blunting or modulatory therapies will be beneficial for patients with ALS.
The chemokine response in the brain and spinal cord upon ALS disease progression can
serve to recruit peripheral lymphocytes and monocytes. With the identification of microglia and
monocyte specific markers (CD39 and Ly6C respectively), Dr. Weiner’s research group found
that contrary to previously published studies, native microglia do not proliferate in ALS. Instead
of “microgliosis”, CCL2 expressed by microglia recruits Ly6Chi monocytes via the CCR2
receptor. Through fate-mapping and gene expression experiments, the authors concluded that
native microglia were selectively lost in the late-stage ALS-model mouse spinal cords while
there was a robust neural recruitment and proliferation of Ly6C+ monocytes. A limitation in
these experiments is the inability to account for potential changes in gene expression during
disease and therefore an inability to definitively claim cell origin based solely on Ly6C and
CD39. Furthermore, the fate-mapping experiment involved bone-marrow ablation by irradiation
in an ALS-model mouse, reconstituted with donor bone marrow cells that express GFP. By
observing an increase in GFP signal in the brain during disease progression, it is impossible to
know if monocyte infiltration occurs naturally in ALS or if this observation is instead an artifact
due to a break down in the blood brain barrier, common with irradiation (Ajami et al., 2007;
9

Diserbo et al., 2002). In 2013, Chiu et al. found no increase in Ly6C/monocyte signal in ALS
model mouse spinal cords as measured with flow cytometry and qPCR (Chiu et al., 2013). These
disparate data may be due to current limitations in techniques, and there is an active interest in
resolving these differences (Chiu et al., 2013). The distinction of microglia and macrophage
involvement is beyond the scope of this dissertation, but in light of these data and this
controversy, these specific inflammatory markers, CD39 and Ly6C, were included in our panel
of neuroinflammatory transcripts when assessing microglia in the ALS model.
As sophisticated experiments further distinguished microglia, macrophages, and
monocytes, the best Cre recombinase driver for studying myeloid cell function has come under
renewed debate. Previously to study microglia, researchers often relied on the integrin M
(CD11b), integrin-αx (CD11c) (Town et al., 2008) and lysozyme M (LysM, or Lyz2) promoters.
However, in 2013, a new mouse was generated that expresses Cre recombinase behind the
chemokine receptor CX3CR1 (fractalkine) driver (Goldmann et al., 2013; Yona et al., 2013). In
comparing three microglial Cre drivers, Goldmann et al. found that the CD11c driven Cre
recombinase only resulted in 7% expression in CD11b+CD45lo FACS gated microglia. The
LysM driver performed much better with a 46% expression of Cre recombinase in Iba-1+ spinal
cord microglia, but the novel CX3CR1 Cre driver showed the best recombination levels with
expression in 99% of the CD11b+CD45lo FACS gated microglia (Goldmann et al., 2013). LysMCre expression by FACS was not determined. Of note, by taking advantage of the low expression
of CX3CR1 in peritoneal macrophages, the high turnover rate of intestinal macrophages and
blood monocytes from stem cell precursors, and the self-renewal properties of microglia, the
authors were able to use an inducible tamaxofen system to drive nuclear translocation and
activation of CX3CR1-Cre-ER to create microglia specific Cre expression (reviewed in (Wolf et
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al., 2013)). In the cell-specific experiments detailed in Chapter 3, our goal is to distinguish
neuron, astrocyte, and myeloid/microglia microRNA expression levels; however, distinguishing
macrophages and microglia is beyond the scope of these studies. Furthermore, the generation of
double-transgenic mouse lines for these experiments began in early 2013 precluding our use of
the novel CX3CR1- Cre driver. Nonetheless, we were pleased with the strong signal of Cre
recombinase in our Lyz2 driver mice (Chapter 3) and are aware of the caveat that we are
potentially only labeling half of the brain and spinal cord microglia.
Astrocytes are an abundant type of glial cell that have been well studied in ALS
(Maragakis and Rothstein, 2006) and serve some immunologic functions similar to that
discussed for microglia under physiological and pathological conditions. That is, under resting
conditions, astrocytes provide trophic support, but upon activation, astrocytes can enhance
inflammation with the secretion of neurotoxic factors and even inflammatory cytokines (Kim et
al., 2011; Philips and Robberecht, 2011). Typically, astrocytes play important roles in
maintaining extracellular neurotransmitter concentrations, supplying nutrition and metabolic
support to neurons, regulating the brain blood barrier, and more (Philips and Robberecht, 2011;
Rossi et al., 2011). Upon activation, termed astrogliosis, astrocytes increase expression of
intermediate filament proteins, including GFAP and vimentin, and may secrete reactive oxygen
species. Furthermore, astrocytes may become dysfunctional themselves leading to an inability to
effectively regulate glutamate, resulting in neuronal death due to hypertoxicity. The importance
of astrocytes in ALS disease pathogenesis was made clear with astrocyte-neuron co-culture
experiments with which several groups found that SOD1G93A expressing astrocytes, from mice
and patients, were sufficient to cause neuronal death (Haidet-Phillips et al., 2011; Nagai et al.,
2007). Given the importance of this cell type to neuronal survival, one goal of this dissertation is
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to further our knowledge of miRNA expression in astrocytes (Chapter 3) while also surveying
the correlation of astrogliosis in response to miRNA modulatory therapies (Chapter 5).

Adaptive immune system in ALS
T cell activation and infiltration into spinal cord tissue is a pathological hallmark of ALS,
both in patients (Engelhardt et al., 1993) and in the SOD1 ALS mouse model (Chiu et al., 2008)
and is well correlated with microglia activation (Beers et al., 2008). T cells are a type of
lymphocyte that play critical roles in adaptive immunity. Relevant to ALS, T cells can mature to
become cytotoxic T cells (CD8), T helper cells (TH; CD4+), or T regulatory cells (Treg;
CD4+CD25+FoxP3+). CD8+ T cells are capable of driving apoptosis in neurons through the
release of cytotoxic molecules including perforin and granzyme and the expression of Fas ligand
(Lewis et al., 2012; Melzer et al., 2009). CD4+ TH cells serve to modulate the activation and
function of other immune cells including other T cells and myeloid cells through the release of
cytokines. T helper type 1 cells (TH1) secrete pro-inflammatory molecules including IFNγ, TNFα and IL-1β that can drive M1 microglia polarization, whereas T helper type 2 cells (TH1) secrete
anti-inflammatory molecules including IL-4, IL-5, and IL-10 capable of driving M2 microglia
polarization (Mosmann and Sad, 1996; Beers et al., 2011; Lewis et al., 2012). Furthermore,
FoxP3+ Tregs can modulate the adaptive and innate immune response and have been shown to
have potent immunosuppressive function in ALS-model mice (Beers et al., 2011).
Early in disease (10 weeks of age), TH2 and Treg cells were observed in ALS-mouse
spinal cord tissue and were correlated with M2 microglia. Later in disease, at approximately 20
weeks of age, CD8+ T cells were also observed (Chiu et al., 2008). Through genetic ablation of
the T cell antigen receptor β chain (TCRβ) in SOD1G93A mice, T cell maturation was prevented
12

and CD4+ and CD8+ T cells were markedly absent in spinal cord tissue. In these mice, disease
progression was accelerated, with mice dying 11 days earlier on average (Chiu et al., 2008)
showing T cells to be important and beneficial in slowing ALS disease progression.
Also, natural killer cells (NK) are a distinct class of cytotoxic lymphocytes and have been
observed to also be present in late disease ALS-model mouse spinal cord tissue (Chiu et al.,
2008) and in patient blood (Rentzos et al., 2012); however, this class of cells has not received
much attention in ALS studies to date. Finally, B cells, an important class of antigen presenting
cells, are not thought to be important mediators of ALS pathogenesis. By crossing SOD1 G93A
mice with immunoglobulin heavy chain, Igµ, knockout mice, B cell deficient ALS-model mice
were generated, and these mice had no alterations in behavioral or survival measures as
compared to SOD1G93A mice with unimpaired B cell function (Naor et al., 2009). In light of
these studies, the immunologic transcripts measured in in Chapter 5 following our ALS-mouse
model intervention treatments focus on innate immunity and cell-mediated immunity over the
humoral component, and include measurements for the number and activation states of
astrocytes, myeloid cells, and T cells in spinal cord tissue.

Insights from immunomodulatory experiments in ALS-model mice
Neuroinflammation has been well characterized in ALS, both in patients and in the
mouse model. Increased numbers of microglia can be observed in affected tissues including the
ventral horns of the spinal cord, corticospinal tracts, brainstem motor nuclei, and the motor
cortex (Weydt and Moller, 2005). A number of recent experiments using the ALS-mouse model
suggest that while overall blunting of the immune system is potentially detrimental, selectively
modulating and even increasing components of the neuroimmune response in ALS may be
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beneficial. However, one of the largest remaining questions in studying neuroinflammation in
ALS is whether microglia and lymphocytes are neuroprotective, neurotoxic, or both and whether
modulating their activation states could be a valid therapy. While Alzheimer’s disease (AD) and
ALS are distinct neurodegenerative diseases, they have several shared pathological mechanisms
including a gain of toxic protein aggregates and marked increases in neuroinflammatory markers,
allowing AD experiments to be potentially useful in furthering our understanding of ALS
pathogenesis. Presented here are a series of experiments in both the ALS-model mice and in AD
model mice that inform the role of the immune system in neurodegenerative disease
pathogenesis.
First, upon removing the spleen, an organ that houses a large percentage of lymphocytes
and monocytes, SOD1G93A mice died 8 days sooner showing that the immune system has a clear
beneficial role in ALS disease progression (Butovsky et al., 2012). These data are supported with
the discovery that preventing myeloid-cell proliferation, by introducing ganciclovir in CD11b
thymidine kinase expressing mice, in AD model mice resulted in increased accumulation of toxic
β-amyloid (Simard et al., 2006), again showing a positive role for monocytes in
neurodegenerative diseases.
It was theorized that increasing the protective M2 response and blunting the detrimental
M1 response would protect against neuronal death and increase survival in the mouse. Based on
this hypothesis, minocycline, a drug that can selectively inhibit M1 microglia (Makeyev and
Maniatis, 2008), was found to be extend survival of SOD1G93A mice (Zhu et al., 2002); however,
administration of minocycline to ALS patients was detrimental (Gordon et al., 2007). While still
unknown why the results of these mouse and human experiments differ, some theorize that the
failed clinical trial was due to the drastically increased dosage (400 mg/day) in the Phase 3
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clinical trial (Leigh et al., 2008). Immunomodulatory studies in Alzheimer’s disease provide an
alternative hypothesis for why blunting microglia responses may be detrimental. Upon treating
(APPSwe)/PS1 AD model mice with the cytokine colony-stimulating factor (M-CSF), mice
displayed a lower β-amyloid plaque burden along with improved performances in learning and
memory tasks. Correlated with these biochemical and behavioral benefits were increased
numbers of activated microglia and the increased expression of proinflammatory cytokines in the
mouse cortex (Boissonneault et al., 2009). These data support a beneficial role of proinflammatory microglia, likely through increased phagocytosis and clearance of toxic proteins
and cells. Overall, it remains unclear the best way to therapeutically modulate monocytes and
microglia in ALS, but it is evident that these immune cells are important drivers of
neurodegenerative disease.
In addition to therapeutic strategies to target myeloid cells, several studies have found
beneficial roles for adaptive immune cells in ALS, largely led by Dr. Appel’s research group.
The role of T cells in ALS was tested by genetic ablation of recombination-activating gene 2
(RAG2), a protein necessary for the genetic recombination required to develop mature
lymphocytes. In these ALS-model mice that lacked functional T and B cells, disease duration
was significantly increased by 19 days. Furthermore, SOD1G93A CD4 knockout mice that lack TH
and Treg cells died on average 16 days sooner than littermate controls (Beers et al., 2008),
suggesting a positive role of lymphocytes in ALS. Adoptive transfer of Tregs into ALS model
mice also enhanced survival, showing that Tregs are potentially the relevant T cell subset that
confer a survival benefit in ALS (Beers et al., 2011). Overall, given the relatively new efforts to
study immunomodulatory therapies in ALS, there remain more questions than answers. While
convincing data have been generated showing neuroinflammation to be important to disease
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progression in ALS-model mice, the very nature of the immune response remains unknown.
Blunting the involvement of myeloid cells and lymphocytes appears detrimental, but varying
success has been achieved through selective immunomodulatory therapies, through targeting
either canonical anti- and pro-inflammatory compartments. However, it has also been recently
suggested that these distinctions are in of themselves inaccurate (Chiu et al., 2013). Given the
fluid nature of research on neuroinflammation related to ALS, care was taken to be unbiased in
the gene targets measured as this dissertation progressed to study potential modulations in the
number, activation, and signaling of immune cells in ALS. Therefore, a diverse panel was
created to measure astrocyte, myeloid, and lymphocyte number and activation states as well as
various signaling molecules canonically associated with pro- and anti-inflammatory effects.

1.3)

MicroRNAs: biogenesis, expression, and applications to disease
In targeting pathogenic pathways in ALS, including neuroinflammation, microRNAs may

prove to be a powerful tool. Since their discovery in 1993 (Lee et al., 1993), microRNAs
(miRNAs) have emerged as key regulators in numerous physiological and pathological
processes. miRNAs are highly conserved single-stranded, non-coding RNA molecules 19-25
nucleotides in length. miRNA sequences are located throughout the genome – in coding and
noncoding genes; in introns and in exons (Rodriguez et al., 2004). Following transcription by
RNA polymerase II, primary-miRNA (pri-miRNA) transcripts form hairpin structures that are
then cleaved by Drosha and Dicer, RNase III enzymes. This results in a ~70 nucleotide fragment
known as the precursor-miRNA (pre-miRNA) (Krol et al., 2010). The pre-miRNA is then
exported to the cytoplasm by Exportin-5 before being further cleaved by Dicer. The result is a
19-25 double stranded RNA that unwinds to form what typically becomes a passenger/degraded
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strand and a guide strand (Winter et al., 2009), although sometimes both strands of the miRNA
are biologically active. The minor species is typically annotated with a “*” as in miR-24-2*.
Typically, miRNAs direct translational repression by binding to the 3’UTR of mRNAs
after first being incorporated into an Argonaute containing RNA-induced silencing complexes
(RISC). While four distinct mammalian Argonaute proteins exist (Ago1-4), research into miRNA
function is typically restricted to Ago2 as it is the only Argonaute protein that has retained
catalytic, endoribonuclease activity (Meister et al., 2004). The second to eighth nucleotide of the
miRNA, called the seed region, is considered to be the most important for target recognition and
is often emphasized in target prediction algorithms (Bartel, 2009). Depending on the level of
miRNA-mRNA complementarity, RISCs will inhibit and/or degrade the target mRNA
(Chekulaeva and Filipowicz, 2009). Currently, there are several substantiated theories on the
method of microRNA mediated translational repression. For example, with partial
complementarity, the RISC can serve to destabilize the target mRNA through deadenylation or
decapping. Alternatively, the target mRNA may simply be inhibited through sequestration, often
in processing bodies (P-bodies). Finally, with near perfect complementarity, the miRNA/RISC
can cause endonucleolytic cleavage of the target mRNA (Morozova et al., 2012). miRNAs are
highly associated with the RISC in vivo, with only 1-3% of miRNAs existing unbound to Ago2
(Tang et al., 2008). This high affinity has allowed researchers to successfully isolate miRNAs ex
vivo using immunoprecipitation against Ago2 (Chi et al., 2009).
Because only partial complementarity is required for miRNA-mRNA interactions, a
single miRNA can potentially regulate hundreds of mRNA transcripts (Selbach et al., 2008).
miRNA-mRNA targets are identified through bioinformatics algorithms and/or experimental
validation. First, several target prediction programs have been designed with most surveying the
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3’UTR of mRNAs for an exact miRNA seed region compliment while also calculating
thermodynamic stability and evolutionary conservation (Min and Yoon, 2010). The predicted
success of this approach is relatively high at 50-85% accuracy for conserved miRNAs (Chen and
Rajewsky, 2006), but there remains a high number of false hits and missed targets through using
a bioinformatics approach alone. Therefore, to confirm predicted mRNA targets for a particular
miRNA, experimental validation is necessary through either genetic or molecular assays. The
most common approach is an in vitro assay in which cells are transfected with a luciferase
reporter that contains the 3’UTR of the predicted mRNA target. By either transfecting the
miRNA, inhibiting the miRNA, or mutating the direct predicted binding site, the predicted
mRNA target for a given miRNA can be confirmed. If a valid 3’UTR target, increasing the
amount of that miRNA will inhibit luciferase expression, and in contrast, inhibiting the miRNA
will derepress/increase luminescence. Likewise, mutating the predicted binding site within the
3’UTR will similarly derepress luciferase signal (van Rooij et al., 2012).
Alternatively, Argonaute high-throughput sequencing of RNAs isolated by crosslinking
immunoprecipitation (HITS-CLIP) is a recent method developed to validate mRNA targets for
miRNAs globally. With this technique, the close proximity of the three molecules (Ago2,
miRNA, and mRNA) allows the generation of ternary structures that can then be sequenced to
generate two data sets: Ago-miRNA and Ago-mRNA binding sites. Bioinformatics analysis can
then be applied to determine interactions between miRNA and target mRNA (Chi et al., 2009).
In our studies, to determine novel miRNA binding targets, we also used a mixture of target
prediction algorithms and luciferase assays. The number of verified miRNAs continues to
increase, with the latest version of miRBase annotating 2578 distinct miRNA sequences in Homo
sapiens, (miRBase.org, v20.0). With the large number of predicted binding targets for a given
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miRNA, miRNAs, as a class, are potential regulators of over 50% of all human genes (Friedman
et al., 2009).
One of the first steps to studying the role of a particular miRNA is to learn its expression
patterns in distinct cell populations. The current popular methods for determining miRNA cell
type specific expression are fluorescence activated cell sorting (FACS), laser capture
microdisections (LCMs), and in situ histology; however, each of these methods has significant
limitations. FACS and LCM introduce cellular stress that can alter gene expression, are low
yield, and may only isolate miRNAs located at the cell body, potentially at a loss of miRNAs
present in the synapses (Lugli et al., 2005) and the dendrites (Tai and Schuman, 2006). Histology
with in situ hybridization using miRNA probes may be used to detect abundant miRNAs but are
difficult, expensive, and only serve to assay a single miRNA at a time.
Recently, He et al. developed a method for determining miRNA specific expression in
distinct GABAergic and gluamatergic cell populations from whole brain and spinal cord tissue,
called miRAP (miRNA tagging and affinity purification). By expressing cell specific Cre
recombinase and ubiquitous floxed stop GFP-myc tagged Ago2, mice were generated that only
expressed GFP-myc-Ago2 in the neural cell type of interest. Using flash-frozen whole tissue
from these miRAP mice, an immunoprecipitation against the GFP or myc tag allowed miRNAs
to be isolated from only the specific cell type of interest. This novel method has several
advantages including its physiological relevance, its sensitivity, and its ability to generate highthroughput data sets (He et al., 2013). Given the importance of both neuronal and non-neuronal
cell populations in ALS, we adapted this method to generate datasets of miRNA expression in
neurons, motor neurons, astrocytes, and myeloid cells in the brain and spinal cord (Chapter 3).
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While most research on the role of miRNAs is focused on cancer (Reid et al., 2011;
Volinia et al., 2006; Yanaihara et al., 2006), significant discoveries have also been made linking
miRNAs to neurodegenerative disease. First, it was discovered that patients who had high levels
of beta-secretase (BACE1, the enzyme responsible for the generation of pathogenic amyloid-β
peptides) also had lower levels of miR-29a/b. The authors then performed in vitro experiments
confirming the predicted direct interaction of miR-29 and BACE1 (Hebert et al., 2008). In
Parkinson’s disease, Pitx3 is a transcription factor required for dopaminergic neuronal survival.
It was found that miR-133b and Pitx3 form a negative feedback loop, and that the midbrain of
Parkinson’s disease model mice have reduced levels of miR-133b (Kim et al., 2007). In ALS,
miR-206 was found to be increased in the skeletal muscles of ALS model mice. Upon knocking
out miR-206, mice died more quickly, determined to be from a lack of neuromuscular synapse
reorganization normally driven by miR-206. Therefore, increased levels of miR-206 is thought to
be a beneficial driver in ALS, although the authors did not pursue a rescue experiment to test if
increasing miR-206 levels more would create a survival benefit (Williams et al., 2009). These
studies all serve as examples of the importance of miRNAs in neurodegenerative disease
pathways and outcomes.
Because a single miRNA can have hundreds of mRNA targets through partial
complementarity, there may be some concern that modulating miRNAs would not be a good
therapeutic approach. However, one study of miRNA in disease is now progressing beyond the
animal model. Following the discovery that miR-122, a liver specific miRNA, drives the
replication of the hepatitis C virus (HCV) (Jopling et al., 2005), Santaris Pharma developed an
antisense oligonucleotide inhibitor against miR-122, called Miriversen. Following successful
chimpanzee studies (Lanford et al., 2010), the authors have continued to complete a successful
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Phase I (Janssen et al., 2011) and Phase IIa trial (NCT01200420) (Janssen et al., 2013). Hepatitis
C patients that received Miriversen reported no significantly greater number of adverse events
over placebo, and their viral titer counts were robustly and significantly reduced, even at the
lowest dosage level tested, 3mg/kg. Reduced HCV RNA was observed over 3 months beyond the
last injection. This clinical trial shows that despite the vast number of potential mRNA targets for
each miRNA, miRNAs remain both powerful and realistic therapeutic targets.

1.4)

Antisense oligonucleotides
Several methods exist to manipulate the function of miRNAs in vivo including

enhancement via miRNA mimics and repression via sponges/decoys and antisense
oligonucleotides (ASOs). When testing the role of downregulated miRNAs in disease,
commercially available synthetic miRNA mimics can be a useful tool for reintroducing the
miRNA – allowing the effect of the miRNA of interest on direct gene targets and/or changes in
physiological and pathological pathways to be determined. miRNA mimics can be introduced at
various stages of the miRNA processing pathway including the precursor hairpin (van Rooij et
al., 2012), the double-stranded mature miRNA duplex (LifeTechnologies, 2012), or the fully
processed single stranded miRNA (Trang et al., 2011). Given the novelty of this method, it is not
yet known which form of the miRNA mimic has the best cellular uptake, specificity, and
potency. If the goal instead is to reduce upregulated miRNAs back to baseline, several
technologies exist for synthetically inhibiting the function of a target miRNA. Recently
developed miRNA sponges are mRNAs that contain multiple miRNA binding sites (often 4-10),
acting as dominant negative inhibitors (Ebert and Sharp, 2010). Since their development in 2007
(Ebert et al., 2007), miRNA sponges are showing promise in their potency and adaptability,
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including an ability to target complete miRNA families that contain homologous seed regions.
However, sponges are sometimes limited in their ability to sufficiently inhibit abundant
microRNAs and are not as prepared for safe delivery in patients as ASO technology (Ebert and
Sharp, 2010).
As seen with Miriversen, antisense oligonucleotides (ASOs) against miRNAs are able to
inhibit the function of the target miRNA in vivo. ASOs are short, synthetic, single-stranded DNA
molecules that hybridize to a target RNA through Watson-Crick base pairing. The ASO then
serves to either sequester the RNA species or degrade it through recruitment of endogenous
RNaseH (Crooke, 2004). The mode of action will depend upon the backbone and sugar
modifications of the ASO. Numerous modifications have arisen from attempts to enhance
potency, extend half-life, increase specificity, and decrease toxicity. The most widely used of
these backbone modifications is the phosphorothioate modification (PS), which involves
substituting the non-bridging oxygen at the phosphodiester linkage with sulfur. The most widely
used modifications at the 2’ sugar are the 2’O-methyl and the 2’-O-methoxyethyl substitutions.
Several ASOs with these backbones have entered clinical trials in the treatment of cancer (Dean
and Bennett, 2003). In contrast with sponges, ASO technology is considered more promising as a
potential therapeutic method in light of recent, successful clinical trials covering a wide range of
diseases (reviewed: (Kole et al., 2012)).
ASO-mediated miRNA inhibition has been successful in the periphery but has not been
readily applied to the CNS. ASOs are highly charged molecules that resist crossing the bloodbrain barrier (BBB). In fact, peripheral dosing would have to be approximately 100-fold higher
than a direct CNS delivery to equal the same level of tissue concentration (Banks et al., 2001).
However, direct CNS delivery has recently become a proven method to deliver ASOs to patients
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for targeting mRNAs. After discovering that a 20-mer anti-SOD1 ASO delivered to the lateral
ventricles resulted in a 10 day survival extension in the ALS-rat model, preclinical primate
experiments were conducted, showing distribution of the ASO throughout the brain and spinal
cord (Smith et al., 2006). In 2013, a clinical trial testing the safety of an intrathecal delivery of
this same anti-SOD1 ASO found no significantly increased occurrence of adverse events. The
most common adverse reactions were related to the lumbar puncture and included back pain and
nausea (Miller et al., 2013). Given these promising studies that safely inhibit mRNAs in the
central nervous system both in patients and in mouse models, we aimed to adapt this technology
to study microRNA inhibition in vivo in order to determine the mechanism and the importance of
dysregulated miRNAs in ALS.

1.5)

Summary and goals of the dissertation:
ALS is a devastating neurodegenerative disease with no adequate therapies but with an

ample number of potential cellular pathways to target. One well studied pathological feature of
ALS is that of neuroinflammation. Many studies have recently shown that the immune response
is not overall a negative driver of disease progression in ALS and other neurodegenerative
disorders. Instead, selective immune modulating techniques have afforded promising survival
benefits whereas global blunting the inflammatory pathways have been shown to be detrimental.
miRNAs are an exciting new avenue of research. These small translation inhibitors have the
potential to target hundreds of targets including entire gene batteries (Makeyev and Maniatis,
2008) including potentially pathogenic pathways involved in ALS. As one approach to modulate
miRNA levels in vivo, recent studies have shown that antisense oligonucleotides can be
administered both safely and effectively.
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To address the need for novel approaches to ALS therapeutics, we researched changes in
miRNA expression levels in spinal cord tissue. For this, we first used the well-studied SOD1G93A
ALS-model mouse line to identify dysregulated miRNAs. In order to enhance the translational
potential of our findings, we screened miRNA targets in two ALS mouse models, the ALS rat
model, and in ALS patient autopsy spinal cord tissues. Understanding the important role of nonneuronal cells in ALS disease progression, we next developed physiologically relevant methods
to determine cellular location of miRNAs in a high-throughput fashion. Specifically, we found
that our top miRNA of interest, miR-155, was robustly enriched in microglia. No study had
previously inhibited miRNAs throughout the brain and spinal cord in a mouse model of
neurodegeneration, so we carefully screened multiple ASO chemical modifications and delivery
methods to develop a way to broadly and potently inhibit a miRNA in the CNS.
After finding that anti-miR-155 treatment successfully extended survival in an ALSmouse model without affecting onset of disease, we performed a panel screen of
neuroinflammatory transcripts in the treated spinal cord and spleen tissue. Previous research has
clearly shown the robust activation of the innate and adaptive immune system in ALS patients
and in the ALS mouse model, and several studies have shown the potential of
immunomodulatory therapies in treating ALS. However, several recent controversies have
emerged concerning the specific nature of neuroinflammation in ALS including the role of
microglia versus macrophages and the beneficial versus detrimental nature of the immune system
in ALS. By performing an unbiased panel screen, we generated correlative data linking the
survival benefit of anti-miR-155 treatment in the ALS-mouse model to increased levels of
specific transcripts for cellular and molecular neuroinflammatory genes. This work serves
several important functions. It identifies several interesting miRNA targets for studying
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neurodegenerative diseases. It develops important methods for identifying miRNA cellular
expression and for inhibiting miRNA function in vivo. Finally, this thesis work identifies an
exciting new therapeutic target for ALS while also informing a potential role of
neuroinflammation in ALS. The experiments and methods discussed here will likely have
important ramifications broadly in both microRNA and ALS research. Overall, this dissertation
aimed to discover novel therapeutic targets for ALS, enhance understanding of pathological
pathways in ALS, and develop methods to study miRNAs in vivo.
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CHAPTER 2

Characterizing microRNA dysregulation in a rodent model of ALS and in
patient autopsy tissue
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SUMMARY
microRNAs (miRNAs) are dysregulated in a variety of disease states, suggesting that this
newly discovered class of gene expression repressors may be viable therapeutic targets. A
microarray of miRNA changes in ALS model SOD1G93A rodents identified 12 miRNAs as
significantly upregulated. Six of these miRNAs tested in human ALS tissues were confirmed
increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords.
Three of these well-correlated target miRNAs are robustly increased at 15-18 weeks of age in a
24-week ALS-mouse model showing the potential of therapeutic intervention. Despite welloptimizing a miRNA extraction protocol for ALS patient serum, these top miRNA targets, miR142-3p, miR-146a, and miR-155, do not appear to be strong serum biomarker candidates at this
time.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig’s Disease) is a fatal adultonset neurodegenerative disease characterized by the selective loss of motor neurons in the
spinal cord and brain leading to stiffness, severe muscle weakness, and death due to respiratory
failure typically within 2-4 years of disease onset (Rothstein, 2009). Riluzole, the only FDA
approved treatment, prolongs survival by only two to three months (Miller et al., 2012).
Therefore, discovering novel therapeutic targets is of critical importance.
Since their discovery in 1993 (Lee et al., 1993), miRNAs have emerged as key regulators
in numerous physiological and pathological processes. miRNAs are highly conserved, singlestranded, non-coding RNA molecules ~22 nucleotides in length. miRNAs repress gene
expression by inhibiting translation of and/or facilitating the degradation of their target mRNAs
via binding to the 3’UTR. Because only partial complementarity is required for miRNA-mRNA
interactions, a single miRNA can potentially regulate hundreds of mRNA transcripts. Testing the
potential therapeutic opportunity of dysregulated miRNAs in any particular disease requires a
careful analysis of the miRNA expression changes in the target tissues.
Using animal models, miRNAs have been studied as potential therapeutic targets in a
wide array of diseases, including cancer (Kota et al., 2009), heart failure (Small and Olson,
2011), blood disorders (Patrick et al., 2010), and multiple sclerosis (O'Connell et al., 2010;
Ponomarev et al., 2011). Notably, one study of miRNA in disease is now progressing beyond the
animal model. Santaris Pharma developed an antisense oligonucleotide inhibitor against miR122, called Miriversen, found to be critical to hepatitis C viral replications (Lanford et al., 2010).
The authors have continued to complete a successful Phase I (Janssen et al., 2011) and Phase IIa
trial (NCT01200420) (Janssen et al., 2013). These clinical trials shows that despite the vast
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number of potential mRNA targets for each miRNA, miRNAs remain both powerful and realistic
therapeutic targets.
Studying miRNA dysregulation and ALS, Williams et al discovered that miR-206 is
critically important in the organization of neuromuscular synapses and that miR-206 knockout
mice display increased ALS disease acceleration (Williams et al., 2009). However, the authors
did not study a rescue effect by increasing miR-206, nor did they study the brain or spinal cord.
Nevertheless, this study demonstrates that one particularly miRNA can clearly affect ALS.
The SOD1G93A transgenic mouse model was developed by Gurney et al. in 1994 based
on a dominantly inherited ALS-causing mutation in patients (Gurney et al., 1994). These
animals overexpress mutant human SOD1 protein with a glycine to alanine switch at position
93. SOD1G93A mice and rats are born at normal Mendelian ratios and develop normally. At 3
months of age, SOD1G93A mice and rats begin to lose weight and develop atrophy in hind limb
muscles. This phenotype progresses rapidly with paralysis typically occurring at 160 days of
age. For ethical considerations and to allow the collection of tissues, mice are euthanized when
unable to right themselves within 30 seconds of being placed on their backs. The SOD1WT
transgenic line has no overt phenotype.
TDP-43 was identified biochemically as a component of aggregates associated with
ALS and Frontotemporal Dementia (Neumann et al., 2006). Subsequently, in 2008, an ALS
causative mutation in TDP-43 was identified, and all TDP-43 mutations are thought to account
for ~5% of familial ALS (Gitcho et al., 2008; Kabashi et al., 2008). A transgenic mouse line
was then developed that expresses this human mutation, TDP-43A315T (Wegorzewska et al.,
2009). TDP-43A315T mice develop progressive weakness and difficulty walking associated with
loss of motor neurons and ubiquitinated inclusions in motor neurons and layer V cortical
38

neurons (Wegorzewska et al., 2009; Wils et al., 2010). Spinal cords and brains from these mice
show neuron loss, as well as astrocyte and microglial activation (Wegorzewska et al., 2009).
Due to a gender disparity in survival times, all of our TDP-43 mouse data presented here focus
on TDP-43 male mice. This line has since come under controversy for having an obstructive
bowel phenotype that eclipses a phenotype that would result from classical motor neuron loss in
the brain and spinal cord (Hatzipetros et al., 2013). Therefore, our use of this line is as a second
confirmation of interesting miRNAs and not as a primary source in generating dysregulation
lists. By using two genetic models for validation, top priority miRNAs can be more rigorously
chosen for future large-scale therapeutic experiments that have a greater chance of success for
translating to ALS patients broadly.
While a number of drugs tested in the SOD1 model have subsequently failed in human
clinical trials, we have taken steps to increase the translational potential of our use of this
preclinical model. We only considered important those miRNAs increased in both the rodent
ALS model and in patient ALS tissue from both familial and sporadic ALS patients. Also,
antisense oligonucleotides have been tested in a Phase I trial in SOD1 human ALS, suggesting
this type of strategy to be safe and realistic (Miller et al., 2013).
In 2007, miRNAs were found in exosomes which are 50-90 nm vesicles present in
biological fluids thought to be important in cell signaling (Valadi et al., 2007). Exosomes are
actively secreted by a myriad of immune and inflammatory cell types including T cells, B cells,
dendritic cells, and macrophages. miRNAs were soon after identified as potential diagnostic
molecules in serum, where, for example, miR-141 could distinguish patients with prostate cancer
from healthy controls (Mitchell et al., 2008). Adding to the usefulness of miRNAs as potential
biomarkers is their extreme stability in biofluids including protection from repeated freeze thaw
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cycles (Mitchell et al., 2008) and a high level of reproducibility between individuals and multiple
extractions (Chen et al., 2008). There have since been a plethora of studies with miRNAs serving
as potential biomarkers in serum and plasma for various cancers (reviewed: Reid et al., 2011),
heart disease (Adachi et al., 2010), sepsis (Wang et al., 2010), and multiple sclerosis (Siegel et
al., 2012).
In order to confidently determine the ability of our target miRNAs to serve as biomarkers
in ALS, we had to first identify a reliable method for quantifying miRNAs. Criteria included a
high yield in extractions, low noise in extractions from the same biofluid source, and an ability to
successfully measure miRNA levels in a dilution curve experiment. To this end, we compared
the most popular miRNA extraction methods and performed a methods screen and optimization
prior to application to ALS serum.
The young field of miRNA research is quickly becoming a leader in the identification of
novel disease pathways while identifying promising therapeutic targets (Jackson and Linsley,
2010; van Rooij et al., 2012). With well-established ALS rodent models and ALS patient autopsy
tissue banks, the first step to identify miRNAs interesting to ALS mechanistically and
translationally requires the formation of a well-validated list of dysregulated miRNAs both in the
rodent model and in patient tissue. Determining the time-course of these miRNA changes will
inform intervention potential, and miRNA patient biomarker research could potentially identify
predictive and prognostic biomarkers as exists for various other diseases.
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MATERIALS AND METHODS
Animals
All animal protocols were approved by the Institutional Animal Care and Use
Committee of Washington University at St. Louis and adhered to NIH guidelines. Animals were
provided food and water ad libitum, and cages were changed once a week. All mice were
maintained in a 12-hour light/12-hour dark cycle and received routine veterinary monitoring.
TDP-43A315T mice were sacrificed for tissue harvesting at end-stage of disease as evidenced by
sudden quiescence following touch, typically at ~90 days of age. SOD1G93A mice were sacrificed
for tissue at either pre-defined time points throughout disease or at end-stage, evidenced by an
inability to right itself within 30 seconds of being placed on either side.
For tissue harvesting, mice were first anesthetized with isoflurane before being
perfused with 20-30mL of PBS. Whole spinal cords and/or 30mg of cortex were then isolated
and flash frozen. All mice used in this chapter were on a pure C57BL/6 background.
LPS
Lipopolysacharide from Escherichia coli O111:B4 (LPS, Sigma) was diluted in PBS
and injected into 10-week nontransgenic male mice at either 0.2mg LPS/kg mouse mass (6x105
endotoxin units/kg) or 0.1mg/kg (3 x 105 endotoxin units/kg). After 1 hour, mice were sacrificed,
perfused, and tissue harvested.
BV-2 cells were plated at 50% confluency in a T-75 flask before being treated with
100ng/mL LPS for 24 hours. Cells were lysed in Qiazol and miRNAs were extracted.
Human tissues
Patient tissues were analyzed with approval from the Institutional Review Board from
Washington University and Massachusetts General Hospital. Spinal cord autopsy tissue was
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obtained from 16 ALS patients (9 male, 7 female; age range 34-79, mean 64; from Washington
University School of Medicine, Massachusetts General Hospital) and 12 non-ALS control
patients (6 male, 6 female; age range 51-80, mean 70; from National Disease Research
Interchange; clinical information in Table 2.2. Postmortem intervals ranged from 1 to 40 hours.
miRNA quantification
RNA was extracted from flash frozen tissue using miRNeasy kits per manufacturer’s
instructions (Qiagen). Mouse RNA integrity and yield were assessed by Nanodrop before
diluting to 150ng/µL for microarray assays and 2ng/µL for miRNA individual assays. miRNA
microarrays were performed without amplification using low density Rodent MiRNA A+B cards
sets 3.0 (Life Technologies) using a 7900HT quantitative real time polymerase chain reaction
(qPCR) machine for 40 cycles. Analysis was conducted on SDSv2.2 software with automatic
thresholding. Microarray hits were confirmed with individual TaqMan miRNA assays (Life
Technologies) as per the manufacturer’s instructions. RNA from patient autopsy samples were
also quantified via Nanodrop and diluted to 2ng/uL. All rodent miRNAs were normalized to
endogenous U6, and human miRNA values were normalized to total RNA input. qPCR samples
were quantified in technical duplicates on an Applied Biosystems 7500 fast Real-Time PCR
System.
Serum/Biomarker extraction methods
For isolating serum, up to 10mL patient blood was collected in a non-additive, siliconecoated BD vacutainer tube (red cap). Following a 30 minute to 1 hour room temperature rest,
blood was centrifuged at 2,000g for 15min at 4oC. The top, serum layer was then aliquoted to
1.5mL microcentrifuge tubes before centrifuging at 2,000g for 3min at 4oC. The supernatant was
then transferred to a new microcentrifuge tube until being stored at -80oC. Blood was always
42

attempted to be collected from an ALS patient and a non-ALS control volunteer within 10
minutes for paired processing and analysis.
For methods optimization, patient serum was pooled in order to create a homogenous
mixture, sufficient to serve as input for all methods being compared within a given experiment.
Four methods were used for miRNA extraction from serum all according to vendor published
protocols: (1) miRCURY RNA Isolation Kit – Biofluids (Exiqon), (2) mirVana miRNA Isolation
Kit (Life Technologies), (3) miRNeasy Serum/Plasma Kit (Qiagen), (4) TRIzol LS. 5.6 x 108
copies of cel-39 spike-in control (Qiagen) was added to each 200uL serum aliquot prior to
extraction. 1ug MS2 RNA (Roche) was added to 200uL serum input, as indicated, also prior to
beginning the extraction protocol. For the serum dilution, methods optimization experiment,
200uL serum was either undiluted or diluted 4:1, 3:2, 2:3, or 1:4 with PBS prior to the addition
of spike-in and MS2 and prior to commencing the extraction protocol.
Statistical analysis
Data are presented as mean ± SEM. All statistical tests were conducted with Graphpad
Prism 6 Software. Gene expression data from end-stage tissue was analyzed with a 2-tailed
Student t test. Quantification of miR-155 in patient populations which was analyzed by ANOVA
followed by Tukey’s post-hoc test. The time course of miRNA changes were analyzed by
ANOVA followed by Dunnett’s multiple comparison test.

RESULTS
6 miRNAs are significantly upregulated in rodent and patient ALS spinal cord tissue.
To identify miRNA therapeutic targets for ALS, we measured miRNA changes in both
the rodent ALS model and in human ALS autopsy samples. Using TaqMan miRNA microarrays
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that assayed 673 miRNAs, we measured miRNA expression levels in both end-stage mouse and
rat spinal cord tissue as compared to their age matched controls. First, in order to generate a
manageable list of most significantly and robustly changed miRNAs to carry forward to in vivo
intervention experiments, we first considered miRNAs either upregulated or downregulated more
than 2 fold in the ALS-model mice at p<0.05. From the 43 resulting miRNAs, we next only
considered miRNAs changed more than 1.5 fold at p<0.2 in the ALS-model rats as compared to
both nontransgenic and SOD1WT controls. 12 miRNA were identified as significantly increased
in both ALS models (Table 2.1).
Using individual miRNA assays, 11 miRNAs were confirmed increased in the mouse, 10
in the rat, and 6 in patient ALS autopsy spinal cord tissues (Fig 2.1A-C). 16 patient ALS autopsy
samples were compared to 12 controls, whose clinical diagnosis and demographic information is
detailed in Table 2.2. Specifically, the most researched amongst these hits, miR-155, was
significantly increased in both familial and sporadic patient ALS spinal cord tissue (Fig 2.1D).
Total RNA integrity from our autopsy spinal cord samples was poor as determined by Agilent
Bioanalyzer; however our miRNA experiments showed well-shaped qPCR amplification curves,
high amplification, low noise, and high consistency between samples and even between multiple
extractions from the same spinal cord. Furthermore, RNA integrity numbers (RIN) did not well
correlate with miRNA qPCR counts (Fig 2.2). This is in agreement with published data showing
miRNAs to be stable despite extensive degradation of mRNA (Hall et al., 2012).
Among the list of dysregulated miRNAs in ALS model mice and human ALS samples,
miR-155 appeared to be an excellent first therapeutic target because of its abundance and fold
change in ALS and extensive prior work linking miR-155 with immunity and inflammation
(Landgraf et al., 2007; O'Connell et al., 2007; Wang et al., 2009). To further validate and
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characterize this targets, we continued analysis from the SOD1G93A ALS-model rodent model to
the TDP-43A315T ALS/FTD mouse model. miR-155 was increased 1.8 fold in TDP-43A315T mouse
spinal cords as compared to nontransgenic age-matched controls (p<0.05) (Fig 2.3).
miR-155 expression levels increase upon LPS treatment, both in the mouse cortex and in
microglia culture.
Next, to test if miR-155 upregulation might be a result of inflammation in the central
nervous system as is true in the periphery (O'Connell et al., 2007), we injected adult
nontransgenic mice with two doses of LPS. After one hour, their perfused brain was collected,
and miR-155 was significantly increased. Finally, to determine if this increase could be
contributed by microglial cells, we treated BV-2, an immortalized murine microglia cell line,
with LPS for 24 hours and found a robust 14-fold increase in miR-155 levels. (Fig 2.3).
miR-142-3p, miR-146a, and miR-155 are upregulated at a mid-disease stage in SOD1G93A
mice and are all well correlated.
Three of the miRNAs identified to be robustly and significantly increased in end-stage
ALS-model rodent tissue and in ALS patient autopsy tissue (Fig 2.1) were further evaluated to
determine when this upregulation occurs in disease. For this, miRNA levels were measured from
the spinals cords from 3 male and 3 female perfused mice at 9, 12, 15, 18, and 21 weeks of age
with an additional set of spinal cords collected at end-stage (approximately 24 weeks of age). For
all 3 miRNAs, a small trending increase was observed at 15 weeks of age (1.4-1.8 fold increase
over 9 weeks) with robust differences were observed at 18 weeks of age (2.5-3.4 fold increases)
(Fig 2.4).
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Pearson correlation values were then determined for each pairing of these 3 miRNAs
using the 36 spinal cords from the time course study. miR-142-3p, miR-146a, and miR-155 had a
near perfect correlation with Pearson Correlation values ranging from 0.98 and 1.0. (Fig 2.5).
miRNEasy provides highest yield and least noise in quantifying miRNAs from patient
serum, but 3 target miRNAs remain unchanged in ALS serum.
Three distinct experiments were conducted in order to find the optimal method for
miRNA extractions from patient serum. For each, patient serum aliquots were combined to
create a homogenous pool of serum sufficient to be input for all extractions. First, triplicate
extractions were performed for 4 methods with and without the RNA carrier MS2: Trizol LS
(non-column based), miRCury, miRNeasy, and miRVana. Two miRNAs, miR-24, and miR196b, were quantified using Taqman primers. miRVana extractions resulted in the highest level
of noise (Fig 2.6 A-D) and also the lowest yield (E,F) and was therefore no longer considered in
methods optimization. Next, the remaining best 5 methods were compared again in their yield
and noise in performing 4 extractions from the same pool of patient serum. Trizol extractions
without the aid of a purification column resulted in the most noise and lowest yield relative to
miRNEasy and miRCury. Furthermore, the RNA Carrier MS2 served to increase yield and
reduce noise (Fig 2.7).
The final two methods, miRNEasy + MS2 and miRCury + MS2 were compared in three
ways: 1) their ability to accurately measure a dilution series; 2) their noise between duplicate
extractions; 3) their miRNA yield. For this, patient serum was again pooled, but also diluted in
PBS to create 100%, 80%, 60%, 40%, 20%, and 0% serum in PBS aliquots. Three miRNAs were
quantified from duplicate extractions from each of these dilutions for both methods. The
measured amount of miRNA from miRNEasy + MS2 extractions much more closely followed
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the predicted values with less noise (Fig 2.8). Furthermore, miRNEasy + MS2 resulted in
roughly twice the yield of miRCury (Fig 2.9) and was therefore chosen as the method to measure
miRNA in ALS patient serum.
miR-142-3p, miR-142-5p, and miR-155 levels were measured in serum from 27 ALS
patients and 17 controls using the miRNEasy + MS2 extraction method. miR-103 was also
measured to be tested as a putative control. While miR-103 normalization did reduce overall
noise, regardless, all 3 target miRNAs showed no significant or even trending difference in ALS
serum as compared to controls (Fig 2.10 A,C). For 17 ALS patients, blood was also collected
from a healthy volunteer at the same time in order to control for any variations in the handling of
the serum or the time to processing. When measuring these three target miRNAs in a paired
analysis, the signal remained consistent between ALS patients and controls (B, D) showing these
three miRNAs to not be suitable ALS serum biomarkers at this time.

DISCUSSION
To determine the therapeutic potential of targeting miRNAs in ALS, we first generated a
list of miRNAs changed in the SOD1G93A rodent model. Six of these miRNAs identified in the
ALS rodent model are also upregulated in familial and sporadic human ALS spinal cord.
Interestingly, all 6 of the patient-confirmed upregulated miRNAs (miR-24-2*, miR-142-3p, miR142-5p, miR-146a, miR-146b, and miR-155) are well studied in the context of immunity and
inflammation. Each of these targets may be potential candidates for therapies for
neurodegenerative disease and testing them will require a similar approach to that highlighted in
chapters 4 and 5 for miR-155. Given the high level of correlation for at least 3 of these targets,
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the most potent effect on modulating disease phenotype and underlying mechanism may be a
combinatorial strategy in which multiple related miRNAs are modulated in concert.
Quantifying when dysregulation begins for our target miRNAs in the ALS model is
important for two reasons. First, it can help inform the underlying mechanism that drives the
upregulation. This concept is further discussed in chapter 5. Second, if the miRNA is a negative
regulator of disease, it is important to know when to target it in any future intervention
experiment. For the three miRNAs measured, an increase in expression is seen at 15 weeks of
age that becomes robust at 18 weeks of age with typical survival being 24 weeks. This affords a
broad time range for potential therapeutic intervention.
While forming a list of dysregulated miRNAs in ALS is mostly descriptive, some insight
into underlying mechanism driving these expression changes can be garnered by correlating the
data with the timing of various pathways in ALS pathogenesis (Turner and Talbot, 2008). These
pathogenic correlations will be further addressed in chapter 5, but the miRNA time course
changes are being presented here as they also inform the therapeutic intervention potential and
the identification of interesting dysregulated miRNAs. In developing a list of our best candidates
for future intervention studies, we wanted to ensure that miRNAs of interest changed at an early
or mid-disease point in our mouse model of ALS. For miR-142-3p, miR-146a, and miR-155,
upregulation occurs at a mid-disease stage roughly one month before the end-stage of disease.
This is a sufficiently long window to allow for therapeutic experiments using miRNA inhibitors
in vivo.
Interestingly, all three miRNAs for which time course data were generated showed a near
perfect correlation. This suggests that these miRNAs, while located on separated chromosomes,
likely result from the same pathological change during ALS. Our best predication of this driving
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force is the influx and activation of inflammatory mediators (Chiu et al., 2008; Chapter 5). These
data also suggest that the most robust effect in intervention studies may arise from a multi-target
approach to prevent compensatory effects of these tightly regulated miRNAs; however, these
ambitious multi-target experiments are beyond the scope of this dissertation.
Growing controversy exists on the usefulness of the ALS-rodent model as more clinical
trials fail to translate rodent targets to patients (Benatar, 2007; Perrin, 2014). This may be due to
the single genetic mutation, SOD1G93A, most often being studied in mice to then apply to patients
who 98% do not harbor this mutation. Also, many targets found in the rodent are not validated as
applicable to patients. We aimed to strengthen our target list in two ways against these justified
concerns. First, we used the TDP-43A315T mouse line as a second validator of our top miRNA hit
before deciding to continue with more ambitious intervention experiments. Second, we used
human autopsy tissue from both familial and sporadic ALS patients to validate our miRNAs of
interest. The stringency used in identifying dysregulated miRNAs in ALS potentially caused
some interesting miRNAs to be overlooked but served to increase confidence and reduce the
number of false positive targets, which is an important consideration given the climate of failed
clinical trials based on rodent research.
Research into the usefulness of miRNAs diagnostic and prognostic biomarkers has been
rapidly expanding. In 2012, it was shown that miR-155 is increased in peripheral monocytes
(CD14+,CD16+) from ALS patients compared with controls (Butovsky, 2012). These data
independently corroborate the increased miR-155 levels that we found in human ALS spinal
cords. One exciting feature of a miR-155 focused trial is the ability to define patients for whom
miR-155 is clearly increased prior to enrolling in the clinical trial. Since this may be a key
component of inclusion criteria for clinical trial, it will be important to independently confirm
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these data. However, serum is experimentally easier and faster to isolate than peripheral blood
mononuclear cells. The ability to use serum would allow us to greatly expand the number of
patients/correlations because we could rely on >1000 banked serums. For these reasons, we
performed a careful experiment to optimize miRNA extraction from serum. After finding a very
good method that showed great reproducibility and low noise, we screened 27 ALS patient
samples and 17 controls for three of our miRNA hits. While discouraging that our top targets
appear unchanged in serum, we may be able to better rely on peripheral blood mononuclear cells
for future miR-142, miR-146, and miR-155 studies. In the meantime, there may be novel miRNA
targets from the serum that were eclipsed in our spinal cord tissue based analysis. We are now
well equipped to study this with the methods and biofluids available.

CONCLUSION
We have successfully generated a well-validated list of miRNAs robustly changed in the
rodent ALS-model and in patient autopsy spinal cord tissue. These miRNAs appear changed in
mid- to late-disease stage and are well correlated. Despite not being a robust biomarker in ALS
serum at this point in time, these targets remain exciting targets for ALS research going forward
given their abundance, their fold change, and their corroboration across ALS models. miR-155
specifically was increased 5-fold in the SOD1G93A ALS model mice, 2-fold in the TDP-43A315T
ALS-FTD model mice, and 2-fold in human spinal cords, and this microRNA served as our
priority therapeutic target moving forward to intervention experiments in ALS-model mice.
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Figure 2.1: miRNA array changes were confirmed in mouse, rat, and human spinal cord
tissues. (A) Using individual TaqMan miRNA assays, 11 out of the 12 miRNA microarray hits
were confirmed significantly increased in end-stage mouse spinal cord tissue (n=5-6). (B) In rat
lumbar spinal cord tissue, 10 out of the 12 miRNAs tested were increased in end-stage SOD1G93A
rats over nontransgenic and overexpressing SOD1WT age-matched controls (n=4,4,4). (C) In
autopsy spinal cord samples from 16 ALS patients and 12 non-ALS controls, 6 miRNAs assayed
were significantly increased in the ALS tissue. (D) Specifically, both sporadic and familial ALS
patients showed a significant increase in miR-155 (n=12 controls; 1.7x increase in n=11 sporadic
ALS; 1.7x increase in n=5 familial ALS; ANOVA with Tukey’s post-hoc test). (RQ=relative
quantification. SC = spinal cord. *p<0.05, **p<0.01, ***p<0.001.)
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Figure 2.2: miRNA abundance is not well correlated with total RNA Integrity. RNA was
extracted from 28 patient autopsy spinal cord tissues and analyzed by Agilent Bioanalyzer to
determine RNA integrity numbers (RIN). ALS samples had an average RIN of 4.0 (SE = 0.28),
and control samples had an average RIN of 4.9 (SE = 0.38). miRNA abundance for all
microarray hits were determined by qPCR and normalized to respective biogroup (non-ALS
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controls or ALS). RIN values were correlated with the relative expression of microarray miRNA
hits, showing poor correlation between RNA integrity and miRNA abundance. (RQ=relative
quantification)
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Figure 2.3: miR-155 is increased in an ALS-FTD mouse model and following LPS challenge
in vivo and in vitro. (A) 4 TDP-43A315T mice showed a 1.8 fold increase of miR-155 in spinal
cord tissue as compared to nontransgenic age-matched controls (p<0.05). (B) 10-week
nontransgenic male mice showed a step-wise increase of miR-155 in cerebral cortex one-hour
after an intraperitoneal LPS injection (n=3 per group; LPS full dose = 0.2mg/kg, 6x105
endotoxin units/kg, from Escherichia coli, p<0.05 for full LPS compared to saline). (C) LPS
treatment (24 hours, 100ng/mL) increased miR-155 14.3 fold in an immortalized microglia cell
line (BV2). (RQ = relative quantification.)
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Figure 2.4: Expression levels for miR-142-3p, miR-146a, and miR-155 significantly increase
in SOD1G93A C57BL/6 mice between 15 and 18 weeks of age. Whole spinal cords were
collected from 3 male and 3 female perfused mice at 9, 12, 15, 18, 21 weeks of age and at endstage (approximately 24 weeks of age). Taqman miRNA RT-qPCR primers were then used to
determine the time course for upregulation of 3 key miRNAs. While a slight trend towards
upregulation is seen at 105 days, robust differences are observed starting at 126 days of age. End
stage tissues were collected when the mouse was unable to right itself within 30 seconds of being
placed on either side. (ANOVA with Dunnett’s multiple comparison test; all comparisons
against 63-day data. (mean +/- SE; *p<0.05, ***p<0.001, ****p<0.0001.))
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Figure 2.5: Upregulation of miR-142-3p, miR-146a, and miR-155 is very well correlated in
SOD1G93A mice. 36 mice at various stages in disease progression had their miRNA expression
levels quantified in ALS-model spinal cord tissue and compared. For all 3 miRNAs tested in this
fashion, expression levels were tightly correlated with the Pearson Correlation between 0.98 and
1 for the 3 pairwise comparisons.
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Figure 2.6: Trizol, miRCury, and miRNEasy extraction methods result in lower coefficients
of variation following miRNA extraction from serum as compared to miRVana. Patient
control serum was pooled, mixed, and aliquoted for miRNA extraction using 7 methods in
triplicate. The use of an RNA carrier, MS2, generally resulted in lower coefficients of variation
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between triplicates. (A-D) miRVana had the greatest level of noise and was therefore ruled out as
an optimal extraction method going forward. Relative expression levels are shown where each
extraction method is normalized to itself such that noise is displayed independent of yield. (E,F)
Relative expression is shown relative to miRVana, whose average from triplicate extractions is
set to 1. Trizol, miRCury, and miRNEasy extraction methods result in much greater yield
following miRNA extraction from serum as compared to miRVana. For two example miRNAs,
miR-24, and miR-196b, miRVana resulted in 20-50 fold less yield as compared to other miRNA
extraction methods. Trizol + MS2 extraction method resulted in the greatest yield. (c.v. =
coefficient of variance; mean +/- SE)
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Figure 2.7: miRNEasy + MS2 and miRCury + MS2 extraction methods resulted in the
greatest yield and least noise when used to extract miRNA from patient serum. To further
optimize miRNA extraction from serum, the best 5 methods were compared again in their yield
and noise in performing 4 extractions from the same pool of patient serum. Trizol extractions
without the aid of a purification column resulted in the most noise and low yield relative to
miRNEasy and miRCury. Furthermore, the RNA Carrier MS2 served to increase yield and
reduce noise. (mean +/- SE)
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Figure 2.8: miRNA expression from miRNEasy extractions best follows predicted values
from diluted patient control serum. The best two methods were compared in their ability to
quantify 3 miRNAs from pooled patient serum that was diluted in PBS in the designated
amounts, performed in duplicates. Red dots show expected values. For all 3 miRNAs, miRNEasy
values more closely matched the expected quantification. Expression levels are normalized to
undiluted serum input for each method such that noise and expected values are shown, but not
overall yield. (mean +/- SE)
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Figure 2.9: miRNEasy serum miRNA extractions result in two fold greater yield as
compared to miRCury. Relative quantification values are shown for miR-24, miR-103, and
miR-191 following duplicate patient serum miRNA extractions at the designated dilution
amounts. Data is shown relative to undiluted miRNEasy extractions for each miRNA. miRcury
extractions resulted in lower yields for all 3 miRNAs measured. (mean +/- SE)
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patient serum as compared to controls. miRNA was extracted from 27 ALS patients and 17
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putative miRNA control. (A) miR-142-3p, miR-142-5p, and miR-155 all show similar levels in
ALS patients and in controls. (B) For 17 ALS patients, serum was collected from a healthy
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trending changes were observed for the 3 miRNAs of interest. (C, D) Noise was reduced
following normalization to miR-103 showing this to be a potentially valid control, but no
significant or trending changes in miRNA expression levels were observed in ALS patients.
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Mouse
RQ:
SOD1G93A/NonTG

miR-17
miR-19b
miR-20a
miR-24-2-5p
miR-106a
miR-142-3p
miR-142-5p
miR-146a
miR-146b
miR-155
miR-223
miR-338-3p

2.66
2.51
2.33
2.44
2.59
3.36
3.27
8.86
3.02
2.08
3.52
2.27

Rat
T-test

0.00
0.00
0.01
0.02
0.01
0.04
0.05
0.00
0.01
0.01
0.05
0.01

RQ:
SOD1G93A/NonTG

T-test

SOD1G93A/SOD1WT

T-test

1.99
1.99
1.79
1.78
2.11
3.81
10.61
3.89
1.84
20.08
1.89
1.75

0.04
0.10
0.10
0.06
0.01
0.06
0.17
0.02
0.04
0.20
0.14
0.16

11.58
9.20
20.60
3.22
11.14
24.84
2.94
8.79
2.95
58.75
10.25
5.33

0.00
0.02
0.01
0.00
0.00
0.02
0.34
0.01
0.01
0.19
0.02
0.03

RQ:

Table 2.1: 12 miRNAs are altered in end-stage ALS mouse and rat spinal cords by
microarray. miRNAs were isolated from end-stage SOD1G93A mouse and rat spinal cords and
from age-matched non-transgenic (NonTG) controls (n=3-4). For rats, miRNAs were also
isolated from age-matched SOD1WT control spinal cords (n=3). 673 miRNAs were assayed using
Applied Biosystem’s TaqMan Rodent Array A+B Cards v3.0. 434 miRNAs amplified and were
quantified. For mice, 6 miRNAs were decreased and 37 miRNAs were increased greater than 2
fold at p<0.05. From these 43 miRNAs, 12 were also changed >50% in the rat samples at
p<0.20. RQ = relative quantification.
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Age Sex Cause of death
Other diagnoses
59
F
Colon cancer with mets Hypertension
Coronary artery disease, diabetes, hypertension,
60
F
Diabetic ketoacidosis
depression, stroke
Chronic
obstructive
69
F
pulmonary disease
none
71
F
Dementia
Hypertension, depression, osteoporosis
Coronary artery disease, hypertension, stroke,
79
F
Renal failure
COPD, Emphysema
80
F
Pulmonary fibrosis
Hypertension, Epilepsy, Asthma,
Myocardial infarction, hypertension, Diabetes
59
M
Respiratory failure
Type II, stroke,
63
M
Stroke
Hypertension, stroke, myocardial infarction
Congestive heart failure, myocardial infarction,
66
M
Heart Failure
rheumatoid arthritis
Cirrhosis of liver presumed secondary to
72
M
Failure to thrive
alcohol, hypertension
COPD, Diabetes Type II, Atrial Fibrillation,
79
M
Respiratory failure
Congestive Heart Failure
79
M
Stroke
Alzheimer's disease

Table 2.2: Clinical diagnoses and basic demographics for patient controls. Autopsy spinal
cord tissues were obtained from 12 non-ALS control patients for miRNA analysis (provided by
NDRI). Males and females were equally represented, and ages ranged from 59 to 80 years of
age.
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CHAPTER 3

Developing a high-throughput method to determine cell-type specific
expression of microRNAs in glial and neuronal cell types in vivo

69

SUMMARY
In order to understand the regulatory role of microRNAs (miRNAs) in the brain and
spinal cord, it is first necessary to know their cellular expression levels. We have adapted the
miRAP system to quantify miRNAs in neurons, motor neurons, astrocytes, and microglia in a
high-throughput and physiologically relevant method in vivo. By generating mice that express a
GFP-myc-tagged miRNA binding protein, Ago2, using cell type specific promoters, we were
able to isolate active miRNAs from specific cell populations by performing anti-myc
immunoprecipitation. These experiments have allowed the generation of large datasets of
endogenous controls, brainstem specific vs spinal cord enriched miRNAs, and neuronal vs. glial
enriched miRNAs. We have applied this system to inform our previously identified dysregulated
miRNAs in ALS and found miR-142-3p, miR-142-5p, miR-146a, and miR-155 to be highly
enriched in microglia in vivo. Specifically, miR-155 was 326 times more abundant in spinal cord
microglia over spinal cord motor neruons. These data inform our future mechanistic experiments
on the role of anti-miR-155 treatment in mice, describes expression patterns for hundreds of
miRNAs, and may serve as a resource in the study of numerous physiological and pathological
cellular processes.

70

INTRODUCTION
miRNAs are recently-discovered, small, non-coding RNAs that regulate translation of
coding RNAs. Typically, miRNAs direct translational repression by binding to the 3’UTR of
mRNAs after first being incorporated into Argonaute2 (Ago) containing RNA-induced silencing
complexes (RISC) (Gregory et al., 2005). Although emerging data clearly suggest miRNAs can
be powerful regulators of physiological and pathological cellular processes, the role of most
miRNA remains relatively undescribed, and how these miRNAs affect neurodegenerative
diseases remains unexplored. Our own recent research demonstrates that miR-155 is particularly
important for the progression of ALS, a severe, rapidly progressive neurodegenerative disease
that disproportionately impacts motor neurons in the spinal cord (Koval et al., 2013). One of the
major hurdles to understanding the role of miR-155 and other miRNAs in the disease process is
the lack of basic information about which miRNAs are expressed in which cell types in the
central nervous system.
Obtaining cell type specific miRNA information is challenging. The most popular current
methods for achieving this are fluorescence activated cell sorting (FACS), laser capture
microdisections (LCMs), cell culture models, and in situ histology; however, each of these
methods has significant limitations. For both FACS and LCM, oftentimes only the neuronal cell
body is acquired at a loss of miRNAs present in the synapses (Lugli et al., 2005) and the
dendrites (Tai and Schuman, 2006). Furthermore, both of these methods require cell
manipulations ex vivo that are inherently stressful and will create cell damage and alter gene
expression. Next, cell culture models, while convenient, often lack physiological relevance.
Finally, in situ’s are difficult, expensive, and only serve to assay a single miRNA at a time.
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Due to these limitations in current methods, we were motivated to translate the novel
BAC-TRAP method of isolating mRNAs to the isolation of miRNAs. With BAC-Translating
Ribosome Affinity Purification (TRAP), mice were generated using BAC constructs that express
EGFP-L10a, a ribosomal protein, under control for specific cell-promoters. Since most active
mRNAs are coupled with the ribosome, immunoprecipitating (IP'ing) GFP (tagged to ribosomal
protein) from brain tissue pulled down active mRNA from only that specific cell population
(Dougherty et al., 2010; Doyle et al., 2008; Heiman et al., 2008). We were interested in adapting
this methodology to miRNAs.
Since most miRNAs in a cell are linked to the miRNA processing protein Ago2
(Hammond et al., 2001), affinity purification via antibodies to Ago2 can be used to capture
miRNAs from tissue lysates (Chi et al., 2009). Furthermore, by expressing a GFP-myc-tagged
version of Ago2 only in a particular cell type such as motor neurons, we can use myc or GFP
antibodies to isolate the miRNAs from just this particular cell type. While we were generating
BAC transgenic mice that expressed GFP-Ago2 behind cell type specific promoters, He et al.
developed a method to achieve GFP-Ago2 expression within particular cell types using a CreLox system. They coined this method miRAP, miRNA tagging and affinity purification. Cre
recombinase is an enzyme that can recognize a pair of LoxP sequences in the genome and
recombine them to excise the intervening DNA. By crossing various neural Cre recombinaseexpressing mice (Camk2α, Gad2, PV, SST, L7) to their newly generated lox-stop-lox-GFP-mycAgo2 mice, the authors were able to express GFP-myc-Ago2 in specific glutamatergic and
GABAergic cell populations. Following lysing and immunoprecipitating whole mouse brains,
the authors were able to define a list of miRNAs with differential expression patterns in distinct
neuronal cell sub-types (He et al., 2012).
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In order to test miRNA expression levels in neuronal vs glial cell populations, we created
double transgenic mice that express lox-stop-lox-GFP-myc-Ago2-GFP and cell-specific Cre
drivers using the following promoters: Synapsin1 (Syn) to label neurons, Choline
acetyltransferase (ChAT) to label all cholinergic neurons including motor neurons, glial fibrillary
acidic protein (GFAP) to label astrocytes, and lysozyme 2 (Lyz2) to label myeloid cells
including microglia in the brain and spinal cord (Table 3.1). With these experiments we were
able to generate a database of miRNAs enriched in glial vs neuronal cell types that will aid
research in physiological and pathological roles of miRNAs.

Materials and Methods
Animals
All animal protocols were approved by the Institutional Animal Care and Use
Committee of Washington University at St. Louis and adhered to NIH guidelines. Animals were
provided food and water ad libitum, and cages were changed once a week. All mice were
maintained in a 12-hour light/12-hour dark cycle and received routine veterinary monitoring.
All mice were on a bred on a B6 background. To generate cell-specifc GFP-Ago2
expressing mice, a homozygous (ROSA)26Sortm1(CAG-GFP/EiF2c2)Zjh mouse (Jax ID: 017626) was
bred to one of four-cre lines: Syn-Cre (Jax ID: 004781), ChAT-Cre (Jax ID: 006410), GFAP-Cre
(Jax ID: 004600; previously back-crossed into C57BL/6), Lyz2-Cre (Jax ID: 004781). Mice used
in experiments were heterozygous for CAG-GFP/Eif2c2 and for a cell-specific Cre driver.
For tissue harvesting, mice were first anesthetized with isoflurane before being perfused
with 20-30mL of PBS. Whole spinal cords, whole brainstem and/or 30mg of relevant tissue were
then isolated and flash frozen. Spleens were isolated prior to the perfusion.
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Histology: miRNA in situ and double label cell-type expression
5µm sections of all spinal cords mounted on Superfrost slides and baked at 60°C for 30
minutes. Sections were deparaffinized for 5 minutes in xylene, immersed in 100% ethanol for 5
minutes then treated with protease (1.5 mg/ml pepsin - DAKO) for 30 minutes at room
temperature. The sections were washed and allowed to air-dry. Two LNA miRNA probes, mmumiR-155 and scrambled-miR, were prepared according to the manufacturer’s recommended
conditions (Exiqon), and each was labeled at the 5’ end with digoxigenin (DIG). Probes were
diluted to 1.5 pmol/uL in Exiqon hybridization buffer. Probe solutions were placed on tissue
sections, covered with polypropylene coverslips and heated to 60°C for 5 minutes, followed by
hybridization at 37°C overnight. Sections were treated with anti-digoxigenin – alkaline
phosphatase conjugate (1:150 dilution in pH 7 Tris buffer; Roche) at 37°C for 30 minutes.
Development was carried out with NBT/BCIP (180 µl of Roche solution was added to 15 ml of
titrated alkaline phosphatase detection solution adjusted to pH 9 to 9.5). Development was
closely monitored and stopped when the control sections appeared light blue. In all cases, the
development time with the chromogen was from 30-60 minutes. Sections were counterstained
with nuclear fast red for 3 to 5 minutes, rinsed and mounted with coverslips. For double-label
experiments, Optimal immunohistochemistry for FOX3 was defined as a dilution range of 1:500
to 1:1000 using heat-mediated antigen retrieval for FOX3. Following a 30-minute incubation
with biotinylated secondary antibody, slides were rinsed and incubated in streptavidin-HRP in
PBS for 30 minutes. Following two washes in TBS, slides were incubated in DAB solution for
approximately one-minute – until color development occurred and before significant signal in
control samples. Sections were washes, dehydrated, and coverslipped. Nuance imaging system
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was used to convert brightfield images to fluorescent images to improve ability to determine
double labeling.
For cell-specific determination, free-floating 40uM sections of brain and spinal cord
were washed in PBS and blocked in 5% normal donkey serum, 0.1% triton, in PBS for one hour.
Rabbit-anti-ChAT (1:100, Millipore AB143) or mouse anti-NeuN antibody (1:200, MAB377,
Millipore, MAB377), both with chicken-anti-GFP (1:1000) in blocking solution were applied to
the tissues overnight at 25oC. AlexaFluor488-conjugated donkey anti-goat (A11062, Life
Technologies) was added with either AlexaFluor 594 goal anti-rabbit or goat anti-chicken
(ab150169, Abcam) in blocking buffer to the tissue for one hour. Slides were washed 3 times in
PBS, mounted on superfrost slides, and coverslipped with Vectashield with DAPI (Vector
Laboratories). All slides were observed at 4x, 10x, and 20x objectives using a Nikon Eclipse 80i
microscope fitted with a Photometrics CoolSnap EZ camera. All images were taken at ambient
temperature with a Cy3 or FITC filter. For image acquisition and formatting, NIS Elements 3.0
(Nikon) and Adobe Photoshop v12.0 were used.
FACS/LPS
Lipopolysacharide from Escherichia coli O111:B4 (LPS, Sigma) was diluted in PBS
and injected into the peritoneum of one CX3CR1-GFP positive adult male mouse at 5mg/kg
(1.5x107 endotoxin units/kg) while a second CX3CR1-GFP mouse received a saline injection.
After 4 hours, mice were sacrificed, perfused, and brain and spinal cord tissues were harvested.
Following dissociation with a dounce homogenizer in homogenization buffer, cells were pelleted
and resuspended in 37% Percoll in HBSS. A Percoll gradient was then poured with the desired
cells being located between the 70% and 37% Percoll layers. These isolated cells were then
pelleted and resuspended in Fc-block in FACS buffer. Cells were next incubated in the viability
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marker propidium iodide, anti-CD11b-PE and anti-CD45-cy7 before being washed and sorted
with a BD FACSAria machine directly into Qiazol.
Cell lines
Primary microglia and astrocyte cultures were prepared from P1 mouse pup cortex as
described by others (Skaper et al., 2012; Tamashiro et al., 2012). Briefly, cerebral hemispheres
were collected minus the cerebellum, brainstem, meninges, and hippocampus. Following mild
dissociation, cells were allowed to grow for 2 weeks before undergoing isolation via differential
adherence where following a 2 hour shake, the supernatant contained the desired microglia and
the astrocytes retained adherence. These isolated cell types were then allowed to grow for an
addition 48 hours before being collected for miRNA isolation.
NSC34 cells were transfected with a GFP-Ago2 construct using Lipofectamine 2000
for 24 hours. After an additional 24 hours, transfected NSC34 cell, untransfected NSC34 cells,
and BV2 cells were washed, collected, and counted with a hemocytometer. Cells were diluted in
PBS and combined to create 4 cell solutions: 100% BV2, 50% BV2/50% transfected NSC34,
100% transfected NSC34, 100% untransfected NSC34. Cells were lysed in cold lysis buffer and
half of the mixture was loaded onto an anti-GFP conjugated beads and the other half onto mouseanti-Ago2 conjugated magnetic beads (2E12-1C9; Anova). See miRAP for further details.
Immunoprecipitation/miRAP
(Adapted from He et al, 2013.) Brainstem and spinal cords from 63 day-old male mice
were harvested and flash frozen in liquid nitrogen and stored at -80º C. For array experiments,
IP’s were conducted on 3 double positive mice from each of the 4-cre driver lines and from an
additional 3 nontransgenic controls at the same time for a given tissue type. Whole brainstem or
spinal cord was lysed in 1mL of ice-cold lysis buffer (10 mM HEPES [pH 7.4], 100 mM KCl, 5
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mM MgCl2, 0.5% NP-40, 1 mM DTT, 100 U/mL RNasin Plus (Promega), and EDTA-free
protease inhibitors (Roche)). Tissue was lysed using a hand blender before centrifuging at +4º C
for 30 min at 13,000 g. 10ug of mouse-anti-Myc (sc-40; Santa Cruz Biotechnology) or mouseanti-Ago2 (2E12-1C9; Anova) in 350µL of PBS-Tween was conjugated to 50µL of protein G
Dynabeads (Invitrogen) for 45 min, rotating at RT. Antibody-conjugated beads were washed
three times with 1mL of PBS-Tween to remove any excess antibody. A BCA assay was
performed on all tissue homogenates to normalize input to the lowest protein concentration.
850µL of supernatant or supernatant diluted with lysis buffer were applied to the antibodyconjugated beads and incubated at +4º C for 4 hours with end-over-end rotation. Beads were
washed twice with low-salt buffer (50mMTris-HCl [pH 7.5], 150mM NaCl, 1mM MgCl2, 0.5%
NP-40, 1mM DTT, 100U/mL RNasin Plus) and twice with high-salt buffer (50mMTris-HCl [pH
7.5], 600 mM NaCl, 1 mM MgCl2, 0.5% NP-40, 1 mM DTT, 100 U/ml RNasin Plus). 700µL of
Qiazol was added directly to the beads, and samples were vortexed for 30 sec and stored at -20º
C. The Qiagen miRNeasy kit was used to isolate miRNA.
miRNA Extraction and quantification
RNA was extracted from flash frozen tissue, cells, or immunoprecipitation using
miRNeasy kits per manufacturer’s instructions (Qiagen). For tissue and cells, muse RNA
integrity and yield were assessed by Nanodrop before diluting to 2ng/µL for miRNA individual
analysis using Taqman miRNA probes (Life Technologies). qPCR samples were quantified in
technical duplicates on an Applied Biosystems 7500 fast Real-Time PCR System and normalized
to endogenous U6.
For immunoprecipitations, extracted miRNA was used in quantification assays without
dilution. miRNA microarrays were performed with amplification using low density Rodent
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MiRNA A+B cards sets 3.0 (Life Technologies) using a 7900HT quantitative real time
polymerase chain reaction (qPCR) machine for 40 cycles. Analysis was conducted on SDSv2.2
software with automatic thresholding.
Data analysis and stats
Data are presented as mean ± SEM. All statistical tests were conducted on either excel
or with Graphpad Prism 6 Software. Array data was normalized by a geometric mean of 9
endogenous controls using invariant set normalization. miRNAs were globally compared
between data sets and outliers were excluded following each comparison until 21 miRNAs were
identified. The 9 with the least amount of noise between samples following a first-pass
normalization were then used as a final normalization set for all microarray data. miRNAs were
listed as enriched if they were highly expressed (CT<33 for all 3 mice in a biological group),
consistently expressed (<2CT variation in any biological group), and changed greater than 10
fold at p<0.01. Significance of miR-155 in different cell types was determined using the KruskalWallis non-parametric test at p<0.05.

RESULTS:
miR-155 is expressed in glial cells as determined by FACS and cell culture, and in neurons
as determined by in situ.
First, to determine if miR-155 is dynamically expressed in microglia, one CX3CR1GFP mouse was given an intraperitoneal injection (5mg/kg) while another mouse received a
saline injection. 4 hours later, CD11bhi-CD45hi , GFP+ cells were FACS sorted and quantified
for miR-155 expression (Fig 3.1A). The mouse that received the LPS injection had about a 20fold increase in miR-155 levels (Fig 3.1B). Therefore, miR-155 is likely present in microglia
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cells and is dynamically expressed following immune cell activation. Next to contrast miR-155
expression across different CNS cell types, miR-155 was quantified in primary cortical neurons,
in an immortalized mouse motor-neuron like cells (NSC-34), and in primary microglia and
astrocytes. It was found that miR-155 has about a 500-fold increase in expression in the glial cell
types over the neuronal cell types (Fig 3.1C).
However, upon performing miR-155 in situ’s in human ALS spinal cords, it was found
that miR-155 colocalizes with Fox3, a neuronal marker. Specifically, large alpha motor neurons
were found to be positive for miR-155 (Fig 3.2). No double labeling of miR-155 was observed in
GFAP+ or Iba1+ cells (data not shown).
miRAP: preliminary in vitro experiments and generation of mice
Combining the strategies to pull-down miRNAs with Ago2 immunoprecipitation and
the strategy to quantify mRNA in specific cells by IP of GFP-tagged ribosomes, we developed a
method for quantifying miRNAs using GFP-tagged Ago2 in specific cell populations. To test the
potential of this methodology, we first performed an IP experiment in BV2 and NSC-34 cell
lines. We first identified 2 miRNAs that are relatively specific for cultured microglia like cells,
BV2 (miR-155) and cultured NSC-34 cells (miR-676), (Fig 3.3A-B). With these two pieces of
data, we tested the ability of a GFP IP to enrich for miRNAs bound to Ago2 only in the cells
expressing the Ago2-GFP construct. To test the cell type specific pull down of miRNA, we
transfected NSC-34 cells with a GFP-Ago2 construct. Both miRNAs should be associated with
Ago2, but only the miR-676 (NSC-34 cell specific miRNA) should be associated with GFP since
only the NSC-34 cells were transfected with GFP-tagged Ago2. We first IP’d this combined
lysate with Ago2 antibody and compared miR-676 and miR-155 levels with levels from the
individual lysates (Fig 3.3C). As expected, the levels of each miRNA were roughly equivalent
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compared with the individual lysates. We next immunoprecipitated this same lysate with a GFP
antibody. In this setting we pulled down only 13% of the miR-155 and 600% of miR-676.
Overall, this represents a 44 fold enrichment of the NSC-34 cell specific miR-676 compared to
miR-155 (Fig 3.3D).
Having validated the ability of IP to pull down tagged Ago2 in mixed cell systems, we
generated four mouse lines that express GFP-myc-Ago2 in specific cell populations. The four
Cre-recombinase lines used are used is this study that are specific for 1) all neurons (Syn); 2)
cholinergic neurons/motor neurons (ChAT); 3) astrocytes (GFAP); 4) myeloid cells/microglia
(Lyz2) (Table 3.1). Syn, ChAT, and GFAP are very popular and well characterized Cre drivers
that are specific and consistently expressed in their relevant cell types. Lyz2, however, has had
mouse-to-mouse variability reported and mosaic expression in some hematopoietic-derived cells
(Clausen et al., 1999; Faust et al., 2000). Despite this, Lyz2 is widely considered the best
available driver for studying myeloid cells. The myeloid cells remaining in the perfused brain
and spinal cord are microglia along with in disease, infiltrating macrophages. These Cre
recombinase expressing mice were crossed into loxp-stop-loxp-GFP-myc-Ago2 generated mice
by He et al., 2013 (Fig 3.4). Upon generation of double positive transgenic mice, Cre
recombinase is expressed behind these cell-type specific promoters and serves to excises the
floxed stop sequence resulting in expression of GFP-myc-Ago2 in only the specific cell type.
Having established double positive mice that should theoretically express GFP-mycAgo2 in only neurons, only motor neurons, only astrocytes, or only microglia/myeloid cells, we
performed double-label histology to observe GFP expression patterns throughout the brain and
spinal cord. The Synapsin-Cre double positive mouse showed strong expression of GFP in
NeuN+ cells throughout the brain and spinal cord including in the hippocampus and the spinal
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cord (Fig 3.5A-B). ChAT-Cre double positive mice, however, did not show any expression of
GFP in the hippocampus. Instead, GFP expression was isolated to the habenula, brainstem motor
nuclei, and spinal motor neurons. Two brainstem motor nuclei with clear GFP labeling are
shown in Fig 3.5C-D. For both of these lines, GFP expression appeared cytoplasmic and not
nuclear, in agreement with known Ago2 localization. While the GFAP-Cre line showed faint
double labeling of GFP and GFAP, GFP was undetectable in Lyz2-Cre by histology. We are
actively trying to improve our methods to detect faint GFP. GFP expression in these mouse lines
has been confirmed instead by RNA (data not shown) and by immunoprecipitation experiments.
GFP-myc-Ago2 cell specific expression successfully allows for the determination of cellenriched miRNAs.
Before performing miRNA microarrays, we tested the ability to accurately determine
predicted miRNA cell specific expression patterns by the double positive transgenic mice (cell
specific-Cre+ and loxp-stop-loxp-GFP-myc-Ago2+). For this, we isolated spinal cords from ChatCre+ double transgenic and negative littermate controls. Following an Ago2 IP, we measured
relatively equal amounts of presumed glial (miR-155, miR-142) and neuronal (miR-124, miR676, miR-196b) miRNAs between the mice, as expected (Fig 3.6A). However, upon an anti-Myc
IP, miR-124, miR-676 and miR-196b were highly enriched in only the Chat-Cre+ mice while
presumed glial miRNAs remained at a baseline level of noise (Fig 3.6B). These data demonstrate
that the predicted in vivo enrichment of motor neuron miRNAs is performing as predicted and
confirms our ability to technically complete the experiment.
Having validated our mice and our immunoprecipitation methods, we performed
TaqMan miRNA microarrays (rodent v3.0) in 3 mice from each of the four Cre-driver lines using
both brainstem and spinal cord tissue independently. Each array set consists of 2 microfluid
81

cards in order to increase the number of miRNAs measured. All 24 arrays sets (48 cards) showed
strong expression levels overall. First, because miRNA yield is too low following
immunoprecipitation to be measured by nanodrop, Agilent small RNA chips, or Qubit, we relied
on the identification of endogenous controls within each microarray card to normalize the data.
Upon comparing all 24 data sets to one another, it was clear that miRNAs were normally
distributed with the majority of miRNAs being equally changed between samples with a left- and
right-tail. These outliers were systematically removed until putative endogenous controls
remained. Following normalization of each putative control to a geomean of the set of controls,
the 9 miRNAs with the lowest coefficient of variation were considered the best final endogenous
controls. All miRNAs measured in all samples were therefore normalized to the geometric mean
of these 9 controls: miR-24, miR-26a, miR-29a, miR-29c, miR-30a-3p, miR-30e, miR-191, miR221, and miR-708. Interestingly, one of these miRNAs, miR-191, was a control recommended by
Exiqon for its stable expression across various tissues.
miRNA expression levels were quantified in both a pan-neuronal Cre line (Syn) and in
a motor neuron specific Cre line (ChAT). In comparing miRNAs in the brainstem and the spinal
crods of these mice, over 300 miRNAs were able to be accurately quantified. In the brainstem, 9
miRNAs were identified as significantly diminished in the ChAT mice whereas 12 miRNAs
were highly enriched (Fig 3.7A), and 16 were de-enriched, 9 enriched in ChAT+ cells in the
spinal cord (Fig 3.7B). See the discussion section for further information on some of these
targets.
Next, miRNA expression was compared between neuronal and glial cells. Because the
miRNAs isolated by the IP were assayed in these arrays without dilution or normalization, a
careful survey of endogenous controls was necessary. Upon locating the 9 controls, it was
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discovered that miRNA signal in the Lyz2+ tissues were roughly 6.8CT translated representing
~100 fold decrease in overall miRNA levels. This was not surprising as double label histology
had previously proven difficult in these mice. Also, microglia contain less cytoplasm and are
greatly outnumbered by other cell types in the brain and spinal cord. Nonetheless, upon
application of the endogenous controls, many miRNAs were found to be significantly increased
in only neuronal cells or only glial cells. Some of these were previously validated by others
while others are newly discovered here. Please see the discussion section for further information.
In the brainstem, 18 miRNAs were found to be robustly and significantly enriched in neurons
over both astrocytes and microglia. In contrast, only 2 miRNAs were identified as glial enriched
(Fig 3.8). It should be noted that these lists merely comprise the most striking ‘hits’ from the
array and are not a complete list. In contrast, 8 miRNAs were identified as neuronal enriched
whereas 17 miRNAs were found to be microglia enriched in the spinal cord (Fig 3.9).
We contrasted neuron, motor neuron, astrocyte, and microglia expression between the
brainstem and the spinal cord. Several examples of internal consistency were observed including
that one miRNA significantly increased in spinal cord microglia over brainstem microglia (Fig
3.10), miR-2134, was determined to be upregulated in microglia over neurons and astrocytes
only in the spinal cord (Fig 3.8-3.9), showing consistency across our data. More so, the miR-10
family and miR-196 family were consistently shown to be enriched in cell types in the spinal
cord over the brainstem (Fig 3.10). To further test miR-196 expression, we isolated miRNA
across different tissues in both a nontransgenic mouse and in autopsy tissue from a patient with
ALS. For both of these tissue sets, miR-196 showed a remarkable enrichment selective to the
spinal cord and muscle. Also, lower spinal cord sections showed higher levels of miR-196 over
the cervical spinal cord. Both miR-196a and miR-196b showed similar expression patterns (Fig
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3.11). These data are in agreement with the cell-specific array data from the various cell lines
that show miR-196 to be consistently increased in the spinal cord cells over brainstem for each
cell type.
In applying the miRNA array data from the GFP-myc-Ago2 specific cell type
expressing mice, we aimed to further understand our previous 6 miRNA targets found to be
dysregulated in ALS. Most miRNAs showed similar expression levels while most of our six ALS
target miRNAs showed a trend towards being enrichmed in astrocytes and microglia for both the
braintem and the spinal cord (Fig 3.12). Paricularly, miR-142-3p had the most marked
enrichment in astrocytes and microglia compared to neruons, especially in the spinal cord tissue.
Likewise, in the spinal cord, miR-155 was robustly increaed in both astrocytes and microglia
over neurons. While miR-24-2* showed consistent expression across cell types and miR-146b
only showed mild enrichment in microglia, miR-142-3p, miR-142-5p, miR-146a, and miR-155
were highly enrichmed in microglia in both the brainstem (Fig 3.13A) and the spinal cord (Fig
3.13B). This is consistent with Chapter 2 data showing miR-142-3p, miR-146a, and miR-155 to
be tightly correlated in their dynamic expression throughout the ALS disease time course.
Of particular interest, miR-155 was found to be upregulated 28 fold in brainstem
astrocytes over neurons and 78 fold in the spinal cord. However, the strongest expression was
clearly in microglia with a 146 fold enrichment in the brainstem and a 326 fold enrichment in the
spinal cord.
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DISCUSSION
In order to understand the physiological and pathological role of miRNAs, it is first
necessary to know their cellular expression patterns. The most popular current methods for
achieving this are FACS, LCMS, cell culture models, and in situ staining; however, each of these
methods has significant limitations. First, both fluorescence activated cell sorting, FACS, and
laser capture microdisection, LCM, is low yield and requires dissociation and staining steps in ex
vivo cells that raises levels of cell stress and therefore makes measures of stress and activation
pathways potentially inaccurate (Avvisato et al., 2007). Cell culture models often do not
accurately describe the nature of in vivo cells, and miRNA in situ are technically very difficult,
expensive, and low throughput, only testing a single miRNA per experiment.
miRAP has several advantages over traditional methods to quantify miRNAs from
specific cell populations. First, one major benefit of a miRAP approach is that once the tissue of
interest is isolated from the mouse, the first experimental step is to lyse the cells. This allows the
RNA that is isolated to closely mimic its native state. This is especially important for
neuroinflammatory regulators that quickly change expression based on their environment.
Second, this method allows for miRNAs throughout the cell to be isolated, including in dendrites
and synapses that were previously hard to isolate with conventional methods. Third, unlike in
situ’s that test one miRNA at a time, miRAP is a highthouput method allowing for quantification
of hundreds of miRNAs. Finally, by isolating miRNAs bound to Ago2, we are isolating the
“active” miRNAs that have been incorporated into RISC.
One concern with the miRAP method is that cells may behave abnormally and exhibit
altered miRNA levels upon expressing an extra copy of Ago2 in specific cell types. However,
this issue was addressed by He et al for various neuronal cells in the cortex (He et al., 2012).
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They found that the transgenic Ago2 was expressed in significantly lower amounts than
endogenous Ago2. Furthermore, the combined levels of transgenic and endogenous Ago2
equaled that of Ago2 in nontransgenic mice suggesting overall Ago2 levels are tightly regulated
by the cell. Therefore, expression of transgenic Ago2 is not thought to alter cellular function, but
we will also quantify Ago2 expression levels in our mice using western blots in neural tissues.
Following discrepant data on miR-155 expression following FACS and in situ
experiments, we developed miRAP mice that express tagged-Ago2 in 4 specific cell types:
neurons, motor neurons, astrocytes, and myeloid cells/microglia. Our microarray datasets
unearthed many predicted and novel cell-type enriched miRNAs. The confirmation of predicted
targets allows for increased confidence in the accuracy of our dataset. For example, miR-219 was
the most significantly miRNA enriched in all neurons (Syn+) cells over motor neurons (ChAT+)
and was found in both the brainstem and spinal cord screen. This miRNA has been well studied
as an important modulator of NMDA receptor signaling cascades (Kocerha et al., 2009) – a
function not relevant to motor neurons. Also, miR-218, found to be significantly enriched in
motor neurons has been previously identified by in situ to be localized to motor neurons in the
brainstem and spinal cord (Kapsimali et al., 2007). As a third example, we found miR-223 to be
23,000 times more abundant in microglia than neurons in the spinal cord. This miRNA has been
well researched as specific to hematopoietic cells and functions to regulate myeloid
differentiation and proliferation (Chen et al., 2004; Sun et al., 2010). These examples of
confirmed miRNA cell specific expression using our miRAP method is as exciting as the
identification of several novel cell-specific miRNAs.
These methods and our data set have many potential ramifications. First, by comparing
the miRNA microarray data to existing datasets on mRNA from astrocytes, neurons and motor
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neurons already generated by Joe Dougherty (Doyle et al., 2008) and others (Cahoy et al., 2008),
it may be able to gain insight into miRNA control over regulatory networks. Furthermore, these
double transgenic mice can be adapted to have implications in studying various disease
networks. Please see chapter 6 for a discussion on these and other future experiments.
For the miRNAs we found to be dysregulated in ALS, we found a striking enrichment
of miR-142-3p, miR-142-5p, miR-146a, and miR-155 in microglia. Specifically, while miR-155
was 28 times more abundant in brainstem astrocytes over neurons (78 times in the spinal cord),
the most drastic upregulation was in microglia. miR-155 was 146 times more abundant in
brainstem microglia over neurons, and 326 times more abundant in spinal cord microglia over
spinal cord motor neruons, although all cell types did show a real signal of miR-155. We are
excited that while we are able to apply the information learned about miR-155 using this dataset,
many other researchers will be able to similarly inform their research for their particular
microRNAs of interest as well. From these data, we will focus our analysis on changes in
microglia gene expression and neuroinflamatory pathways overall following miR-155 inhibition
in vivo.

CONCLUSIONS
We have developed an exciting new method for quantifying miRNA enrichment in
specific neuronal and glial cell populations in the brain and spinal cord. By expressing GFPmyc-Ago2 protein in only neurons, motor neurons, astrocytes, or microglia, we have generated
datasets that identify several confirmed and novel cell-specific miRNAs. By applying these
methods to our ALS targets, we have identified miR-142, miR-146, and miR-155 as enriched in
astrocytes and especially in microglia in the brainstem and spinal cord over neruonal cell types.
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These data will inform our analysis of the role of these miRNAs and the mechanism of
therapeutic intervention moving forward.
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Figure 3.1: miR-155 is upregulated in CX3CR1+ cells following LPS activation in vivo and
is enriched in glial subtypes. (A) CD11bhi-CD45hi/GFP+ cells were collected from one
CX3CR1-GFP mouse given a saline IP (top row) and a mouse given a 5mg/kg LPS IP.
CD11b/CD45 gating are show in first column, and GFP gating is shown in the second column.
(B) Following miRNA extraction, miR-155 levels were quantified. miR-155 in GFP+ monocytes
derived from the mouse that received an LPS injection was 20-fold increased over cells derived
from the control mouse. (C) miRNA was extracted from four distinct cell lines. NSC-34 are an
immortalized mouse motor-neuron like cell line. Primary cultured neurons were gifted from Dr.
Jeffrey Millbrandt’s lab from p1 mouse pups. Primary microglia and primary astrocytes were
purified by differential centrifugation described by others (Skaper et al., 2012). While miR-155
was detectible in all cell lines, expression was much greater in the glial lines (708x microglia,
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593x in astrocytes over NSC-34). No statistical data is possible as all experiments in this figure
were conducted with an n=1.concusions are therefore possible.
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Figure 3.2: miR-155 co-expresses with Fox3 in human ALS spinal cords. (A) miR-155
positive cells were observed with miRNA in situ’s using a diogoxigenin-conjugated miR-155
probe developed with anti-digoxigenin – alkaline phosphatase conjugate and NBT/BCIP. These
cells are identified as large alpha motor neurons with Fox3 staining (B) and by morphology. (C)
Fox3+ cells clearly double label for miR-155 in blue; overlap shown in yellow. (D) Brightfield
illumination showing miR-155 labeling in blue and Fox3 labeling in brown.
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Figure 3.3: Immunoprecipitation with GFP pulls down NSC-34 cell specific miRNA. (A)
miR-155 was identified as expressed in BV2 cells and not NSC-34 cells. (B) In contrast, miR676 was only detectible in NSC-34 cells. miR-676 expression was similar following transfection
with an Argonaute2-GFP (Ago2-GFP) construct. (C) Separate lysates from untransfected BV2
cells and transfected NSC-34 cells or a combination of NSC-34 cells and BV2 lysates were
immunoprecipitated with an Ago2 antibody. Only miR-155 was detectable in the BV2 cell lysate
and miR-676 from the NSC-34 cell lysate input. However, a mixed cell lysate yielded both miR155 and miR-676. (D) Following a GFP immunoprecipitation of BV2 cell lysate, miRNAs were
not detectable. In contrast, miR-676 was isolated from NSC-34 cell transfected with a GFP-Ago2
construct. Upon applying the mixed cell lysate, the GFP immunoprecipitation pulled down miR676 selectively.
92

Figure 3.4: Schematic of miRAP mouse model design. Upon generation of double positive
transgenic mice, Cre recombinase causes a recombination and removal of the floxed stop
sequence resulting in expression of GFP-myc-Ago2 in only the specific cell type.
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Figure 3.5: Mice double positive for cell-type specific Cre expression successfully express
GFP protein in the target cell types. An adult mouse that is Syn-Cre+ and loxP-stop-loxP-GFPmyc-Ago2+ has robust GFP staining (green) in NeuN+ cells (red) in both the hippocampus (A)
and in the spinal cord (B) (merge shown in yellow; 10x). (C,D) An adult mouse that is ChATCre+ and loxP-stop-loxP-GFP-myc-Ago2+ has robust GFP staining (green) in ChAT+ cells (red)
in two distinct brainstem nuclei (merge shown in yellow; 20x).
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Figure 3.6: Myc-IP from ChAT specific GFP-myc-Ago2 mice enriches for neuronal
miRNAs. Spinal cords were isolated and homogenized from mice expressing lox-stop-lox-GFPmyc-Ago2 and Cre recombinase under the motor neuron specific ChAT promoter. (A) An IP of
Ago2 yields relatively equal amounts of presumed glial (miR-155, miR-142) and neuronal (miR124, miR-676, miR-196b) miRNAs from spinal cords from a nontransgenic (NonTG) mouse and
the ChAT-Cre+ mouse. (B) An IP with anti-myc antibody greatly enriches for neuronal miRNAs
in the lox-stop-lox-GFP-myc-Ago2/ChAT-Cre mouse and not in the non-transgenic mouse. (RQ
= relative quantification)
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Figure 3.7: TaqMan microarrays identify several miRNAs enriched in either neuronal or
motor neuron cells from the brainstem and spinal cord. Brainstems and spinal cords were
isolated from mice expressing lox-stop-lox-GFP-myc-Ago2 and Cre recombinase under either
the pan-neuronal promoter (Syn) or the motor neuron specific promoter (ChAT). Following a
myc-conjugated immunoprecipitation, miRNAs were quantified using TaqMan rodent v3.0 A
and B microarray cards (n=3 group). miRNAs were analyzed if and only if all 3 mice had a
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corrected CT count less than 33 that also showed stable expression, defined as <2 CT variation
between mice. Following a normalization to 9 identified control miRNAs, miRNAs were listed if
changed more than 10 fold at a p<0.01 for either tissue. (A) In the brainstem, 333 miRNAs met
the expression criteria to be analyzed for significant variation between cell-type specific
expression. 9 miRNAs were identified as significantly de-enriched in motor neurons over all
neurons, and 13 miRNAs were identified as enriched. (B) In the spinal cord, out of 337 miRNAs
compared, 16 miRNAs were de-enriched in motor neurons and 9 were enriched.
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Figure 3.8: miRNA enrichment in neuronal and glial cell types from whole brainstem
tissue. Several predicted and novel neuron-enriched miRNAs were discovered in the brainstem.
Out of 750 miRNAs quantified, only miRNAs that were highly expressed and were consistent in
one or more biological group were considered. 271 miRNAs were thusly quantified in
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comparison of neuronal (Syn) vs microglia (Lyz2) expression; 387 in comparing neurons to
astrocytes (GFAP); and 254 in comparison microglia to astrocytes. Listed are the most robust
and significant miRNAs with cell-type specificity. Specifically, 18 miRNAs were identified as
neuronal enriched and 2 miRNAs were identified as glia enriched.
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Figure 3.9: In spinal cord tissue, 8 miRNAs are significantly enriched in neurons and 17 in
microglia. Following the same rigid standards for expression and noise previously explained,
374 miRNAs were compared in expression levels between astrocytes (GFAP) and neurons (Syn),
213 for comparing microglia (Lyz2) and neurons, and 155 for comparing microglia and
astrocytes. From these, several altered expression patterns were observed with the most robust of
these being highlighted here. We identified 8 miRNAs significantly increased in neurons over
both astrocytes and microglia. In contrast, 17 miRNAs were found to be expressed in much
greater levels in microglia over both neurons and astrocytes.
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Figure 3.10: Particular miRNAs have altered expression levels in the brainstem compared
to spinal cord tissue within distinct cell types. Mice were generated that expressed GFP-mycAgo2 protein in specific cell types: all neurons (Syn), motor neurons (ChAT), astrocytes
(GFAP), and microglia/myeloid cells (Lyz2). Following a myc-IP, 3 brainstems and 3 spinal
cords were compared for each line to determine differential expression between tissue types for a
given cell type. The overlapping number shown for each comparison describes the number of
miRNAs that had a CT<33 for all 3 mice in either tissue as well as less than a 2 CT count
variation between mice. Tissue-enriched miRNAs were identified for each cell type. Highlighted
here are those changes greater than 5 fold that were significant at p<0.01. Of particular note, the
miR-10 family and miR-196 family were consistently shown to be enriched in cell types in the
spinal cord over the brainstem.
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Figure 3.11: miR-196 is highly enriched in descending spinal cord and muscle. miR-196a
and miR-196b levels were quantified in various tissues in a nontransgenic adult mouse and in
human ALS autopsy tissue. (A) Very little expression of miR-196 was observed in the frontal
cortex (cx), parietal cortex, midbrain, cerebellum, liver, spleen heart, or lung. However a robust
increase was observed in the spinal cord that was greatest in the lumbar section (32x cervical SC,
166x thoracic SC, 534x lumbar SC over frontal cortex). The quadriceps and tail muscles also had
robust increase in expression (1320x, 475x respectively). These same expression patterns were
observed for miR-196b as well (B). (C) In the autopsy tissue for an ALS patient, miR-196 again
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showed increasing expression in the SC that was greatest in the lumbar region (54x, 76x, 110x
over motor cortex for cervical, thoracic, lumbar SC respectively). The quadriceps muscle showed
the greatest level of miR-196 at a 143 fold enrichment over the brain. (D) miR-196b expression
mirrored the trends observed with miR-196a.
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Figure 3.12: Target miRNAs dysregulated in ALS are glial enriched. Mice were generated
that expressed GFP-myc-Ago2 in only neurons (Syn), motor neurons (ChAT), astrocytes
(GFAP), or microglia/myeloid cells (Lyz2). miRNAs were isolated from a myc-IP and quantified
on TaqMan microarrays. Following normalization to a geometric mean of 9 identified
endogenous controls, miRNA expressions were plotted as the fold difference in average
expression between each cell type. The x-axis denotes the index of miRNAs quantified with the
y-axis showing the average fold change of motor neurons, astrocytes, or microglia over the
average synapsin expression (from average of n=3). Because sensitivity in the assay is not yet
know, the values between 10 fold de-enrichment and enrichment have been shaded. While our
six ALS dysregulated miRNAs showed a trend towards glial enrichment for both the braintem
and the spinal cord, miR-142-3p had the most marked enrichment in astrocytes and microglia
compared to neruons, especially in the spinal cord tissue. Likewise, in the spinal cord, miR-155
was robustly increaed in both astorcytes and microglia over neurons.
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Figure 3.13: 4 out of 6 ALS dysregulated miRNA targets are highly enriched in glia cell
types. Following a myc-IP that pulls down GFP-myc-Ago2 in specific cell types (Syn: neurons;
ChAT: motor neurons; GFAP: astorcytes; Lyz2: microglia/myeloid cells) miRNAs were
quantified by a TaqMan microarray. Following normalization, the expression levels of the six
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dysregulated miRNAs were quantified in both brainstem and spinal cord tissue from 3 mice
each. miR-24-2* showed consistent expression across all four cell types assayed. miR-146b only
showed mild enrichment in microglia. miR-142-3p, miR-142-5p, miR-146a, and miR-155,
however, show high enrichment in microglia in both the brainstem (A) and the spinal cord (B).
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Figure 3.14: miR-155 is moderately enriched in astrocytes over neurons and robustly
enriched in microglia. Following the cell-type specific pull-down of miRNAs in specific cell
types (neurons, motor neurons, astrocytes, and microglia/myeloid cells using the Syn, ChAT,
GFAP, or Lyz2 promoter respectively), miR-155 levels were analyzed in the brainstem and
spinal cord from 3 mice for each cell-type as part of a larger TaqMan microarray. Although
underpowered, miR-155 levels from the Lyz2 brainstem and spinal cord were found to be
significantly increased over Syn (* p<0.05; Kruskal-Wallis test).
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Cell Promoter
Synapsin1
(Syn)

Targeted Cells
Pan neuronal(Hilfiker et al., 1999)

Choline acetyltransferase
Cholinergic neurons including all motor
(ChAT)
neurons(Rotolo et al., 2008)
Glial fibrillary acidic protein Astrocytes, oligodendroglia, ependyma,
(GFAP)
and few neurons(Zhuo et al., 2001)
Lysozyme 2
Myeloid cells including monocytes,
(Lyz2, aka LysM)
microglia, macrophages, granulocytes

Promoter Function
Regulates synaptic vesicles,
neurotransmitter release
(Hoesche et al., 1993)
Enzyme necessary for synthesis of
neurotransmitter acetylcholine
Intermediate filament (cytoskeletal
protein)
Glycoside hydrolases, innate
immune response

Jax #
003966

006410
004600
004781

Table 3.1. Four Cre-recombinase drivers are used is this study that are specific for distinct
glial and neuronal cell types. Detailed are the cells identified to express Cre recombinase for
each driver and the promoter’s biological function. The four promoters used are specific for 1)
all neurons; 2) cholinergic neurons/motor neurons; 3) astrocytes; 4) myeloid cells/microglia. All
mice were acquired from Jax with the exception of GFAP which were a gift from Dr. David
Gutmann at Washington University School of Medicine. While the Jax mice are carried on the
FVB mouse background, these GFAP mice had been backcrossed onto a pure B6 background.
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CHAPTER 4

Global microRNA inhibition throughout the rodent central nervous system
using antisense oligonucleotides
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SUMMARY
Having previously identified microRNAs (miRNAs) significantly increased in ALS
spinal cords in both patient autopsy tissue and in the rodent model, we required a technique to
modulate these miRNAs in vivo in order to determine their mechanism of action and the effect of
therapeutic intervention. Antisense oligonucleotides are short DNA-like synthetic molecules that
inhibit a target sequence through Watson-crick base pairing. We created a novel anti-miR-155
capable of robustly inhibiting miR-155 as evidenced by derepression of miR-155 target mRNAs.
Following treatment in non-transgenic mice with 4-week continuous infusion of anti-miRs
directly into the cerebral lateral ventricles, we confirmed broad distribution of the anti-miR by
both histology and by RNA analysis of confirmed miRNA targets. With this technique, we are
now able to test the effect of miRNA inhibition in our ALS-mouse model.
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INTRODUCTION
miRNAs (miRNAs) are a recently discovered regulatory-class of RNA molecules. These
short single-stranded molecules inhibit as many as hundreds of mRNAs through partial
complimentary with the seed region (2-8nt) of the miRNA considered the most important in
directing the binding to target mRNAs (Hall et al., 2012). miRNAs are dysregulated in a variety
of diseases and have proven themselves to be viable therapeutic targets (Janssen et al., 2013a;
Miller et al., 2013). After screening miRNAs in SOD1G93A and control rodent spinal cords, we
discovered miR-155 to be robustly and significantly upregulated in ALS. We also confirmed
miR-155 to also be significantly increased in ALS human autopsy spinal cord tissue as compared
to controls. Testing the potential therapeutic opportunity of dysregulated miRNAs in any
particular disease requires not only a careful analysis of the miRNA expression changes in the
target tissues but also a method to modulate miRNA function in disease models.
Antisense oligonucleotides (ASOs, oligos) are synthetic DNA-like single stranded
molecules that can be used to inhibit mRNA/miRNA function by binding tightly to their target
through Watson-Crick base pairing. Their mode of action can either be inhibition through steric
blocking of translation or degradation through recruitment of RNaseH, depending on the
modifications on the phosphodiester backbone and at the 2’-sugar position. While the precise
mechanism of distribution and uptake by cells is not known, it is believed that ASOs are actively
brought into cells by absorptive endocytosis and fluid phase pinocytosis (Dias and Stein, 2002).
Once in cells, ASOs may have very long half-lives, on the order of a few to several months (Hua
et al., 2010; Kordasiewicz et al., 2012).
There are four common phosphate backbone modifications that aim to increase
specificity and affinity for target RNA, increase uptake into cells, and extend half-life via
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protection from endogenous nucleases. First, the most popular modification remains the
phosphorothioate modification (PS) which involves replacing the non-bridging phosphate
oxygen with sulfer. This modification typically involves recruitment of RNAseH and improves
serum binding (Magen and Hornstein, 2014). Unfortunately, these backbones are thought to have
sequence-independent effects though affinity for heparin-binding growth factor and other
heparin-binding molecules (Dias and Stein, 2002). In an attempt to prevent these off-target
effects, three more modifications arose that are RNAse-independent. The thiophosphoramidate
modification (NPS) refers to an alternating replacement of the phosphate oxygen atom with
sulfer and nitrogen (Gryaznov, 1999). This modification aids in nucleic acid resistance. Next, the
peptide nucleic acid modification (PNA) and the phophorodiamidate morpholino (PMO) both
involve replacement of the ribose nucleic acid backbone with either peptide nucleic acid or a sixmembered morpholine ring, respectively (Magen and Hornstein, 2014). These final two
modifications promote RNaseH-independent inhibition and are also highly resistant to nucleases
(Summerton, 1999).
There are also multiple common 2’-sugar ring modifications that aim to enhance target
binding while also conferring nuclease resistance. The 2’-O-methyl (ME) and 2’-Omethoxyethyl (MOE) are the most common. However, the bridging locked nucleic acid (LNA)
design is thought to improve binding and nuclease resistant but also may incur more toxicity
(Swayze et al., 2007). Additionally, fluoro modifications have increased thermal stability over
2’-O-methyl substitutions while also conferring nuclease resistance but may increase oligomediated toxicity as well (Akhtar, 1995; Kawasaki et al., 1993). Following an unpublished
screen of various phosphate backbone and 2’-sugar modifications for anti-miR-155 ASOs, our
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oligos here tested were synthesized with a full phosphorothioate backbone with alternating
blocks of 2’-MOE and 2’fluoro sugar-modified nucleosides.
The strategy of using ASOs to target miRNAs has been successful in recent rodent
experiments and even in a limited number of clinical trials. Following the discovery that miR122, a liver specific miRNA, drives the replication of the hepatitis C virus (HCV) (Jopling et al.,
2005), Santaris Pharma developed an antisense oligonucleotide inhibitor against miR-122, called
Miriversen. Following successful chimpanzee studies (Lanford et al., 2010), the authors have
continued to complete a successful Phase I (Janssen et al., 2011) and Phase IIa trial
(NCT01200420) (Janssen et al., 2013). Hepatitis C patients that received Miriversen reported no
significantly greater number of adverse events over placebo, and their viral titer counts were
robustly and significantly reduced, even at the lowest dosage level tested, 3mg/kg. Reduced
HCV RNA was observed over 3 months beyond the last injection. This clinical trial shows that
despite the vast number of potential mRNA targets for each miRNA, miRNAs remain both
powerful and realistic therapeutic targets.
While ASO-mediated miRNA inhibition strategies have been successful in the periphery,
they have not been readily applied to the CNS. ASOs are highly charged molecules and do not
readily cross the blood-brain barrier (BBB). Peripheral dosing would have to be approximately
100-fold higher than a direct CNS delivery to equal the same level of tissue concentration (Banks
et al., 2001). Therefore, to target miRNAs in the CNS, we delivered anti-miRs directly to the
cerebral spinal fluid as previously described for mRNA inhibitors (Smith et al., 2006). Alzet
osmotic pumps are small implantable pumps that sit in a sub-cutaneous pocket in the back of the
mouse. These pumps absorb fluid from the surrounding tissue to then promote the fluid within
the pump to travel up through the tubing and into a catheter that we place directly into the lateral
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cerebral ventricles. CSF circulates from the ventricles to all CNS tissue, making it an excellent
drug delivery vehicle. Using this method, we demonstrate here the ability of these anti-miRs to
inhibit their cognate miRNA target throughout the CNS.
Among the list of dysregulated miRNAs in ALS model mice and human ALS samples,
miR-155 appeared to be an excellent first therapeutic target because of its abundance and fold
change in ALS, reproducibility across species and various ALS models, and extensive prior work
linking miR-155 with immunity and inflammation (Landgraf et al., 2007) (O'Connell et al.,
2009) (Wang et al., 2009). More intensive background on miR-155 is available in Chapter 5.

MATERIALS AND METHODS
Animals
All animal protocols were approved by the Institutional Animal Care and Use Committee
of Washington University at St. Louis and adhered to NIH guidelines. Animals were provided
food and water ad libitum, and cages were changed once a week. All mice were maintained in a
12-hour light/12-hour dark cycle and received routine veterinary monitoring. Post-surgical mice
were single-housed as to protect the sutures and tubing.
anti-miR sequences
All anti-miRs were synthesized with a full phosphorothioate backbone with alternating
blocks of 2’-MOE and 2’fluoro sugar-modified nucleosides. Sequences are denoted in Table 4.1.
Alzet osmotic pump surgeries
Osmotic pumps were prepared per manufacturer protocol (pump model 2004 for 28 day
experiments; Alzet). For implantation, mice were anesthetized in a chamber with 5%
isoflurane/oxygen mixture and confirmed to be unconscious before being placed in Kopf Model
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940 small animal stereotaxic apparatus, fitted with ear bars (Miller, 2013). The catheter was
oriented at 2.00mm lateral and 1.1mm posterior to bregma.
mRNA quantification
For mRNA Affymetrix microarray and Sylamer analysis, RNA, extracted with
miRNEasy, was diluted to 100ng/µL and sent to Expression Analysis, Inc for running the
Affymetrix Mouse Genome 430 2.0 array. Analysis was then conducted as previously described
by others (van Dongen et al., 2008). For RT-qPCR of mRNA targets, RNA was normalized to
20ng/µL using Nanodrop. Primers and probes for mRNA targets were purchased from Integrated
DNA Technologies and are detailed in Table 4.1. For let-7 target analysis, 40ng total RNA was
quantified with Express One-Step Superscript Kits (Invitrogen) as per the manufacturer’s
protocol. For miR-155 targets, 40ng total RNA was quantified with Power SYBR Green RNAto-CT 1-Step Kit (Life Technologies) as per the manufacturer’s protocol. One-step qRT-PCR
was conducted on a 7500 fast Real Time PCR System (Applied Biosystems). RNA was
quantified as technical duplicates and normalized to GAPDH.
miR-155 target array
RNA from treated nontransgenic mouse cortex was profiled for miR-155 target
engagement using a 2-step RT/qPCR method. First, cDNA was created from 300ng total RNA
extracted using miRNEasy kits (Qiagen) using Qiagen’s RT2 First Strand Kit according to
vendor protocols. Next, cDNA was amplified and quantified on an ABI 7900 fast machine using
miR-155 target arrays plates (RT2 profiler PCR Array Format E 384 (4x96), Catalog No.
PAMM-6002ZE-4, Qiagen) according to the vendor protocol. Four samples were run on each
plate with at least one sample being from a saline treated, a scrambled treated, and an anti-miR155 treated mouse (20ug/day, 4 week treatment, 2 week washout). Array data was normalized to
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a geometric mean of 4 endogenous controls: Actb, Gapdh, Gusb, and Hsp90ab1. Primers for the
14 most derepressed mRNAs in the anti-miR-155 treated samples were then ordered (IDTDNA,
Table 4.1), and individual RT/qPCR assays were performed with 40ng total RNA using the
Power SYBR Green RNA-to-CT 1-Step Kit (Life Technologies) as per the manufacturer’s
protocol.
anti-miR-155 in vitro luciferase assay
miRNA antisense oligonucleotides were screened for in vitro function as described
previously (Esau, 2008). Briefly, Hela cells were co-transfected with a miR-155 expressing
plasmid and with a luciferase reporter with perfect 2x miR-155 complementary sequences at the
3’UTR. 4 hours later, anti-miR-155 was added to the media at concentrations ranging from 1 to
200nM. 24 hours later, luciferase activity was determined and plotted.
Isolation of peritoneal macrophages
Adult C57BL/6 mice were given an intraperitoneal (IP) injection of thioglycollate
followed by 3 daily IPs of 25mg/kg anti-miR or saline. On day 4, peritoneal macrophages were
isolated, plated, and stimulated with LPS for 24 hours (20ng/mL). RNA was then extracted and
analyzed by Sylamer analysis.
Cy3-anti-miR-155 histology
Adult C57BL/6 mice were implanted with a subdermal Alzet osmotic pump to deliver
10ug/day of cy3-labeled anti-miR-155 (Regulus Therapeutics) directly into the lateral ventricle.
After 2 weeks of treatment, mice were perfused with phosphate buffered saline (PBS) and 4%
paraformaldehyde (PFA). Brain and spinal cord tissues were post-fixed in PFA for 48 hours and
then submerged in 30% sucrose for 2 days. The spinal cord was embedded in O.C.T. (VWR)
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before it and the brain were sliced at 40um. Tissue for distribution analysis was then washed in
PBS and mounted with Fluoromount G (Southern Biotech) before being coverslipped.
For cell-specific determination, tissues were washed in PBS and blocked in 5% natural
horse serum in PBS for 30 minutes. A dilution of 1:1000 of chicken-anti-GFAP polyclonal
antibody (ab4674, Abcam), 1:1000 goat-anti-Iba1 polyclonal antibody (ab5076, Abcam) or
1:200 mouse anti-NeuN antibody (MAB377, Millipore, MAB377) in blocking buffer was then
applied to the tissues overnight at 4oC. Tissues were then washed with PBS and blocked with 5%
natural horse serum for 30 minutes before incubating in their relevant 1:1000 AlexaFluor488conjudated secondary antibody for 1 hour (goat anti-chicken (ab150169, Abcam), donkey antigoat (ab150129, Abcam), or goat anti-mouse (35502, Thermo Scientific, Waltham, MA)). All
slides were observed at 4x, 10x, and 20x objectives using a Nikon Eclipse 80i microscope fitted
with a Photometrics CoolSnap EZ camera. All images were taken at ambient temperature with a
Cy3 or FITC filter. For image acquisition and formatting, NIS Elements 3.0 (Nikon) and Adobe
Photoshop v12.0 were used.
Statistical analysis
Data are presented as mean ± SEM. All statistical tests were conducted with Graphpad
Prism 6 Software. All gene expression data were analyzed with a 2-tailed Student t test.

RESULTS
Anti-let-7 delivered through ventricular osmotic pumps successfully derepresses its targets
individually and globally.
To determine whether anti-miRs could inhibit targets broadly in the CNS, we used a
miRNA inhibitor of let-7. We first assayed anti-let-7 because this oligonucleotide is known to be
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a potent miRNA inhibitor in the periphery (Esau, 2010). let-7 is not known to be important in
ALS and is best known for its role in cell cycle regulation, cell differentiation, and cancer
(Androsavich et al., 2012). After treating animals with anti-let-7 via an osmotic pump directed
into the lateral ventricles (Fig 4.2A), mRNAs with 3’-UTR let-7 binding sites were globally
derepressed in cortical tissue (Fig 4.2B). Further Sylamer analysis was conducted for these mice
in various brain regions including the cortex, striatum, and hippocampus (Fig 4.3). After
confirming the suitability of GAPDH as an endogenous control (Fig 4.1), analysis of a subset of
these mRNAs demonstrated derepression of targets in the parietal cortex, midbrain, occipital
cortex, cerebellum, cervical and lumbar spinal cord (Fig 4.2C,D).
A novel anti-miR-155 derepresses predicted targets globally in the periphery and
individually in the brain and spinal cord.
Having established that anti-miRs can target the CNS including the spinal cord, we
developed an anti-miR-155 oligonucleotide to test whether this inhibitor would affect the ALS
rodent model. First, miR-155 targets had not been previously described in the brain and spinal
cord. Therefore an array containing 46 confirmed and 38 predicted miR-155 direct targets was
conducted on 16 cortex RNA samples from adult nontransgenic mice treated with either saline
(n=5), scrambled-anti-miR (n=5), or anti-miR-155 pumps (n=6) at 20ug/day for 4 weeks
followed by a 2 week washout prior to harvesting tissue. 45 biologically confirmed targets and
31 predicted targets amplified on these arrays. Of these 76 targets measured, 66 were increased
20% or more in the anti-miR-155 treated mice over both saline and scrambled treated mice.
48/76 were increased more than 50%, and 24/76 were increased more than 100% (Fig 4.4).
The top 14 targets from the array (Fig 4.5A) were then assayed individually in a pooled
analysis by biogroup in order to identify the best miR-155 targets to follow for target
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engagement (Fig 4.5B). From this, Card11 and Cyr61 were added to previously identified miR155 targets PU.1 and SHIP1 as top markers for anti-miR-155 target engagement.
In Hela cells transfected with miR-155 and a luciferase reporter containing a 3’UTR
recognized by miR-155, the novel anti-miR-155 derepressed luciferase and led to increased
luciferase activity (Fig 4.6A). To test efficacy of miR-155 inhibition peripherally in vivo, we
administered three daily IP injections of anti-miR-155 in non-transgenic mice. An mRNA profile
from lipopolysaccharide (LPS)-stimulated peritoneal macrophages from anti-miR-155 treated
mice showed global derepression of mRNAs with a miR-155 3’-UTR binding site (Fig 4.6B).
Finally, to test efficacy in CNS tissue, we implanted 28 day osmotic pumps with saline,
scrambled control, or anti-miR-155 that infused directly into the lateral ventricles. We confirmed
4 known and/or predicted miR-155 mRNA targets (O'Connell et al., 2009; Vigorito et al., 2007;
Xu et al., 2010; Zhang et al., 2010) to be derepressed in the cortex following anti-miR-155
treatment (Fig 4.6C). Furthermore, quantification of one of these targets, SHIP1, across the CNS
demonstrated a significant increase over saline in all areas assayed (Fig 4.6D).
Cy3-labeled anti-miRs infused into the cerebral lateral ventricles distribute throughout the
brain and spinal cord and are incorporated neurons, astrocytes, and microglia.
In a separate experiment, mice treated with cy3-labeled anti-miR-155 osmotic pumps for
two weeks demonstrated clear cellular uptake throughout the brain and spinal cord (Fig 4.7).
More so, double-label histology showed cy3-anti-miR-155 to be incorporated into distinct cell
types including neurons (NeuN+), microglia (Iba1+), and astrocytes (GFAP+) (Fig 4.8).
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DISCUSSION
Antisense oligonucleotides can function as potent inhibitors of miRNAs (anti-miRs), but
it remained unclear whether these inhibitors could achieve broad CNS distribution similar to
antisense oligonucleotide inhibitors of mRNA (Smith et al., 2006). We first assayed anti-let-7
because this oligonucleotide is known to be a potent miRNA inhibitor in the periphery (Esau,
2010). let-7 is not known to be important in ALS and is best known for its role in cell cycle
regulation, cell differentiation, and cancer (Androsavich et al., 2012). Following a 28-day
infusion of anti-let-7 into the cerebral lateral ventricle in mice, we saw robust derepression of let7 targets throughout the brain and spinal cord as determined by both global Sylamer analysis and
targeted mRNA assays. While other studies have demonstrated anti-miR function in limited
sections of cortical tissue (Lee et al., 2012; Selvamani et al., 2012), these data establish a method
of widespread inhibition of miRNAs and are the first to show inhibition of miRNAs in the spinal
cord.
Next, we developed a novel anti-miR against miR-155, previously identified as
significantly upregulated in ALS. We screened candidate anti-miR-155 molecules in a luciferase
assay where luciferase was fused to a 3’UTR that contained a miR-155 binding site.
Derepression of luciferase following transfection with anti-miR-155 was a sign of a functional
anti-miR.
In progressing to in vivo studies, we had to first define miR-155 targets. Because our
anti-miRs are not designed to necessarily degrade their target miRNA, we instead measured
target engagement by quantifying derepression of the miRNA’s target mRNAs. miR-155 has
been well studied in the periphery (Faraoni et al., 2009; Vigorito et al., 2013), but no study has
yet defined miR-155 targets in the brain and spinal cord. Therefore, we performed a miR-155
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target array to measure derepression following anti-miR treatment from the perfused mouse
cortex. As our goal was to identify mRNAs to track as opposed to exhaustively identifying novel
mRNA targets, we only confirmed the most upregulated mRNA targets of miR-155. From this,
we identified Card11 and Cyr61 as miR-155 targets in the central nervous system. Card11 was
previously only a bioinformatically predicted target, but Cyr61 had been previously
experimentally verified as a direct target in the periphery (Zhang et al., 2010). The caspace
recruitment domain (CARD) family protein Card11 is essential for protein kinase c-mediated
cytokine production in T and B cells (Hara et al., 2003), and cytoseine-rich protein 61
(Cyr61/CCN1) is a secreted signaling protein that regulates cell adhesion, proliferation, and
differentiation (Han et al., 2003). These two novel targets were added to our previously
identified miR-155 targets, PU.1 and SHIP1, to allow us to well track anti-miR-155 efficacy in
vivo.
Our novel anti-miR-155 also showed widespread functional distribution in both the
peripheral and central compartments. We measured this both through derepression of mRNAs
and through histology. By infusing a cy3-labeled anti-miR-155, we were able to track its uptake
throughout the brain and spinal cord and into neurons, microglia, and astrocytes. Given the
importance of miR-155 in the periphery (Akhtar, 1995; Faraoni et al., 2009) and its abundance in
microglia (Figure 3.14), we considered it essential that our anti-miR-155 reach the dominant
immune cell of the brain, microglia. The distribution of anti-miR-155 throughout the brain and
spinal cord and its uptake by cells known to be critical to ALS disease pathogenesis, we were
prepared to continue on to testing the therapeutic potential of anti-miR-155 in the ALS mouse
model.
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Anti-miRs have been used safely and effectively in the periphery in recent human clinical
trials (NCT00688012 and NCT00979927); (Janssen et al., 2013b) and CSF infusion of antisense
oligonucleotides designed to lower mRNA have recently been applied to patients with ALS
(Miller et al., 2013). Thus, CSF delivery of anti-miRs has the real potential for utility in clinical
trials.

CONCLUSION
We have demonstrated a therapeutically relevant method to inhibit miRNAs broadly in
the brain and spinal cord for the first time. Our novel anti-miR-155 robustly derepresses PU.1,
SHIP1, Cyr61, and novel, Card11. We confirmed broad distribution of anti-miRs following
infusion into the lateral cerebral ventricles by both histology and global RNA readout. With this
method, we are able to test the role of dysregulated miRNAs in ALS-model rodent spinal cords
in vivo.
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Figure 4.1: GAPDH does not vary between samples or between treatment groups. RNA was
extracted and diluted to 20ng/uL before qPCR amplification. GAPDH was run on each plate as
the endogenous control, and its cycle threshold did not significantly vary between samples within
groups or between treatment groups (n=5-6 per group).
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Figure 4.2: let-7 anti-miR distributes throughout CNS and derepresses target mRNAs.
(A) Saline, scrambled anti-miR control, or anti-let-7 was infused directly to the lateral ventricle
for 28 days with an osmotic pump. At 42 days, RNA was extracted. (B) Using Affymetrix 430
2.0 mouse gene arrays and Sylamer software analysis, cortical mRNA with let-7 binding sites
(blue and red lines denoting mRNAs that contain the 1-7nt, or 2-8nt miRNA seed region
compliment respectively) were enriched among the upregulated (derepressed) mRNAs for antilet-7 treated mice as normalized to scrambled treated mice. (C,D) mRNA of two confirmed let-7
targets (TGFBR1, NRAS) were significantly increased in anti-let-7 treated mice in all regions
assayed (p<0.05 TGFBR1; p<0.01 NRAS).
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Figure 4.3: let-7 anti-miR distributes from lateral ventricle infusion to globally derepress
target mRNAs throughout brain. Using Affymetrix 430 2.0 mouse gene arrays and Sylamer
software analysis, anti-let-7 treatment globally derepressed mRNAs that contain the 1-7nt, or 28nt miRNA seed region compliment in various brain regions including the cortex, hippocampus,
and striatum.
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Figure 4.4: miR-155 target mRNAs are derepressed in anti-miR-155 treated mouse cortex.
A miR-155 target array (Qiagen) assayed 76 confirmed and predicted miR-155 targets. Mice
were treated for 4-weeks with osmotic pumps directed to their cerebral lateral ventricles
containing either saline (n=5), scrambled anti-miR (n=5), or anti-miR-155 (n=6). Data are here
presented as the average of anti-miR-155 treated mice compared to the average of scrambled
anti-miR treated mice. Of these 76 targets measured, 66 were increased 20% or more in the antimiR-155 treated mice over both saline and scrambled treated mice. 48/76 were increased more
than 50%, and 24/76 were increased more than 100%.
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Figure 4.5: miR-155 target array identified several putative mRNAs to track for anti-miR155 target engagement including Card11 and Cyr61. (A) The top 14 hits are shown from the
miR-155 target array that assayed 76 mRNAs with proven or predicted miR-155 binding sites.
(B) The RNA from treated mouse cortices was pooled by treatment group and analyzed by Sybr
Green RT/qPCR. Card11 and Cyr61 were clearly derepressed (3.9x and 3.2x respectively)
following anti-miR-155 treatment and were chosen as target mRNAs for the study of anti-miR155 target engagement.
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Figure 4.6: anti-miR-155 successfully derepresses miR-155 targets in vitro, in the periphery
in vivo, and in the central nervous system. (A) Hela cells were transfected with a miR-155
expression plasmid and a luciferase reporter containing two miR-155 binding sites. After 4
hours, either anti-miR-155 or a scrambled control anti-miR was transfected into cells (1 to
200nM). Quantified 24 hours later, luciferase levels were increased in anti-miR-155 treated cells,
indicating inhibition of miR-155. (B) After 3 daily IP injections of either anti-miR-155 or
scrambled anti-miR control, peritoneal macrophages were isolated from adult mice, stimulated
with LPS, and RNA was extracted. An Affymetrix microarray of mRNA followed by Sylamer
analysis shows derepression of mRNAs that contain the heptamer seed region compliment to
miR-155 (blue line denotes 1-7nt miRNA heptamer compliment, red for 2-8nt heptamer).
(C) anti-miR-155 was infused into the lateral ventricles of adult mice for 4 weeks. 2 weeks later,
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mRNA was extracted. mRNA levels of 4 confirmed and/or predicted miR-155 targets were
significantly increased in anti-miR-155 treated mice over both saline and scrambled treated mice
(SHIP1 p<0.001, PU.1 p<0.001; Card11 p<0.01, Cyr61 p<0.001). (D) SHIP1, a confirmed miR155 target, was significantly increased in anti-miR-155 treated mice in all regions assayed
(p<0.05).
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Figure 4.7: cy3-anti-miR-155 distributes from lateral cerebral ventricle throughout brain
and spinal cord. Mice were treated for 2 weeks with an osmotic pump delivering 10ug/day cy3labeled anti-miR-155 directly into the lateral ventricle. Anti-miR-155 distributes throughout the
(A) subventicular zone (4x), (B) cortex (4x), (C) hippocampus (10x), and (D) spinal cord (10x).

136

A

B

C

D

E

F

G

H

I

Figure 4.8: cy3-anti-miR-155 distributes into neurons, microglia, and astrocytes. Mice were
treated for 2 weeks with an osmotic pump delivering 10ug/day cy3-labeled anti-miR-155 directly
into the lateral ventricle (B,E,H). 40um brain slices were collected, and cell specific antibodies
were used against NeuN to mark neurons (A), Iba1 to mark microglia (D), and GFAP to mark
astrocytes (G). cy3-anti-miR-155 is present in all cell types assayed (C, F, I, arrowheads mark
examples of double positive cells) (20x, scale bar = 100um).
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Arid2

Forward
CAGCCCAGCAACCATTTTCC

Reverse
TTTCCCTGACTCACAGTCGC

Card11

CACTGGATGCGTGCACAAAA

AGATGTTCAGGTTCAGGCGG

Cebpb

CTTATAAACCTCCCGCTCGGC

TGGCCACTTCCATGGGTCTA

Cyr61

AGAGGCTTCCTGTCTTTGGC

CCAAGACGTGGTCTGAACGA

Fadd

CTCATTTCCTGCTCCCTGCT

CAACAATGCGGAAGGCGATT

Ifngr1

ACAGCTCTCCGTCCTCGTAT

GGATCTCCCCACTCCGGTTA

Ikbke

CCACGTCTTTTCCCTACCCC

GCTCAAGGACACAAGGGTGA

Irak3

GCTGGCTGCATATTTCACGG

TGATTCGAACGTGCCAGGAA

Mafb

GTAGTGTGGAGGACCGCTTC

CTTCTGCTTCAGGCGGATCA

Msh2

TAAGGCTTCTCCCGGCAATC

CAAGCCTAGCTTCCTCTGGG

Rhoa

AGGATTGGCGCTTTTGGGTA

TTCCCACGTCTAGCTTGCAG

Ripk1

CGGGAGGTTGGACTCTTCTT

GTCTTCTCCAGCAGGTCACT

Socs1

GCTCACTGCCTCTGTCTCC

GGTTGCGTGCTACCATCCTA

Trp53inp1

CTCACGGGCACAGAAATGGA

TTTATCCACTGGGAAGGGCG

Hsp90ab1

AGGAAGTGCACCATGGAGAG

AGAGATCAACTCGCGGAGGA

GAPDH

GGTTGTCTCCTGCGACTTCA

TAGGGCCTCTCTTGCTCAGT

anti-miR-155

CCCCUAUCACAATUAGCAUUAA

N/A

anti-let-7

AACUAUACAACCTACUACCUCA

N/A

Scrambled anti-miR

CCCCAUUACCAATTACGUAATA

N/A

Table 4.1: Primer and antisense oligonucleotide sequences.
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CHAPTER 5

Inhibition of microRNA-155 significantly extends survival in a mouse model
of ALS & further insights into neuroinflammation in ALS
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SUMMARY
ALS is a fatal, adult onset neurodegenerative disease characterized by the selective loss
of motor neurons in the brain and spinal cord. MicroRNAs (miRNAs) are a new class of
translational repressors shown to be viable therapeutic targets in mouse models for multiple
sclerosis (Ponomarev et al., 2011) and in patients for Hepatitis C treatment (Janssen et al., 2013).
Having previously identified dysregulated miRNAs in the mouse model and in patient autopsy
samples and having developed a method to inhibit miRNAs broadly and globally in the central
nervous system using antisense oligonucleotides, we next aimed to test the therapeutic potential
of miRNA modulation in a mouse model of ALS. We found that inhibition of miR-155,
previously identified to be enriched in immune and inflammatory cell types, resulted in a
significant extension in survival and a 38% increase in disease duration. While the end-stage
mice in this treatment experiment showed no altered neuroinflammatory transcripts in their
spleens or spinal cords, a separate cohort of treated ALS-model mice sacrificed at a mid-disease
stage had a significant increase in 6 distinct inflammatory cellular and molecular markers. While
it is unclear if these observations are related the mechanism driving the survival benefit, miR155 clearly remains an exciting target for neurodegenerative research.
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INTRODUCTION
ALS is a fatal adult-onset neurodegenerative disease with no adequate therapies despite
being first characterized in 1869 (Cleveland and Rothstein, 2001). Therefore, innovative
approaches for the discovery of therapeutic targets is necessary. miRNAs are a newly discovered
class of translational repressors that have the power to regulate entire cellular networks
(Makeyev and Maniatis, 2008). Antisense oligonucleotides are synthetic DNA-like molecules
that can specifically inhibit an mRNA or miRNA through Watson-Crick base pairing. Having
previously defined 6 miRNAs significantly changed in both the ALS-mouse model and in ALS
patient autopsy tissues and having established a method to modulate these miRNAs in vivo, we
next studied the therapeutic potential and the role of miR-155 in a mouse-model of ALS.
Among the list of dysregulated miRNAs in ALS model mice and human ALS samples,
miR-155 appeared to be an excellent therapeutic target because of its abundance and fold change
in ALS, reproducibility across species and various ALS models, and prior work linking miR-155
with immunity and inflammation. miR-155 is highly expressed in hematopoietic cells including
T cells and monocytes (Landgraf et al., 2007) and can serve to promote pro-inflammatory
pathways through targeted repression of anti-inflammatory mediators including SHIP (O'Connell
et al., 2009) and SOCS (Wang et al., 2009). Immune system involvement is important in ALS
(Beers et al., 2008; Boillee et al., 2006; Zhu et al., 2002), and recent data suggest that miR-155 is
increased in peripheral monocytes from ALS model mice and ALS patients (Butovsky et al.,
2012). However, as with many changes in the ALS model, whether the miR-155 increase
positively or negatively affects ALS remained untested and required development of a method to
inhibit miRNAs both in peripheral blood cells as well as in the central nervous system (CNS).
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miR-155 is located within an exon of the non-coding B-cell Integration Cluster (BIC)
gene on chromosome 21 (Eis et al., 2005). miR-155 is highly homologous in many species
including human, dog, rat, mouse, zebrafish, and xenopus (miRBase v20.0). This miRNA is
expressed in lymphoid and myeloid cells and plays important roles in haematopoesis,
inflammation, and immunity (Faraoni et al., 2009). miR-155 has been shown to be upregulated
in patient tissues in a variety of diseases including rheumatoid arthritis (Stanczyk et al., 2008),
multiple sclerosis (MS) (Stanczyk et al., 2008), cystic fibrosis (Bhattacharyya et al., 2011),
and several cancers including leukemia (Eis et al., 2005), breast cancer (Iorio et al., 2005),
colon cancer (Volinia et al., 2006), and lung cancer (Yanaihara et al., 2006). Recently, miR155 knockout mice were shown to be significantly protected against a model for two of these
diseases: experimental autoimmune encephalomyelitis (EAE, a mouse-model of multiple
sclerosis) (O'Connell et al., 2010) and collagen induced arthritis (Bluml et al., 2011).
miR-155 is especially well-studied in the context of macrophages and microglia.
Macrophages are white blood cells derived from monocytes, and microglia are the resident
macrophages in the brain and spinal cord. These cells play important roles in innate and acquired
immunity. In the context of neurodegeneration, microglia are typically thought of as existing in
one of two polarized states. When primed by interferon gamma and activated by T-helper cell
Type I-cytokines, these cells may enter their classically activated M1 state. In this state,
macrophages serve to destroy the surrounding insult and amplify tissue damage by releasing
reactive oxygen species, nitric oxide, and pro-inflammatory cytokines like TNF-α, Il-1β, and Il6. When exposed to T-helper cell Type II-cytokines, macrophages can become alternatively
activated (M2). In the M2 state, macrophages are thought to reduce inflammation, promote cell
growth, and aid with tissue repair by releasing anti-inflammatory cytokines and trophic factors
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(Classen et al., 2009). However, there is a new controversy in the polarization of microglia in
ALS. Recently, publications have argued for the M2/M1 role of microglia in ALS (Beers et al.,
2011) (Kobayashi et al., 2013). In contrast, it has also been recently reported that a ‘good’ vs
‘bad’ microglia is not an accurate description; instead, microglia in ALS express concurrently a
mix of anti-inflammatory and pro-inflammatory factors. For example, cytotoxic CD8+ T cells
are typically considered to cooperate with M1, toxic microglia, but it was found that CD8 T cells
can drive the phagocytic properties known to be beneficial/protective in some diseases (Chiu et
al., 2013). While the field continues to resolve these discrepancies, there remains a consensus
that microglia are powerful modulators of disease course and may be viable therapeutic targets.
Several studies have suggested that microglia are important for disease pathogenesis in
ALS. In 2002, Zhu et al. showed that minocycline significantly delayed ALS onset and extended
survival in the mouse model (Zhu et al., 2002). Minocycline is a tetracycline derivative that
inhibits microglial activation and cytokine release. However, in a Phase 3 clinical trial, ALS
patients declined more rapidly with minocycline (Gordon et al., 2007)). Many consider the
problem to lie in the dosage of 400mg/day, an amount that some consider to be neurotoxic
(Leigh et al., 2008). Beers et al. transplanted bone marrow from either SOD1G93A or WT mice
into PU.1 knockout ALS mice, which lack macrophages from birth (Beers et al., 2006). Boillee
et al. created a mouse line with a floxed mutant SOD1 protein and with cre recombinase under
the microglia specific CD11b promoter (Boillee et al., 2006). In both of these studies, removing
SOD1G93A from microglia alone was sufficient to significantly extend survival. More recently, an
appreciation for the beneficial role of lymphocytes in ALS has emerged. It was found that
removing T cell infiltration in a mouse model of ALS was detrimental while transplantation of
T-regulatory cells into a mouse model of ALS robustly extended survival (Beers et al., 2011).
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With information gathered from these and other studies, many consider the best therapeutics that
target neuroinflammation won’t be immune suppressors, but instead will be immune modulators.
A new variant in a myeloid cell activating receptor has recently been identified as a risk
factor for both Alzheimer’s disease (Guerreiro et al., 2013) and ALS (Cady et al., 2014). This
p.R47H variant in the triggering receptor on myeloid cells 2, TREM2, confers a single amino
acid substitution on the extracellular domain of a receptor. Upon activation, TREM2 forms a
signaling complex with its binding partner TYROBP, also known as DAP12 (Kierdorf and Prinz,
2013) which typically leads to increased phagocytosis and a blunting of inflammation.
(Takahashi et al., 2005). While it us unknown how the p.R47H variant affects the function of
TREM2, it has been found that a truncation mutation leading to a loss-of-function in TREM2 is
sufficient to cause early onset frontotemporal-like dementia known as polycystic
lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL or Nasu-Hakola
Disease) (Paloneva et al., 2000; Paloneva et al., 2002). Therefore, many consider this variant to
also confer a loss-of-function mutation that diminishes the neuroprotective role of microglia in
neurological disease (Guerreiro et al., 2013; Jonsson et al., 2013). These TREM2 mutations serve
to strengthen the motivation for translational research in neuroinflammation in
neurodegenerative diseases.
For our miRNA intervention experiments, we used the Gurney SOD1G93A transgenic
mouse model that overexpress an ALS-causing human SOD1 mutation (Gurney et al., 1994).
These mice recapitulate the ALS phenotype with progressive muscle weakness and paralysis
followed by death. Onset and survival time course is dependent on the mouse strain. Here, we
are using the B6/SJL hybrid background. These mice typically begin losing weight at 90-100
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days with a reported median survival of 128.9 (Leitner, 2009). The animals are euthanized
when unable to right themselves within 30 seconds of being placed on their backs.
Mouse models of ALS are attracting increased controversy as more trials that amelerate
symptoms in the mouse fail to translate to patients (Perrin, 2014). For these reasons, we have
taken steps to increase the translational potential of our research. First, we are only considering
miRNAs that are increased in both the rodent model and in human ALS autopsy tissue. Because
miR-155 levels are increased in peripheral blood cells in ALS patients (Butovsky et al., 2012),
enrollment for a clinical trial might be determined by elevated miR-155 levels. Similarly, the
efficacy of this targeted miR-155 therapy can be read out in peripheral cells throughout
treatment. Finally, antisense oligonucleotides have been tested in a Phase I trial in SOD1 human
ALS, suggesting this type of strategy to be safe and realistic (Miller et al., 2013).
Furthermore, most therapeutic studies in the mouse model prolong survival by delaying
onset of the disease rather than slowing progression of the disease (Benatar, 2007). However,
patients enter the clinic already sick. Therefore, an important metric for success is an extension
in disease duration as opposed to a delay in symptom onset. With the growing understanding of
the importance of neuroinflammation on disease pathogenesis and on miRNAs in diseases, the
work detailed here aims to further characterize the role of inflammatory mediators in ALS while
also testing the therapeutic potential of dysregulated miRNAs in ALS.

MATERIALS AND METHODS
Animals
All animal protocols were approved by the Institutional Animal Care and Use
Committee of Washington University at St. Louis and adhered to NIH guidelines. Animals were
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provided food and water ad libitum, and cages were changed once a week. All mice were
maintained in a 12-hour light/12-hour dark cycle and received routine veterinary monitoring.
Post-surgical mice were single-housed as to protect the sutures and tubing.
Alzet osmotic pump surgeries
Osmotic pumps were prepared per manufacturer protocol (pump model 2004 for 28 day
experiments; 2006 for 42 day experiments; Alzet). For implantation, mice were anesthetized in a
chamber with 5% isoflurane/oxygen mixture and confirmed to be unconscious before being
placed in Kopf Model 940 small animal stereotaxic apparatus, fitted with ear bars (Miller, 2013).
The catheter was oriented at 2.00mm lateral and 1.1mm posterior to bregma.
Treatment and analysis of B6/SJL SOD1G93A ALS mice
All B6/SJL SOD1G93A were gifted from Prize4Life and were previously confirmed to
have high and consistent SOD1G93A copy counts. Mice were implanted with osmotic pumps at 60
days of age containing 20ug/day anti-miR-155, 20ug/day scrambled control, or saline. Pumps
were removed at 102 days. Weekly IP injections (25mg/kg) began at 60 days of age and
continued until the mouse reached end-stage. For the first two weeks only, mice received an
additional weekly IP injection. Mice were weighed and assessed for neurological score biweekly
in blinded fashion starting at 60 days. A neurological score of 1 was given when 1) when the
mouse was no longer able to fully extend its legs; 2) when the mouse could no longer spread its
legs past midline when lifted by its tail; or 3) when significant hind limb tremors were present.
End-stage was defined as when the mouse was no longer able to right itself after being placed on
either side within 30 seconds. All involved in the administration and monitoring of the animals
were blinded with separate people involved in injecting and scoring the mice. Blinding was
broken only once all analyses were completed.
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Treatment and analysis of FVB SOD1G93A ALS mice
B6.FVB SOD1G93A mice were implanted with osmotic pumps at 80 days of age
containing 20ug/day anti-miR-155, 20ug/day scrambled control, or saline. Weekly IP injections
(25mg/kg) began at 60 days of age and continued until the mice were sacrificed. For the first two
weeks only, mice received an additional weekly IP injection. At 117 days mice were
anesthetized, euthanized, and tissue was harvested and flash frozen.
Human tissues
Patient tissues were analyzed with approval from the Institutional Review Board from
Washington University and Massachusetts General Hospital. Spinal cord autopsy tissue was
obtained from 16 ALS patients (9 male, 7 female; age range 34-79, mean 64; from Washington
University School of Medicine, Massachusetts General Hospital) and 12 non-ALS control
patients (6 male, 6 female; age range 51-80, mean 70; from National Disease Research
Interchange; clinical information in Table 2.2). Postmortem intervals ranged from 1 to 40 hours.
miRNA quantification
RNA was extracted from flash frozen tissue using miRNeasy kits per manufacturer’s
instructions (Qiagen). Mouse RNA integrity and yield were assessed by Nanodrop before
diluting to 2ng/µL for miRNA individual analysis. All rodent miRNAs were normalized to
endogenous U6. qPCR samples were quantified in technical duplicates on an Applied
Biosystems 7500 fast Real-Time PCR System.
mRNA quantification
For RT-qPCR of mRNA targets, RNA was normalized to 20ng/µL using Nanodrop.
Primers and probes for mRNA targets were purchased from Integrated DNA Technologies
(Coralville, IA). 40ng total RNA was quantified with either Express One-Step Superscript Kits
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(Invitrogen, Carlsbad, CA) or Power SYBR Green RNA-to-CT 1-Step Kit (Life Technologies,
Carlsbad, CA) as per the manufacturer’s protocol. Rodent RNA was quantified as technical
duplicates and normalized to GAPDH.
For TREM2 expression analysis in patients, extracted RNA was quantified and 40ng was
used as input for the Express One-Step Superscript qRT-PCR Universal (Invitrogen: 11781-200)
with validated Taqman assays for human TREM2 and three endogenous controls, GAPDH,
PPIA, and RPLPO (Applied Biosystems 4331182, 4333764F, 4333763F, 4333761F
respectively). Reactions were run in duplicate on an ABI 7500 fast thermocycler. TREM2
expression was normalized to the geometric mean of the three endogenous controls.
For TREM2 expression analysis in mice, total RNA was extracted from saline-perfused
and snap-frozen spinal cords of 8 end-stage SOD1G93A transgenic mice (Jackson Lab B6.CgTg(SOD1*G93A)1Gur/J) and 6 negative littermate controls. TREM2 expression was quantified
using a mouse-specific TREM2 TaqMan assay (Applied Biosystems; 4331182) and normalized
to the endogenous control SMRT using primers and probe from IDT DNA (Probe:
AGACGTCTCACACAAGGAAGGACTCGCC, Forward primer: GGGTATATTTTTGATACCTTCAATGAGTTA, Reverse primer TCTGAAACAGTAGGTAGAGACCAAAGC).
Reactions were run in duplicate on an ABI 7500 fast thermocycler.
Statistical analysis
Data are presented as mean ± SEM. All statistical tests were conducted with either
Graphpad Prism 6 Software or R version 3.0.1. Fisher’s exact test was used to compare
proportions of p.R47H carriers in cases and controls. Comparisons of TREM2 expression
utilized student t-tests, while correlations between TREM2 expression and subject characteristics
utilized Spearman correlations (continuous variables) or Mann-Whitney U (dichotomous
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variables). All neuroinflammation gene expression data were analyzed by ANOVAs followed
by Durnette’s post-hoc test. All survival and onset data were analyzed using both the MantelCox Log-Rank test and the Gehan-Breslow-Wilcoxon test.

RESULTS
anti-miR-155 significantly extends survival and disease duration in the SOD1G93A mouse
model. To test the therapeutic potential of antagonizing miR-155 in ALS, we treated a large
cohort of SOD1G93A mice at 60 days of age with continuous intraventricular infusion of antimiR-155 (n=22), scrambled control anti-miR (n=21), or saline (n=20). To account for any
peripheral role of miR-155, we supplemented the CNS treatment with weekly anti-miR or saline
IP injections (Fig 5.1A).
Beginning at 60 days of age, weights and neurological scores (Leitner, 2009) were
recorded biweekly. Onset was determined in two ways: age when weight peaked and age when a
neurological score of 1 was observed marking abnormal hind limb motility. Treatment and
monitoring continued until the animal reached end-stage, defined as when the animal was unable
to right itself within 30 seconds after being placed on its side (Fig 5.1B). There was no
significant change in disease onset as defined by either a neurological score of 1, although a
trending delay in neurological score 2 and 3 occurrence marking mid- and late- disease
phenotypes was observed in the anti-miR-155 treated mice (Fig 5.2). Likewise, no change in
onset as defined by age at weight peak was observed as well (Fig 5.3). However, survival was
significantly increased in only the anti-miR-155 treated mice (Fig 5.4A). These mice had a 9.5
day extension in survival over saline treated mice (p=0.006). There was no significant difference
in survival between scrambled treated and saline treated animals (Table 5.1). Our controls
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agreed with published survival data for SOD1G93A B6/SJL animals (129.5 vs 128.9 days)
(Leitner, 2009). Furthermore, disease duration was only significantly increased in the anti-miR155 treated animals (Fig 5.4B). These mice had a disease duration 14.5 days longer than saline
(38% extension, p=5.0x10-4) and 11 days longer than scrambled (27% extension, p=2.7x10-3).
There was no significant difference in disease duration between scrambled treated and saline
treated animals (Table 5.1).
Neuroinflammation Analysis in ALS-model mice and ALS Patient Autopsy Spinal Cord
Tissue
In the end-stage spinal cord tissue from four SOD1G93A C57BL/6 mice compared to four
littermate, non-transgenic controls, pro-inflammatory cytokines assayed showed marked
upregulation of their RNA transcripts (15 fold increase in IL-1β, 20 fold increase in TNFα) (Fig
5.5A). Furthermore, in a panel of seven chemokine ligands and four chemokine receptors, we
observed a drastic and highly significant increase in only two of the ligands (CCL2, CXCL10)
and one of the receptors (CXCR4) (Fig 5.5B).
Following the identification of a TREM2 risk allele by Janet Cady et al., (2014), I
examined spinal cord expression of TREM2 in lumbar spinal cord sections from 18 subjects with
ALS and found a 2.8-fold upregulation compared to controls (p=2.8x10-4; Fig 5.6A). Expression
levels did not correlate with age of onset, site of symptom onset, or presence of a known diseasecausing mutation (data not shown). However, the degree of upregulation showed a modest
inverse correlation with disease survival that was not statistically significant after correction for
multiple comparisons. Because markers of microglial activation are also upregulated in models
of SOD1 ALS (Hall et al., 1998), we evaluated TREM2 expression in SOD1G93A transgenic mice
and found a 13-fold increase compared to non-transgenic littermates (p=2.8x10-9; Fig 5.6B).
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Next, we measured when these and other neuroinflammation markers change during
disease progression by measuring mRNA in spinal cord tissue from 6 SOD1G93A C57BL/6 mice
and 6 non-transgenic controls at 3-week time point intervals between 9 weeks and end-stage
(~24 weeks). Most neuroinflammation markers, both cellular and molecular, were well
correlated and showed a small trending increase in expression as early as measured that became
robust and significant between 15 and 18 weeks of age (Fig 5.7). Of note, GFAP was
significantly increased by 2.2 fold at 15 weeks, and microglia/macrophage markers CD68 and
Iba1 were increased 2.6 fold by 18 weeks (p<0.001. Typical survival is 24 weeks of age. The
pan T cell marker, CD3, was more variable in expression and only reached significance at endstage. The 12 mice in the dynamic range of miR-155 expression, between 105 and 126 days of
age in the SOD1G93A C57/BL6 mouse model, showed strongest correlation with Iba1 and GFAP
over CD3; however, there was a correlation with all pro-inflammatory markers assayed (Fig 5.8).
anti-miR-155 treatment in SOD1G93A mice correlates with a distinct set of
neuroinflammatory markers in the mid-disease state, but not at end-stage.
To test if anti-miR-155 altered cellular or molecular inflammatory transcripts, we
quantified 16 immune and inflammation mRNAs in the end-stage spleen and 19 in the end-stage
spinal cord from 6 SOD1G93A B6/SJL mice per treatment group. In a mostly pooled analysis,
there was no robust change observed for any of these markers in end-stage mice. This included
markers for astrocytes (GFAP), microglia/macrophages (CD68, Iba1), lymphocytes (CD3, CD8,
TBX21), pro-inflammatory cytokines (IL1β, IL8, and TNFα), anti-inflammatory cytokines (IL4,
IL10), chemokines (CCL2, CXCL10, CXCR4) and growth factors (GDNF, IGF1, and IGFBP2)
(Fig 5.9).
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The lack of observable changes in neuroinflammatory transcripts in end-stage mice could
be attributed to a difference in survival/age upon harvesting tissue or to an overwhelming
increase in neuroinflammatory transcripts at the end-stage of disease that ultimately obscured
any subtle effect of our treatment. Therefore, we treated a separate cohort of ALS-model mice
and scarified them at a mid-disease stage to try to assess changes in immune cell number and
activation. In this second intervention experiment, we treated SOD1G93A FVB mice with either
saline, scrambled oligo, or anti-miR-155 oligo with osmotic pumps (20ug/day) and IP injections
(25mg/kg). This treatment lasted from 80 days of age until 117 days of age at which point all
mice were sacrificed and spinal cord tissues were harvested (n=7/group). In these mice, a panel
of 18 neuroinflammatory markers were measured by RT/qPCR. Of these, 6 targets were
significantly increased in only the anti-miR-155 treated mice over both saline treated and
scrambled treated mice. These included the pan T cell marker (CD3) a cytotoxic T cell marker
(CD8), a pro-inflammatory T-helper cell marker (TBX21), the pro-inflammatory cytokine (IL6),
and 2 chemokine ligands, CCL2 and CXCL10. Interestingly, previously correlated
neuroinflammatory markers including two other pro-inflammatory cytokines (TNFα, IL1β), an
astrogliosis marker (GFAP), and the chemokine ligand (CXCR4) were not significantly
upregulated (Fig 5.10).

DISCUSSION
To determine the therapeutic potential of targeting miRNAs in ALS, we first generated a
list of miRNAs changed in the SOD1G93A rodent model. Six of these miRNA changes are also
upregulated in familial and sporadic human ALS spinal cord. However, for each of these
miRNAs, whether the change contributes to disease progression or represents a
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compensatory/beneficial response remained unclear. To test the importance of the miRNA in
disease, we developed an antisense oligonucleotide strategy to inhibit miRNAs in the brain and
spinal cord.
We treated a large cohort of ALS-model mice with our novel anti-miR-155. Mice treated
with anti-miR-155 lived 10 days longer and had a 38% extension in disease duration. Therefore,
our data establish that the increased miR-155 negatively contributes to ALS disease progression
in the SOD1G93A mouse model. While it is self-evident that patients present after onset of
disease, the fact that miR-155 inhibition slowed disease progression may suggest that this
preclinical drug trial is particularly relevant for therapies. The majority of drugs tested in the
rapidly progressive SOD1G93A model prolong survival by delaying onset of the disease rather
than slowing progression of the disease. Of those studies that have reported extended disease
duration in the mouse model, the weighted mean difference in a meta-analysis was 10%, while
we here report a 38% extension in disease duration (Benatar, 2007). For further context, a
previous study using antisense oligonucleotides against SOD1 in rats did not significantly alter
onset, but extended survival by 10 days and extended disease duration by 37% (Smith et al.,
2006).
While a number of drugs tested in the SOD1 model have subsequently failed in human
clinical trials, we have taken steps to increase the translational potential of this preclinical model.
In order to have a validated in vivo experimental system for targets applicable to ALS patients,
we focused on miRNAs changed in both the rodent ALS model and in patient ALS tissue from
both familial and sporadic ALS patients. Because miR-155 levels are increased in peripheral
blood cells in some ALS patients (Butovsky et al., 2012), enrollment for a clinical trial could be
determined by elevated miR-155 levels. Similarly, the efficacy of this targeted miR-155 therapy
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can be read out in peripheral cells throughout treatment. Finally, antisense oligonucleotides have
been tested in a Phase I trial in SOD1 human ALS, suggesting this type of strategy to be safe and
realistic (Miller et al., 2013).
Our data clearly identify miR-155 as a promising therapeutic target for ALS and may
potentially apply more broadly to neurological disorders where miR-155 is increased including
multiple sclerosis (Junker et al., 2009) and in glioblastoma (D'Urso et al., 2012). However, as an
ALS therapeutic, some key preclinical issues still need to be addressed. It will be important to
test how CNS inhibition alone or peripheral blood cell inhibition alone affects survival in this
model since this will have direct implications for which compartment is the most important to
target with an anti-miR-155 therapy. In addition, how the timing of miR-155 inhibition will
affect survival needs to be examined. Also, our data defines other miRNAs that are increased in
ALS spinal cord tissue. Interestingly, all 6 of the patient-confirmed upregulated miRNAs (miR24, miR-142-3p, miR-142-5p, miR-146a, miR-146b, and miR-155) are well studied in the
context of immunity and inflammation (Pedersen and David, 2008; Sonkoly et al., 2008). Each
of these targets may be potential candidates for therapies for neurodegenerative disease and
testing them will require a similar approach to the one taken here. Another miRNA identified
here may have a more potent effect either alone or in concert with other miRNA targets.
Neuroinflammation has long been recognized to be an important component to disease
progression in ALS (Beers et al., 2006; Boillee et al., 2006) and in other neurological diseases
including Alzheimer’s disease (Hirsch and Hunot, 2009) and Parkinson’s disease (Eikelenboom
et al., 2006). Given the increased expression of our top miRNA targets in inflammatory cell
types, we were interested in better defining neuroinflammation events in ALS and in measuring
the role of our anti-miRs on these pathways.
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After finding that this same TREM2 variant, p.R47H, confers a 3 fold increased risk of
ALS, we studied the expression levels of TREM2 in patient autopsy tissue and in our ALSmodel mice. We found a 2.8-fold increase in TREM2 expression in the ALS spinal cord tissue,
and a 13 fold increase in the ALS-mouse model. Interestingly, higher TREM2 expression in
patient tissue correlated with shorter survival. These data support the recent finding that higher
levels of microglia activation correlated with the amount of upper motor neuron symptoms and
correlated with a more rapid disease progression (Brettschneider et al., 2012). These data further
suggest that studies of microglial activation and their phagocytic function may provide insights
relevant to human ALS.
As further characterization of neuroinflammation in ALS, we measured several pro- and
anti-inflammatory markers in the ALS-mouse model throughout various disease stages. In
agreement with published work (Beers et al., 2011), we found significant increases in proinflammatory cellular and molecular markers at a mid-disease stage that were well correlated.
Specifically, we observed robust increases in markers for astrogliosis, microgliosis, and T cell
infiltration. We further defined 3 chemokines as enriched in the ALS-model mouse spinal cords.
CCL2, CXCL10, and CXCR4 were selectively increased out of the 7 chemokine ligands and 4
receptors quantified. Because several neuroinflammatory markers were highly correlated in our
panels, we were unable to discern if one cell type or signal best characterizes the increase in
miR-155 levels, either by cause or by consequence. For future study, we would like to isolate
RNA and protein from particular cell types at various disease stages and correlate the change in
expression of inflammatory markers with miR-155. This can be achieved by either FACS or with
our miRAP method characterized in chapter 3. To this end, we are currently generating tripletransgenic mice in which selective neuronal or glial subtypes express GFP-tagged miRNA
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processing proteins in the ALS-mouse model. Please see chapter 6 for more details for this
experiment.
While all SOD1G93A treated mice had markedly similar quantities of neuroinflammation
specific transcripts in end-stage spinal cord tissue independent of anti-miR treatment, these data
may not be indicative of a lack of mechanism of our oligos on neuroinflammation. Instead, it is
possible that difference in survival/age upon harvesting tissue negated any delay or alteration in
neuroinflammatory pathways, and/or that the immune system ultimately overwhelms the tissue at
the end-stage of disease making it difficult to observe any subtle effect of our treatment.
Therefore, we treated a separate cohort of ALS-model mice and scarified them at a mid-disease
stage to try to assess changes in immune cell recruitment and activation. We performed these
subsequent experiments on the FVB background due to mouse availability, and we therefore
attempted to scale the ages to correlate to our B6/SJL treatment experiment. While B6/SJL ALSmodel mice live on average to 128.9 days (Melanie Leitner, 2009), our FVB mice live to 149
days on average. We therefore delayed treatment commencement from 60 days to 80 days.
Likewise, because miR-155 is increased between 105 and 126 days in the C57BL/6 line whose
typical survival is 157 days (Melanie Leitner, 2009), we collected spinal cord tissue from the
FVB mice at 117 days.
In SOD1G93A FVB mice treated with anti-miR-155, interestingly, we observed a
significant increase in 6 transcripts from our neuroinflammation panel. These included the pan Tcell marker (CD3) a cytotoxic T-cell marker (CD8), a pro-inflammatory T-helper cell marker
(TBX21), the pro-inflammatory cytokine (IL6), and 2 chemokine ligands, CCL2 and CXCL10.
Of note, while these neuroinflammatory markers were previously shown to be well correlated in
the ALS-mouse models with several other assayed neuroinflammation transcripts, only these
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particular markers were increased following our anti-miR treatment. For example, while IL6 was
robustly increased in anti-miR-155 treated ALS-model mice, three other typically well-correlated
cytokines, TNFα IL1β, and IL8, were unchanged following miR-155 inhibition. Likewise, while
the two chemokine ligands previously identified as increased in ALS were increased, the
chemokine receptor CXCR4 was not significantly different between treatment groups. The
specificity of these 6 neuroinflammatory changes in responses to miR-155 inhibition suggest
against an off-target, oligo toxicity response. Furthermore, our scrambled oligo is synthesized
with an identical backbone to account for off-target and toxic effects. Nonetheless, these data are
counterintuitive given the work by others in the periphery and in vitro showing miR-155 to be a
pro-inflammatory mediator (Androulidaki et al., 2009; Kurowska-Stolarska et al., 2011).
However, these discrepancies may be explained by tissue specific differences or by a more
complex role for miR-155 in particular. For example, miR-155 has an almost perfect correlation
with miR-146a, thought to be an anti-inflammatory mediator (Bhaumik et al., 2009; Lu et al.,
2010). Multiple miRNAs may be tightly regulated such that modulating one effects the
expression and function of other correlated miRNAs leading to coordinated and complex results.
Therefore, as performed here, it is important to measure the effect of miRNA modulation in the
state of the cell downstream of direct miRNA-mRNA targets.
Typically, microglia are thought to enter an alternatively activated state (M2) early in
disease that confers protection and then switch to a pro-toxic and deleterious classically activated
state (M1) later in disease (Beers et al., 2011). M1 microglia are characterized with toxic
cytokines including IL-6 and TNF-α whereas M2 microglia are characterized by antiinflammatory cytokines including IL-4 and IL-10 (Mantovani et al., 2002). However, a recent
study suggested that ALS microglia differ from this strict M1/M2 paradigm (Chiu et al., 2013).
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That is, ALS microglia concurrently express factors thought to suppress neurodegeneration
including IGF-1 and progranulin as well as factors thought to be neurotoxic including Nox2. In
fact, cytotoxic CD8+ T cells were found to potentially stimulate phagocytosis in microglia, long
considered to be a beneficial role of microglia (Rogers et al., 2002). Overall, it remains difficult
to attribute a beneficial or determinate role of microglia to a polarized phenotype (ie M1 vs M2)
or with specific markers of neuroinflammation, including these six altered neuroinflammatory
markers following anti-miR-155 treatment. Therefore, unbiased approaches to modulate
microglia number and activation states paired with behavioral and survival readouts remain
important in order to gain insight into the complex role of immune cells in ALS.
While these data may be considered supportive for a role in increasing microglia and
lymphocyte activation and recruitment in the ALS-mouse model, it is unclear if this is the
mechanism of action for our anti-miR treatment. In data presented in Chapter 3, we saw a
reduced but real signal of miR-155 in neurons, and in Chapter 4, we showed that anti-miR-155 is
taken up by neurons, microglia, and astrocytes. We do not know if there is one cell type that is
critical to the ameliorating effect of anti-miR-155 in the ALS-mouse model or which cell type
this may be. One possible future experiment to discern this would be a peripheral vs central
treatment experiment, further detailed in the Chapter 6.

CONCLUSION
We have demonstrated a therapeutically relevant method to inhibit miRNAs broadly in
the brain and spinal cord for the first time. We have also supplied the first published list of
altered miRNAs in ALS spinal cord tissue, and we have demonstrated that miRNA inhibition can
prolong survival in a neurodegeneration model. Anti-miR-155 treatment extended survival in a
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mouse-model of ALS by 10 days, corresponding to a 38% increase in disease duration. Given the
putative role of miR-155 in immune cells, we characterized neuroinflammatory pathways in
ALS-model mice and again in our anti-miR treated mice. Among the characterized targets,
TREM2 and distinct chemokines were found to be upregulated in ALS. While our end-stage
anti-miR treated ALS-model mice showed no alterations in a mRNA neuroinflammation panel, a
separate cohort of treated mice sacrificed at a mid-disease stage showed a striking increase in 6
specific inflammatory markers. However, it remains unclear if this observation represents the
mechanism through which anti-miR-155 extended survival. miRNA inhibition, and miR-155
specifically, remain exciting avenues for ALS research as potential therapeutic targets.
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Figure 5.1: anti-miR-155 treatment and observation experiment overview in SOD1G93A
mice. (A) SOD1G93A B6/SJL mice were treated with osmotic pumps directed to the cerebral
lateral ventricle and with weekly intraperitoneal (IP) injections (25mg/kg) starting at 60 days of
age (n=21/group). Osmotic pumps contained either saline, scrambled oligo, or anti-miR-155
(20ug/day). For the first two weeks, mice received an additional IP injection. At 102 days, the
osmotic pumps were removed, but the catheter and tubing remained intact, and the weekly IP
injections continued. (B) Mice were weighed and neurological scores were determined biweekly.
A score of 1 marked onset and was characterized by the following: 1) failure to fully extend legs
when lifted by tail; 2) failure to spread legs past midline when lifted by tail; or 3) marked tremors
when lifted by tail. Mice were euthanized when unable to right itself within 30 seconds of being
placed on either side. Age at weight peak until end stage gave an overall measure of disease
duration.
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Saline
Scrambled
anti-miR-155

Figure 5.2: No significant change in neuroscore onsets occurred for any treatment group.
The ALSTDI neurological scoring system was used to track disease onset and progression. A
score of 1 defines onset and marks 1) failure to fully extend legs when lifted by tail; 2) failure to
spread legs past midline when lifted by tail; or 3) leg tremors when lifted by tail. A neuroscore of
2 is given when a mouse’s toes curl under twice in walking 2 cage lengths. A neuroscore of 3 is
assigned when either leg is fully paralyzed and not used to generate any forward movement. (A)
Saline, scrambled, and anti-miR-155 treatment groups all showed similar ages at time of onset,
defined by reaching a neuroscore of 1 (median age: 115, 115, 113 days respectively). (B,C) Time
to mid- and late- disease stages, defined by neuroscores of 2 and 3 respectively, were similar
between treatment groups with anti-miR-155 group beginning to show a non-significant trend in
delay (median NS2: 124, 127, 131 days; median NS3: 129, 134, 138 days for saline, scrambled
and anti-miR-155 groups respectively).
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Figure 5.3: Weight peak, as an alternative measure of disease onset, was also insignificantly
changed between treatment groups for both genders. Saline, scrambled, and anti-miR-155
treatment groups showed no significant change in weight peak (A) which was true when only
females were analyzed (B) and only males (C). Median values for weight peak were not
significantly changed for any treatment group (saline: 91.5 days, scrambled: 90 days, anti-miR155: 87 days) (D).
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Figure 5.4: Survival, but not onset, is extended in anti-miR-155 treated ALS mice. AntimiR-155 treated mice had a significant extension in survival and a 38% extension in disease
duration over saline. (median values shown, log-rank test, *p<0.01, **p<0.01, ***p<0.001).
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Figure 5.5: Distinct cytokines and chemokines are robustly increased in end stage ALSmodel mice. RNA was extracted from whole spinal cords from 4 end-stage SOD1G93A mice and
4 littermate controls and analyzed for expression of neuroinflammatory mediating signaling
transcripts. (A) Two pro-toxic cytokines, IL-1β and TNFα, were robustly increased in the ALSmodel mice, 15 fold and 20 fold respectively. (B) A Panel of 7 chemokine ligands showed CCL2
to be significantly increased 15 fold and CXCL10 by 10 fold. All other chemokine ligands were
insignificantly changed. One receptor, CXCR4, was significantly increased by 4 fold as well.
(*** p<0.001)
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Figure 5.6: TREM2 expression is increased in human ALS and in SOD1G93A mouse spinal
cord. (A) TREM2 expression was measured by qPCR in patient autopsy spinal cord tissue from
18 ALS subjects and 12 controls and normalized to the geometric mean of three endogenous
control genes, GAPDH, PPIA, and RPLPO, and was found to be significantly increased by 2.8fold. (B) In mice, expression was measured in spinal cords from 8 SODG93A mice and 6 wildtype littermate controls with normalization to an endogenous control, U6, and was found to be
significantly increased by 13-fold. P-values were calculated using two-tailed student’s t-test.
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Figure 5.7: Several cellular and molecular markers for neuroinflammation are well
correlated and robustly increase at a mid-disease stage. Spinal cords were harvested from 6
SOD1G93A mice every 3 weeks from 9 weeks until end-stage in disease, and extracted mRNA
was quantified via qPCR. Cellular markers for astrocytes (A) is significantly increased by 105
days of age (2.2 fold increase over 63-days, p<0.01). CD68 (B) and Iba1 (C), two markers for
microglia and macrophages, are both significantly increased by 126 days (2.6 fold increase,
p<0.001). (D) Cybb, a maker for pro-inflammatory M1 macrophages/microglia, was
undetectable until 126 days, in a pooled analysis. (E,F) Two activation markers, Trem2 and
CD39, likewise show large enrichment starting at 126 days, by pooled analysis. (G) CD3, a pan
T-cell marker, had inconsistent expression between mice during each time point and only
reached a significant level of increase at end-stage (6.7 fold increase, p<0.05) but showed a
trending increase at 126 days. (H) CD8, a marker for cytotoxic T cells, begins increasing
expression at 10 days by pooled analysis. (I) IL-1β, a pro-inflammatory cytokine, is undetectable
until 105 days, whereas TNFα (J), also a pro-inflammatory cytokine, is upregulated beginning at
126 days. (K-M) 3 chemokines previously identified as increased in end-stage ALS tissue are all
mildly increased at 126 days with robust upregulation occurring at 146 days by pooled analysis.
Statistics determined by ANOVA with Dunnett’s multiple comparison post-hoc test.
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Figure 5.8: Markers for microgliosis and astrogliosis more closely correlate with miR-155
levels over a marker for T Cells. Because miR-155, miR-146a, and miR-142-3p begin
upregulation at 105 days that becomes robust and significant at 126 days (Chapter 2, Figure 5.4),
we correlated inflammatory cell specific transcripts in the 12 ALS-model mice whose spinal
cords were collected between these time points. While many neuroinflammatory markers showed
correlations with miR-155 levels, Iba1 and GFAP were particularly well correlated with miR155 expression (r=0.84 and 0.83 respectively).
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Figure 5.9: No significant changes in a panel of neuroinflammatory markers were observed
in end-stage B6/SJL SOD1G93A mice treated with saline, scrambled, or anti-miR-155 oligo.
Spinal cord RNA from 6 SOD1G93A mice from each treatment group and from non-transgenic
mice were quantified by qPCR in a panel of neuroinflammatory markers. These markers include
those for astrogliosis (GFAP), microglia activation and proliferation (CD68, Iba1, Ly6C, Cybb,
TREM2, CD39), for T cell infiltration (CD3, CD8, TBX21) chemokine signaling (CCL2,
CXCL10, CXCR4), pro-inflammatory cytokine signaling (IL1β, IL8, and TNFα), anti172

inflammatory cytokine signaling (IL4, IL10), and various growth factors (GDNF, IGF1, and
IGFBP2). Most of these markers were assayed in a pooled analysis by treatment group. Any
marker that appeared changed in anti-miR-155 treated mice over both saline and scrambled mice
was then analyzed individually in order to determine significance. This was completed for both
end-stage spinal cords (A) and spleens (B); however, no significant change was observed
following treatment for any marker here quantified.
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Figure 5.10: FVB SOD1G93A ALS-model mice treated with anti-miR-155 and sacrificed at a
specific mid-disease time point have a robust increase in a distinct set of
neuroinflammatory markers. SOD1G93A FVB mice were treated with osmotic pumps and IP
injections containing either saline, scrambled oligo, or anti-miR-155 (20ug/day pump; 25mg/kg
IP) beginning at 80 days of age (n=7/group). All mice were sacrificed at a mid-disease stage, 117
days, and mRNA from their whole spinal cords were quantified by qPCR. (A) A panel of 18
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cellular and molecular markers for pro- and anti-inflammatory pathways was quantified.
Interesting targets were those in which anti-miR-155 treated mice had a significant difference in
a transcript over both saline and scrambled treated mice. 6 out of the 18 markers tested were
significantly increased in anti-miR-155 treated mice at a p-value less than 0.01 by ANOVA with
a Tukey’s post-hoc multiple comparison correction. Showing the individual data points for each
mouse, anti-miR-155 treated ALS-model mice had significantly increased pro-inflammatory cell
type markers including a pan T cell marker (C), a cytotoxic T cell marker (C), and a proinflammatory Th1 cell marker (E). Also, the cytokine IL6 was robustly increased (F), as were 2
chemokines (G,H), previously identified as increased in ALS. A microglia specific marker, Iba1,
showed a non-significant trend towards also being increased following anti-miR-155 treatment
(B).
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Onset (days)
Saline
Scrambled
anti-miR-155
Saline
Scrambled
anti-miR-155
Survival (days)
Saline
Scrambled
anti-miR-155
Saline
Scrambled
anti-miR-155

Weight Peak
p-value:
91.5
Sal - Scr
90
Sal - 155
87
Scr - 155
Neuroscore
112.5
Sal - Scr
115
Sal - 155
115
Scr - 155
Survival
p-value:
129.5
Sal - Scr
133
Sal - 155
139
Scr - 155
Disease Duration
38.5
Sal - Scr
42
Sal - 155
53
Scr - 155

Log-Rank Wilcoxon
0.10
0.26
0.13
0.12
0.82
0.49
0.60
0.29
0.21
0.19
0.54
0.81
Log-Rank Wilcoxon
0.51
0.24
0.007**
0.007**
0.018*
0.035*
0.081
<0.001***
0.038*

0.15
0.003**
0.047*

Table 5.1: anti-miR-155 treated mice have extended survival and disease duration over
both saline and scrambled treated mice. Median onset values are denoted for saline (n=20),
scrambled (n=21), and anti-miR-155 (n=22) treated mice as determined by both age when the
mouse reached weight peak and by a neurological score of 1. There was no significant change
between either onset condition by both Mantel-Cox log-rank and Gehan-Breslow-Wilcoxon
tests. However, survival and disease duration were significantly extended in only the anti-miR155 treated mice over both saline and scrambled mice as determined by both log-rank and
Wilcoxon tests. P-values are given for the indicated paired comparison (ex: Sal – Scr).
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CHAPTER 6

Conclusions, implications, and future directions
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Summary
MicroRNAs (miRNAs) are a newly discovered class of translational repressors with the
power to modulate large numbers of genes upon incorporation into the Ago2 containing RNA
induced silencing complex (RISC) via partial complementarity to target mRNAs (Bartel, 2009;
Selbach et al., 2008). In studying the role of miRNAs in ALS, a microarray of miRNAs in ALS
model SOD1G93A rodent spinal cord tissues identified 12 miRNAs as significantly upregulated.
Six of these miRNAs tested in human ALS tissues were confirmed increased. Specifically, miR155 was increased 5-fold in mice and 2-fold in human spinal cords. miR-142-3p, miR-146a, and
miR-155 showed an almost perfect correlation in dynamic expression patterns throughout
disease in the ALS mouse model. Despite optimizing methods for miRNA isolation from lowabundance samples, these miRNA targets do not appear to be ALS serum biomarkers.
Following conflicting data on the cell-specific expression of miR-155 using conventional
methods, we developed mice that permit high-throughput identification of cellular expression of
microRNAs in neurons, motor neurons, astrocytes, and microglia. This was achieved by creating
mice that express a GFP-myc tagged microRNA binding protein, Ago2, driven by Syn, ChAT,
GFAP, or Lyz2 promoters, respectively. Using whole brainstem or whole spinal cord tissue
input, immunoprecipitation with anti-myc conjugated magnetic beads allowed the pull-down of
GFP-myc-Ago2 and its associated miRNAs from only the specific cell type of interest.
Following validation of these mice though molecular and histological analysis, we performed
miRNA microarrays on 3 mice from each line with brainstem and spinal cord whole tissue
inputs. From this, we have generated a dataset of several hundred miRNAs and their cellular
expression patterns in neural tissues. Specifically, we found miR-155 to be expressed at over 300
fold greater level in spinal cord microglia over neurons.
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To test miRNA inhibition in the central nervous system as a potential novel therapeutic,
we developed oligonucleotide-based miRNA inhibitors (anti-miRs) that could inhibit miRNAs
throughout the central nervous system and in the periphery. Anti-miR-155 caused global
derepression of targets in peritoneal macrophages and, following intraventricular delivery,
demonstrated widespread functional distribution in the brain and spinal cord. After treating
SOD1G93A mice with anti-miR-155, we significantly extended survival by 10 days and disease
duration by 15 days (38%) while a scrambled control anti-miR did not significantly improve
survival or disease duration.
Given the enrichment of miR-155 in glial cells in the brainstem and spinal cord, we tested
if anti-miR-155 treatment affected the expression levels of neuroinflammatory transcripts for the
prevalence and activation of astrocytes, myeloid cells, and lymphocytes. While no significant
changes were observed in tissues from treated end-stage ALS-model mice, a separate cohort of
SOD1G93A treated mice sacrificed at a defined mid-disease stage showed that anti-miR-155
treatment correlated with significant increases in 6 specific markers of inflammation. Increased
were transcripts for cytotoxic T cells, CD8 and TBX21, the pro-inflammatory cytokine Il6, and
the chemokine ligands CCL2 and CXCL10. While not necessarily the mechanism through which
anti-miR-155 confers a survival benefit, these studies better inform the complex nature of
neuroinflammation in ALS. Overall, we have found that microRNAs are dysregulated in ALS,
developed a high-throughput method of determining cell-specific expression of microRNAs,
developed antisense oligonucleotides that can be used to successfully inhibit miRNAs
throughout the brain and spinal cord, and discovered that miR-155 is a promising new
therapeutic target for ALS.
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Implications of the dissertation
Lists of dysregulated miRNAs have been generated for a myriad of neurodegenerative
diseases including Alzheimer’s disease (Delay and Hebert, 2011), Parkinson’s disease
(Mouradian, 2012), Huntington’s disease (Lee et al., 2011), and ALS (Campos-Melo et al.,
2013). However, fewer studies examine the role of the dysregulated miRNAs, if these
microRNAs are important to disease progression, or if they are beneficial or detrimental
contributors to disease pathology. Limitations in understanding the function of miRNAs in
neurological disease is likely due in part to an inability to effectively modulate miRNA
expression in vivo. Given our lab’s experience using antisense oligonucleotide (ASO) technology
to inhibit mRNAs (Miller et al., 2013; Smith et al., 2006), we were well suited to translate these
methods to inhibit miRNAs – both in terms of optimal delivery methods to target the central
nervous system and with optimal ASO modifications that serve to increase potency and decrease
drug toxicity.
To test the function of particular miRNAs of interest in the brain and spinal cord, we
needed to develop a method to safely and effectively modulate miRNA expression and/or
function in the CNS. After screening multiple anti-miR modifications in vitro and in vivo, we
found superior target engagement and minimal toxicity with alternating blocks of 2’-MOE and
2’fluoro sugar-modified nucleosides. Because ASOs are highly charged molecules that do not
readily cross the blood-brain barrier, we tested the ability to broadly inhibit miRNAs of interest
throughout the brain and spinal cord with implanted Alzet osmotic pumps that continuously
infused anti-miRs directly into the cerebral lateral ventricle. We found that mice that received
anti-miR treatment with this method had a broad distribution of the anti-miR in brain and spinal
cord tissue and that the oligo was taken up by multiple cell types including neurons, microglia,
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and astrocytes. Also, the miRNA of interest was successfully inhibited following anti-miR
treatment, as determined by observing a derepression of target mRNA transcripts. Developing a
method to effectively inhibit miRNA function in the CNS in vivo was essential to test the
function of our miRNAs of interest in ALS and will likely prove useful to other studies of
upregulated miRNAs in various neurological disorders.
While we directly infused anti-miRs to the rodent cerebral lateral ventricle, success in
clinic has been achieved using a similar direct-infusion method. Recently, in a Phase I safety
trial, ALS patients treated with an ASO against SOD1 via intrathecal spinal cord injections
showed no adverse events related to the drug or the dose showing that a direct infusion method
for ASO therapy is not only valid for preclinical rodent-based experiments but also has
translational promise. More so, anti-miRs have been used safely and effectively in the periphery
in recent human clinical trials (NCT00688012 and NCT00979927) (Janssen et al., 2013). The
inability to target miRNA inhibitors broadly to the central nervous system was previously a
limitation in miRNA research. Our novel treatment method to inhibit miRNAs in the brain and
spinal cord using ASOs delivered directly to the CSF can now be used to study the importance of
dysregulated miRNAs in various neurological disease rodent models in a manner that has true
translational relevancy.
The most common model used for ALS translational research is the SOD1G93A mouse
model; however, growing controversy exists on the usefulness of SOD1 ALS rodent models as
more clinical trials fail to translate rodent targets to patients (Benatar, 2007; Perrin, 2014).
Therefore, in studying the role of miRNA in ALS, we have taken steps to increase the
translational potential of our use of this preclinical model. The considerations detailed here serve
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to both increase confidence in the relevancy of our rodent-based data and also serve as a
potential guide to other therapeutic studies using the ALS mouse model.
One limitation of the popular SOD1G93A rodent model is that it only represents ALS
caused by a single genetic mutation, which 98% of ALS patients do not harbor. Furthermore, in
order to accelerate in vivo experiments, the ALS-rodent model was created to be highly
aggressive, with the genomic insertion of approximately 15 copies of the ALS-causing gene.
Due to these concerns over the ability of the SOD1G93A rodent line to accurately model ALS
disease broadly, we used multiple rodent models and patient tissue samples to determine
miRNAs of interest. Dysregulated miRNAs were only considered if they were identified in both
the mouse and rat SOD1G93A models over nontransgenic rodents. More so, for rats, these
miRNA targets had to be similarly altered over the SOD1WT rat line, which expresses
approximately 15 copies of the wild-type human SOD1 gene. Furthermore, the morecontroversial TDP-43A315T ALS-FTD mouse line was used as a secondary validator of our top
targets. Finally, we only considered important those miRNAs increased in both the rodent ALS
model and in patient ALS tissue from both familial and sporadic ALS patients. The stringency
used in identifying dysregulated miRNAs in ALS potentially caused some interesting miRNAs
to be overlooked but served to increase confidence and reduce the number of false positive
targets, which is an important consideration given the climate of failed clinical trials based on
rodent research.
This dissertation work has strong therapeutic implications in ALS research given the
numerous considerations taken in the design, execution, and analysis of these experiments in
order to increase translational relevancy. Most therapeutic experiments in ALS-model mice
that report a positive effect serve to delay onset (on average by 12 days) but do not robustly
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extend disease duration (on average 3 days) (Benatar, 2007). As ALS patients typically enter
the clinic after symptom onset, the most relevant therapeutic targets will likely be those that
slow disease progression. Therefore, we carefully tracked both onset and survival measures in
our treated ALS-model mice through both weight and neurological score assessments in order
to accurately determine if our anti-miR treatment served to delay onset or extend disease
duration. Also, we performed sample size calculations to determine the required number of
mice required to observe a 10-day effect at 80% power, a necessary step in planning therapeutic
experiments that is often overlooked in ALS research resulting in many underpowered
experiments (Perrin, 2014). More so, while important studies, several published experiments in
the ALS-model use methods that are not translatable to patients including genetic ablation
(Beers et al., 2008) or target genes not expressed in humans (Butovsky et al., 2012). With the
goal to determine potential miRNA therapeutic targets, we only considered miRNAs that were
also human targets and only modified them in a manner relevant to potential clinical trials. Of
published studies that have reported an extension in disease duration in the ALS-mouse model,
the weighted mean difference in a meta-analysis was 10%, while we report a 38% extension in
disease duration following anti-miR-155 treatment (Benatar, 2007). For further context, a
previous study using antisense oligonucleotides against SOD1 in rats did not significantly alter
onset, but extended survival by 10 days and extended disease duration by 37% (Smith et al.,
2006). Our data clearly identify miR-155 as a promising therapeutic target for ALS and may
potentially apply more broadly to neurological disorders where miR-155 is increased including
multiple sclerosis (Junker et al., 2009) and in glioblastoma (D'Urso et al., 2012). Importantly,
inhibition of miR-155 extended survival using an ASO and a method with application to
patients showing real therapeutic potential.
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One possible limitation of our research is that we began treatment in the ALS-mouse
model at 60 days of age – approximately 30 days prior to the most common definition of the
onset of disease - weight peak. However, the definition of symptom onset remains controversial
in the ALS field. For example, subtle changes in the gait SOD1G93A mice can be observed at 8
weeks of age, well before weight loss is observed (Mancuso et al., 2011). Given the importance
of conducting rodent preclinical studies in a manner best applicable to patients, we will test the
effects of anti-miR-155 on survival in SOD1G93A mice with later treatment commencements.
Because miR-155 expression begins to be upregulated at a mid-disease stage, we hypothesize
that starting treatment at a later age will be similarly efficacious.
Next, arguably the most difficult aspect of miRNA research is understanding the
function of the miRNA of interest. Because several miRNA experiments use animal and patient
samples comprised of multiple cell types, the first step to understanding the role of a particular
miRNA is to understand its cellular expression. The most popular methods for determining
miRNA expression patterns in distinct cell types are fluorescence activated cell sorting (FACS),
laser capture microdissection (LCM), cell culture models, and in situ staining; however, each of
these methods has significant limitations. First, both FACS and LCM are low yield and require
cellular dissociation and manipulations ex vivo that can introduce cellular stress and alter gene
expression (Avvisato et al., 2007). Cell culture models often do not accurately describe the
nature of in vivo cells, and miRNA in situs are technically difficult, expensive, and low
throughput, only testing a single miRNA per experiment. In response to these limitations, we
have adapted the recently published miRNA tagging and affinity purification (miRAP) method
(He et al., 2012) to generate high-throughput and physiologically relevant lists of miRNA
expression levels in neurons, motor neurons, microglia, and astrocytes in the mouse brain and
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spinal cord. By creating mice that express a tagged miRNA binding protein behind cell type
specific drivers, we were able to isolate miRNAs from specific cell types through
immunoprecipitation of whole tissue input. miRAP has several advantages over traditional
methods to quantify miRNAs from specific cell populations. One major benefit of a miRAP
approach is that once the tissue of interest is isolated from the mouse, the first experimental step
is to lyse the cells. This allows the isolated RNA to closely mimic its native state. This is
especially important for neuroinflammatory regulators that quickly change expression patterns
based on their environment. Second, this method allows for miRNAs throughout the cell to be
isolated, including in dendrites and synapses that were previously hard to isolate with
conventional methods. Third, unlike in situ’s that test one miRNA at a time, miRAP is a highthroughput method allowing for quantification of hundreds of miRNAs. Finally, by isolating
miRNAs bound to Ago2, only “active” miRNAs that have been incorporated into the RNA
induced silencing complex (RISC) are being isolated. Overall, our high-throughput and
physiologically relevant lists of miRNA expression patterns in neuronal and glial cell
populations can potentially aid miRNA research broadly. Several lists of dysregulated miRNAs
in disease have been generated using whole brain and spinal cord tissue, and in order to
understand the physiological and pathological role of miRNAs, it is first necessary to know their
cellular expression patterns for which these miRAP lists may be a reference.
The miRAP expression data sets may serve as a first-step to use descriptive lists of
dysregulated miRNAs using whole tissues to design mechanistic experiments that aim to
determine miRNA function. Our ALS-based research serves as one example of this potential. By
quantifying miRNAs in end-stage ALS-model mouse spinal cord tissue as compared to littermate
controls, we identified 6 miRNAs that were also upregulated in ALS patient autopsy spinal cord
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tissue. Using the miRAP data sets that compare neuron, motor neuron, microglia, and astrocyte
miRNA expression levels, we identified that one particular miRNA of interest, miR-155, was
most enriched in microglia in the brain and spinal cord over the other cell types measured. With
this expression data and the understanding that microglia play critical roles in neuroinflammation
in ALS, we were therefore interested in studying alterations in neuroinflammatory pathways
following anti-miR-155 treatment in ALS-model mice as a potential mechanism of action for
miR-155. This serves as one example of the ability of the miRAP data sets to bridge descriptive
and mechanistic miRNA experiments in the central nervous system. Finally, with the use of
additional established Cre-drivers, the method for generating, validating, and using the miRAP
mice detailed in Chapter 3 can be adapted for studying miRNA expression patterns in other cell
types of interest.
Neuroinflammation has been well characterized in ALS, both in patients and in the
mouse model. Increased numbers of microglia can be observed in affected tissues including the
ventral horns of the spinal cord, corticospinal tracts, brainstem motor nuclei, and the motor
cortex (Weydt and Moller, 2005). A number of recent experiments using the ALS-mouse model
suggest that while overall blunting of the immune system is potentially detrimental, selectively
modulating and even increasing components of the neuroimmune response in ALS may be
beneficial. However, one of the largest remaining questions in studying neuroinflammation in
ALS is whether microglia and lymphocytes are neuroprotective, neurotoxic, or both and whether
modulating their activation states could be a valid therapy.
Given the putative role of miR-155 in being an immunomodulator (O’Connell et al.,
2007), its heightened expression in microglia, and the well characterized role of microglia in
neuroinflammation in ALS, we quantified several transcripts of cellular and molecular markers
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of neuroinflammation in ALS mice treated with anti-miR-155. While SOD1G93A mice treated
with anti-miR-155 showed no significant change in the expression of any of the 19
neuroinflammatory transcripts measured in spinal cord tissue at the end-stage of disease, middisease stage treated mice had a significant increase in transcripts for a pan T-cell marker (CD3)
a cytotoxic T-cell marker (CD8), a pro-inflammatory T-helper cell marker (TBX21), a proinflammatory cytokine (IL6), and 2 chemokine ligands, CCL2 and CXCL10. These alterations
are not thought to be caused by oligo toxicity as other pro-inflammatory transcripts were
unchanged (including TNFα, IL-1β) and because treatment with a scrambled oligo that contains
the same backbone modifications did not alter these transcript levels.
These data are interesting as they suggest that relatively recent definitions in ALS of
‘good’ M2 microglia correlated with anti-inflammatory transcripts and ‘bad’ M1 microglia
correlated with pro-toxic cytokines is either too simplistic or incorrect. In 2013, by performing
deep RNA sequencing, microglia from ALS-model mice were shown to have the potential to be
concurrently both cytotoxic and protective by expressing a mixture of “M2” and “M1” genes
throughout disease including IGF-1, Progranulin, DAP12 and MMP-12, Optineurin, and Nox2
respectively (Chiu et al., 2013). Furthermore, research in Alzheimer’s disease suggests a
beneficial role for microglia that express proinflammatory cytokines. By treating (APPSwe)/PS1
AD model mice with the cytokine colony-stimulating factor (M-CSF), mice had a lower βamyloid plaque burden along with improved performances in learning and memory tasks
(Boissonneault et al., 2009). These data support a beneficial role of microglia likely through
increased phagocytosis and clearance of toxic proteins and cells. Overall, it remains unclear the
best way to therapeutically target the immune response in ALS. However, in light of these recent
studies, our observation of an increase in pro-toxic cytokines and T-cells transcripts following
192

anti-miR-155 treatment can be potentially better understood. One possible model in which antimiR-155 treatment results in a survival benefit in ALS-model mice is through alterations in
neuroinflammatory properties, resulting in the increased clearance of detrimental proteins and/or
cells potentially through augmenting microglia number or their activation profiles. Future
experiments that target components of the inflammatory response will be required to test the
validity and refine this hypothesis.
While our data may be considered supportive for a beneficial role in furthering microglia
and lymphocyte activation and recruitment in the ALS-mouse model, it is unclear if this is the
mechanism of action for our anti-miR treatment. In data presented in Chapter 3, we saw a
reduced but real signal of miR-155 in neurons, and in Chapter 4, we showed that anti-miR-155 is
taken up by neurons, microglia, and astrocytes. We do not know if there is one cell type that is
critical to the ameliorating effect of anti-miR-155 in the ALS-mouse model or which cell type
this may be but have proposed experiments to discern this that are detailed later in this chapter.
Overall, we have demonstrated a therapeutically relevant method to inhibit microRNAs
broadly in the brain and spinal cord for the first time. We have also supplied the first published
list of altered microRNAs in ALS spinal cord tissue. To aid in understanding the role of miRNAs
in the CNS, physiologically relevant, high-throughput data sets were generated that detail
relative expression levels of approximately 400 miRNAs in neuronal and glial cell types. The
microglial enriched miRNA, miR-155, was identified as an exciting therapeutic target whose
inhibition led to a robust survival increase in the ALS-mouse model along with a correlated
increase in specific neuroinflammatory transcripts. MicroRNA inhibition, and miR-155
specifically, remain exciting avenues for ALS research as potential therapeutic targets.
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Future directions
Further applications of miRAP mice
We have generated datasets of miRNA expression levels in neurons, motor neurons,
astrocytes, and microglia in the brain and spinal cord which have allowed for the identification of
cell type enriched and cell type specific microRNAs. While these lists are potentially useful as a
resource for informing cell type specific expression for researchers using mixed cell type
systems, several more sophisticated and intriguing applications of these datasets remain. These
include ongoing experiments that will strive to identify miRNA drivers of cell type
differentiation, provide insight into miRNA biogenesis and regulation, and identify miRNA
dysregulation in neurodegenerative disease in a more precise manner.
Recently, Andrew Yoo and others have discovered a method to reprogram patient
fibroblasts to neurons in culture using a cocktail of microRNA mimics (Yoo et al., 2011),
enabling mechanistic and translational research on affected cell types of disease that are
otherwise difficult and/or impossible to isolate from patients. However, one limitation in this
research is an inability to fine-tune these cellular programming pathways to more specific
relevant cell types including motor neurons, and more so specifically to affected spinal motor
neurons in ALS. By identifying miRNAs distinct between similar cell types (for example, spinal
motor neurons versus brainstem motor neurons), additional miRNA drivers of cell-determination
pathways may be identified that can allow for more precise reprogramming of cellular
differentiation. To better identify miRNAs that have potential regulatory control over mRNAs
known to be important to cellular differentiation, we will compare the miRAP miRNA
microarray data to existing datasets on mRNAs from astrocytes, neurons and motor neurons
already generated by others (Cahoy et al., 2008; Doyle et al., 2008). This integrated analysis of
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microRNA and mRNAs will be conducted with multiple algorithms. These may include MMIA
(microRNA mRNA Integrated Analysis), MAGIA (miRNA and genes integrated analysis), and
others (Naifang et al., 2013). Therefore, we will be able to not only identify miRNAs uniquely
expressed in distinct cell types, but also identify which of those miRNAs are potential drivers of
mRNAs known to be important in cellular differentiation and identity. While ambitious, the
importance of developing tissue culture models of difficult to isolate cells in neurological
diseases warrants the effort necessary to test the utility of this approach to identify novel miRNA
drivers of cellular differentiation.
Furthermore, integrated miRNA-mRNA analysis may better inform direct binding
partners. Identification of putative mRNA targets for a given miRNA typically begins with target
prediction algorithms based on nucleotide sequences (for example, TargetScan); however, many
false positives are generated with this method alone (Lewis et al., 2005). Therefore, experimental
validation is then necessary which can be difficult and time consuming – often employing the
use of miRNA mimics, antagomirs, or genetic ablation (van Rooij et al., 2012). However, a more
refined list of putative mRNA targets can be generated prior to experimental validation by only
considering mRNAs that exhibit inverse expression patterns as compared to the miRNA of
interest by using a combinatorial analysis of miRAP datasets with mRNA expression lists. Thus,
this extra, simple computational step could easily be used to generate putative target lists with a
higher degree of confidence than by using target prediction algorithms alone, potentially
allowing for fewer false positives to be screened through more ambitious experimental validation
experiments.
Next, by using both BAC-TRAP and miRAP mice, we can explore the regulation of
microRNA biogenesis. Joe Dougherty has recently discovered that the GFP-L10a BAC-TRAP
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mice have GFP+ nuclei. This has allowed us to sort GFP+ nuclei from specific cell populations
from whole tissue. MicroRNAs are first transcribed from protein coding and non-coding genes
by RNA polymerase II where a primary-miRNA (pri-miRNA) transcript is generated. The primiRNA is then cleaved by the RNAse II enzymes Drosha and Dicer to generate a 70 nucleotide
fragment known as the precursor-miRNA (pre-miRNA) (Krol et al., 2010). The pre-miRNA is
then exported to the cytoplasm by Exportin-5 before being further cleaved by Dicer to form
mature miRNA. This is referred to as the ‘linear’ or conical pathway (Winter et al., 2009).
However, there have been reports of regulatory events in this processing that can suppress the
maturation of let-7, as one example (Viswanathan et al., 2008). In collaboration with Joe
Dougherty, we will compare and contrast primary miRNA transcripts, precursor miRNA
transcripts, and mature miRNA transcripts for a given cell type. These data will have the
potential to greatly inform the biogenesis of miRNAs. For example, we discovered miR-196 to
be selectively expressed in neurons in the spinal cord and not the brainstem. By comparing pri-,
pre-, and mature miRNA levels in these mice using ChAT-L10a-GFP mice and ChAT-Ago2GFP mice, we will be able to attribute the selective expression of miR-196 to be either a
difference in transcription or a difference in processing regulation. Overall, we are well suited to
perform these experiments that will strive to inform the importance of regulation of miRNA
biogenesis
Next, by isolating specific motor pools, we may be able to elucidate pathways that
differentially confer resistance and susceptibility within a cell type across different tissues. In
ALS, while most motor neurons succumb to disease, those that innervate the eyes, pelvic
sphincters, and slow limb muscles are selectively spared. By comparing mRNA expression
between resistant and vulnerable motor neurons in ALS model mice, Kaplan et al. were able to
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identify a gene selectively expressed in vulnerable motor neurons, MMP9, that could be
inhibited to reduce apoptosis (Kaplan et al., 2014). In experiments underway, we are using the
ChAT-Cre line and the lox-stop-lox Ago2 as described in chapter 3 to isolate miRNAs from
motor neurons from distinct affected or unaffected motor nuclei. We will test if a similar
resistance or vulnerability mediating miRNA can be identified as was recently completed for
mRNA.
Finally, we have begun crossing our neuronal and glial specific miRAP mice into disease
models which will allow for the identification of miRNAs dysregulated in neurodegenerative
disease in a more precise manner. We are also currently generating triple transgenic mice that
express the cell type specific GFP-myc-Ago2 protein in the SOD1G93A mouse model. We have
currently produced over 10 triple transgenic positive mice for the ChAT line and are actively
generating mice for the other three cell specific lines as well. These triple transgenic mice will
allow not only comprehensive identification of dysregulated miRNAs but an assignment of
which cell types have altered miRNA expression levels in disease. This will increase insight into
potential mechanisms of miRNA dysregulation in specific cell types while also identifying those
miRNAs altered in disease. More so, these experiments might allow additional dysregulated
microRNAs to be unearthed that were previously diluted by other cell types in disease.
Furthermore, these data may aid in the design of therapeutics as it will inform which cell types
have to be targeted.
While we have determined the relative expression levels of miR-155 in specific cell types
in the brain and spinal cord (Chapter 3), we have not determined if miR-155 increases in ALS
due to an increased number of cells that express miR-155 or due to an increase of miR-155
within cells. We do not know either which cell types are responsible for the robust increase in
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expression levels for our miRNAs of interest. The triple transgenic mice being generated in the
ALS line will allow us to determine the responsible cells that cause miR-155 levels to be
increased in whole spinal cord tissue in ALS. This information will allow us to predict which
pathological pathways miR-155 operates on during ALS and will suggest the necessary cells to
target therapeutically. However, it requires noting that anti-miR-155 treatment may be beneficial
in ALS model mice independent of miR-155 dynamics in various cell types. To definitively
determine the important cells that confer a survival benefit following anti-miR-155 treatment,
further large scale therapeutic intervention experiments are required and are detailed below.

Further miR-155 studies: role on neuroinflammation and preclinical experiments
By inhibiting a dysregulated miRNA in ALS, miR-155, using antisense oligonucleotides
we were able to afford a significant survival extension by increasing disease duration in ALSmodel mice. For this, we treated mice with anti-miR-155 both through osmotic pumps directed to
the lateral ventricles and with intraperitoneal injections. Given miR-155 expression in both cells
resident to the brain and spinal cord (microglia, astrocytes) and cell that circulate in the blood (T
cells, monocytes), we first tested miR-155 as a potential therapeutic with a total approach (Fig
6.1A). We will next test how CNS inhibition alone or peripheral cell inhibition alone affects
survival in SOD1G93A ALS-mouse model (Fig 6.1B). This information will provide mechanistic
information on the role of miR-155 in ALS. If peripheral inhibition alone is sufficient to
recapitulate the survival extension, the best theory of how anti-miR-155 confers protection is by
modulating activation and proliferation of circulating monocytes and lymphocytes. If a central
treatment alone is sufficient, we will not know if infiltrated immune cells are the critical
mediating cell type or if endogenous cells including neurons, astrocytes, and microglia are
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instead. However, a follow-up novel treatment experiment can then be performed to discern the
mediating cell type in the central nervous system using cell type specific delivery of miRNA
sponges to ALS model mice using adeno-associated viruses. miRNA sponges are mRNAs that
contain multiple miRNA binding sites (often 4-10), acting as dominant negative inhibitors (Ebert
and Sharp, 2010). To test cell specific treatment of miR-155 knockdown in ALS model mice,
miRNA sponges can be expressed behind cell type specific promoters and packaged into AAV9
capsids using methods similar to published experiments that selectively target neurons (Gray et
al., 2011) and astrocytes (Lawlor et al., 2009; von Jonquieres et al., 2013). These experiments
using miRNA sponges are being proposed secondary to antimir experiments using oligos
because while miRNA sponges are showing promise in their potency and adaptability since
being developed in 2007 (Ebert et al., 2007), they can be limited in their ability to sufficiently
inhibit abundant microRNAs and are not as prepared for safe delivery in patients as ASO
technology (Ebert and Sharp, 2010). These are ambitious experiments being proposed to
definitively determine the important cell(s) to target with miR-155 knockdown drugs, but beyond
being mechanistically informative, these experiments may inform future preclinical trials.
Peripheral dosing is much easier than intrathecal delivery; however, both are possible in patients
(Miller et al., 2013). Furthermore, as additional backbone modifications are being developed for
antisense oligonucleotides, there may be an opportunity to select for those oligos that show
greatest potency in the cell type of interest.
Before carrying out these treatment experiments, we are first testing novel anti-miR-155
oligos. Our collaborators at Regulus Therapeutics have generated five new anti-miR-155 oligos
with alternative backbone and sugar modifications. Following an in vitro luciferase target
engagement assay, three of these novel anti-miR-155 oligos outperformed the anti-miR-155 used
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in our previous ALS-mouse model experiments. We are now in the process of screening these
new oligos in vivo for toxicity and target engagement. We will pursue the central vs peripheral
treatment experiment with the top oligo from this screen.
Finally, the timing of administration will also have to be tested. While SJL SOD1G93A
mice do not have an overt phenotype until 90-100 days of age, cellular pathology including ER
stress are observed earlier (Matus et al., 2013). Therefore, in our first therapeutic experiment, we
began treatment at 60 days of age. Given that miR-155 levels are not increased until later in
disease (Fig 2.4), a later start date for treatment might be equally beneficial and more
therapeutically relevant and will require testing.
Our descriptive experiments using ALS model mice and patient autopsy tissue data
defined 6 dysregulated miRNAs in ALS. Another miRNA identified here may have a more
potent effect either alone or in concert other miRNA targets. For example, miR-142-3p, miR146a, and miR-155 all had a near perfect correlation in their time course of upregulation in the
ALS mouse model (Fig 2.5). A combinatorial strategy may afford the greatest survival benefit;
however, as miRNAs have several downstream targets, the risk of toxicity and detrimental
effects are likely to increase as the number of miRNAs targeted also increases. Nonetheless,
given the highly correlative nature of these target miRNAs, a combinatory treatment strategy
warrants testing for an even greater survival benefit. Overall, several therapeutic experiments
remain in order to optimize microRNA inhibition therapies in ALS. First, the most potent antimiR-155 oligo will be identified, and then the best mode of delivery will be determined (central
vs peripheral administration). Next, the effect of delaying the start of treatment can be tested as
well as the effect of combinatorial strategies to inhibit miRNAs dysregulated in ALS. Beyond
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identifying the method that allows for the greatest survival benefit, these experiments will also
help elucidate the mechanism through which blunting miR-155 function in ALS is beneficial.

Concluding remarks:
In this dissertation work, we have generated exciting microRNA data, including a list of
dysregulated miRNAs in ALS, a dataset of cell type specific miRNA expression patterns, and the
identification of novel therapeutic targets. More so, we have also identified many promising
research avenues to carry forward. The novel glial/neuronal specific miRAP mice have the
potential to inform basic miRNA biology in terms of the regulation of miRNA biogenesis, the
identification of drivers of cell type differentiation, and discovery of miRNA-mRNA targets. We
are also applying these miRAP mice to models of neurodegeneration in order to create a list of
miRNAs actively dysregulated in specific cell populations. Also, we have identified miR-155 as
an exciting potential immunomodulator that may also be a therapeutic target in ALS. We are
now pursuing more potent anti-miRs before testing central versus peripheral intervention
experiments in the mouse model of ALS. These experiments may elucidate the necessary and
sufficient cell types to target with anti-miR-155 to recapitulate a survival benefit in ALS-model
mice while also informing the role of neuroinflammation in ALS. With a blend of mechanistic
and translational work, the data presented here serves to inform the role of microRNAs in ALS
while also developing methods to assist in future miRNA experiments.
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Figure 6.1: Experimental plan for comparing anti-miR-155 treatment administered in
the periphery vs in the central nervous system. (A) In the original anti-miR-155 experiment
in ALS model SOD1G93A mice, we targeted both cells in the brain and spinal cord with osmotic
pumps directed to the cerebral lateral ventricles and targeted peripheral cells with weekly IP
injections. (B) In our next large-scale anti-miR intervention experiment in the SOD1G93A
mouse model, we will compare administration of a novel anti-miR-155 only to the central
nervous system using Alzet osmotic pumps directed to the lateral ventricles, only to the
periphery by IP injections, to a combination of the two (as completed previously).
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